

(19)



(11)

EP 2 699 593 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
30.08.2017 Bulletin 2017/35

(51) Int Cl.:
C07K 14/705 ^(2006.01) **C12N 15/85** ^(2006.01)
A61K 38/17 ^(2006.01)

(21) Application number: **12720040.0**

(86) International application number:
PCT/US2012/034051

(22) Date of filing: **18.04.2012**

(87) International publication number:
WO 2012/145384 (26.10.2012 Gazette 2012/43)

(54) **BETA-2 MICROGLOBULIN-DEFICIENT CELLS**

BETA-2 MICROGLOBULIN-ARME ZELLEN

CELLULES DÉFICIENTES EN BÊTA-2 MICROGLOBULINE

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **20.04.2011 US 201161477474 P**

(43) Date of publication of application:
26.02.2014 Bulletin 2014/09

(73) Proprietor: **University of Washington through its
Center for
Commercialization
Seattle, WA 98105 (US)**

(72) Inventor: **RUSSELL, David, W.
Seattle
WA 98112 (US)**

(74) Representative: **Ettmayr, Andreas et al
KEHL, ASCHERL, LIEBHOF & ETTMAYR
Patentanwälte
Emil-Riedel-Strasse 18
80538 München (DE)**

(56) References cited:
WO-A1-92/09688 US-B1- 6 514 752

- "7th Australasian gene therapy society meeting",
THE JOURNAL OF GENE MEDICINE, vol. 13, no.
7-8, 1 July 2011 (2011-07-01) , pages 410-446,
XP55032708, ISSN: 1099-498X, DOI:
10.1002/jgm.1582
- GATTONI-CELLI S ET AL: "BETA-2
MICROGLOBULIN GENE IS MUTATED IN A
HUMAN COLON CANCER CELL LINE HCT
DEFICIENT IN THE EXPRESSION OF HLA CLASS
I ANTIGENS ON THE CELL SURFACE", CANCER
RESEARCH, vol. 52, no. 5, 1992, pages 1201-1204,
XP002680036, ISSN: 0008-5472

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 699 593 B1

Description

BACKGROUND OF THE INVENTION

[0001] Human pluripotent stem cells have the potential to treat diseases affecting almost every organ system. However, the clinical use of human pluripotent stem cells and their derivatives has a major limitation - rejection of transplanted cells by the recipient due to differences in the major histocompatibility complex.

[0002] The major histocompatibility complex (MHC) is a cell surface multi-component molecule found in all vertebrates that mediates interactions of leukocytes with other leukocytes or other cells. The MHC gene family is divided into three groups: class I, class II and class III. In humans, MHC is referred to as human leukocyte antigen (HLA). The HLA class I (HLA-I) protein is expressed on all nucleated cells and consists of an HLA class I heavy chain (or α chain) and β -2 microglobulin (B2M). HLA class I protein presents peptides on the cell surface to CD8+ cytotoxic T cells. Six HLA class I α chains have been identified to date, including three classical (HLA-A, HLA-B and HLA-C) and three non-classical (HLA-E, HLA-F and HLA-G) α chains. The specificity for peptide binding on the HLA class I molecule peptide binding cleft is determined by the α chain. Recognition by CD8+ T cells of the peptides presented by the HLA class I molecule mediates cellular immunity.

[0003] The HLA class I protein itself from an allogeneic source constitutes a foreign antigen in the context of transplantation. The recognition of non-self HLA class I protein is a major hurdle in using pluripotent cells for transplantation or replacement therapies. The first two clinical trials of human embryonic stem cells (ESCs) have been conducted that delivered ESCs to immune-privileged sites (such as spinal cord and eye) where allogeneic cells might survive. However, even these immune-privileged sites can eventually reject allogeneic cells, and most potential clinical applications do not involve immune-privileged sites. Alternatively, HLA-matched or partially matched cells from HLA-typed stem cell banks or pluripotent stem cell (iPSC) lines derived from each patient can be developed for transplantation. However, the development of individually matched cell line requires significant costs, months of cell culture, highly trained personnel, and extensive validation of the final product, all of which must be done with the approval of regulatory agencies. Furthermore, each cell line will likely behave somewhat differently in gene expression patterns, culture characteristics, differentiation potentials, and genetic variations.

[0004] Thus, although individualized stem cell preparations or HLA-diverse stem cell banks may address the current problem of transplantation, they require that multiple cell lines be characterized, differentiated into therapeutic cell products, and approved for human administration. This time-consuming, technically difficult, and expensive process is a major factor preventing stem cell-based therapies from entering clinical trials. Thus, there exists a need for a more effective and less expensive cell-based therapies that are not impeded by rejection.

[0005] US 6,514,752 B1 describes the inactivation of genes associated with MHC antigens resulting in reducing or eliminating the expression of functional MHC class I antigens. WO 92/09688 A1 describes mutant heterologous non-human mammals (mice) having a disruption β 2-m gene and also relates to MHC class I deficient cells.

SUMMARY OF THE INVENTION

[0006] In accordance with the present invention, in one aspect the invention provides an isolated cell comprising a genetically engineered disruption in a beta-2 microglobulin (*B2M*) gene, wherein the cell is a primate cell, wherein the cell further comprises one or more recombinant immunomodulatory genes, each capable of expressing an immunomodulatory polypeptide in the cell, wherein the one or more immunomodulatory genes comprise a polynucleotide capable of encoding a single chain fusion human leukocyte antigen (HLA) class I protein comprising at least a portion of the B2M protein covalently linked, either directly or via a linker sequence, to at least a portion of an HLA-I α chain, wherein the single chain fusion human HLA class I protein is capable of normal HLA class I function with respect to forming proper secondary structure of single chain fusion heterodimers on the cell surface, presenting peptides in the HLA I peptide binding cleft, and engaging the inhibitory receptors on the surface of NK cells. In certain particular embodiments, the cell comprises genetically engineered disruptions of all copies of the *B2M* gene. In a particular embodiment, the invention provides an isolated cell comprising a genetically engineered disruption in a beta-2 microglobulin (*B2M*) gene, wherein the cell is a primate cell, wherein the cell further comprises one or more recombinant immunomodulatory genes, each capable of expressing an immunomodulatory polypeptide in the cell, wherein the one or more immunomodulatory genes comprise a polynucleotide capable of encoding a single chain fusion human leukocyte antigen (HLA) class I protein comprising at least a portion of the B2M protein covalently linked, either directly or via a linker sequence, to at least a portion of an HLA-I α chain, wherein the single chain fusion human HLA class I protein is capable of normal HLA class I function with respect to forming proper secondary structure of single chain fusion heterodimers on the cell surface, presenting peptides in the HLA I peptide binding cleft, and engaging the inhibitory receptors on the surface of NK cells.

[0007] In certain other embodiments, the cell further comprises one or more recombinant immunomodulatory genes. Suitable immunomodulatory genes include without limitation a gene encoding a viral protein that inhibits antigen pres-

entation, a microRNA gene, and a gene that encodes a single chain (SC) fusion human leukocyte antigen (HLA) class I protein as described below. In certain preferred embodiments, the primate cell is a human cell.

[0008] In certain preferred embodiments, the one or more immunomodulatory genes comprise a polynucleotide capable of encoding a single chain fusion HLA class I protein. In certain particular embodiments, the single chain fusion HLA class I protein comprises at least a portion of B2M covalently linked to at least a portion of an HLA class I α chain selected from the group consisting of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F and HLA-G. In certain preferred embodiments, the single chain fusion HLA class I protein comprises at least a portion of B2M and at least a portion of an HLA class I α chain selected from the group consisting of HLA-C, HLA-E and HLA-G. In certain other preferred embodiments, the single chain fusion HLA class I protein comprises at least a portion of B2M and at least a portion of an HLA class I α chain selected from the group consisting of HLA-A, HLA-E and HLA-G. In certain particular embodiments, the single chain fusion HLA class I protein comprises at least a portion of B2M and at least a portion of HLA-A0201 (e.g., SEQ ID NO:16). In certain other particular embodiments, the single chain fusion HLA class I protein comprises at least a portion of B2M and at least a portion of HLA-E (e.g., SEQ ID NOs:18 and 20).

[0009] In yet other particular embodiments, the cell has a normal karyotype. In certain other particular embodiments, the cell is a non-transformed cell. In particular, the cell can be a stem cell selected from the group consisting of a hematopoietic stem cell, an induced pluripotent stem cell, a liver stem cell, a neural stem cell, a pancreatic stem cell and a mesenchymal stem cell. Furthermore, an embryonic stem cell is disclosed without being claimed. In certain further embodiments, the cell further comprises one or more recombinant genes capable of encoding a suicide gene product. In certain particular embodiments, the suicide gene product comprises a protein selected from the group consisting of thymidine kinase and an apoptotic signaling protein.

[0010] In certain preferred embodiments, the stem cell is a pluripotent stem cell that expresses a single chain fusion HLA class I protein comprising at least a portion of B2M and at least a portion of an HLA class I α chain selected from the group consisting of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F and HLA-G. In certain particular embodiments, the single chain fusion HLA class I protein comprises at least a portion of B2M and at least a portion of HLA-A0201.

[0011] In certain other particular embodiments, the stem cell is a differentiated cell. In certain embodiments, the differentiated cell is selected from the group consisting of a dendritic cell, a pancreatic islet cell, a liver cell, a muscle cell, a keratinocyte, a neuronal cell, a hematopoietic cell, a lymphocyte, a red blood cell, a platelet, a skeletal muscle cell, an ocular cell, a mesenchymal cell, a fibroblast, a lung cell, a GI tract cell, a vascular cell, an endocrine cell, an adipocyte and a cardiomyocyte. In certain preferred embodiments, the differentiated cell is a human cell expressing a single chain fusion HLA class I protein comprising at least a portion of B2M and at least a portion of an HLA class I α chain selected from the group consisting of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F and HLA-G. In certain particular embodiments, the single chain fusion HLA class I protein comprises at least a portion of B2M and at least a portion of HLA-A0201.

[0012] In certain other embodiments, the cell further expresses a target peptide antigen that is presented by the single chain fusion HLA class I protein on the cell surface. In certain particular embodiments, the target peptide antigen is covalently linked to the single chain fusion HLA class I protein. In certain preferred embodiments, the target peptide antigen is derived from a protein of a pathogen or a cancer cell. Thus, in a related aspect, the invention provides a vaccine comprising the B2M^{-/-} cells of the invention, wherein the vaccine is capable of eliciting in a primate an immune response specific for the target peptide antigen. In certain particular embodiments, the vaccine comprises a cell of the invention that is a differentiated dendritic cell. In certain other embodiments, the cell is a human cell of the invention, wherein the cell expresses a cytokine that further enhances the immune response. In certain preferred embodiments, the cytokine is IL2. In certain other preferred embodiments, the cytokine is IFN- γ . In certain embodiments, the immune response comprises a humoral immune response; while in other embodiments, the immune response comprises a cellular immune response. In a further related aspect, the invention provides a kit comprising a vaccine that comprises the isolated cells of the invention and an immune adjuvant. In certain embodiments, the cell is a human cell.

[0013] Furthermore, a method of transplantation in a patient in need thereof is disclosed comprising the step of administering to the patient an effective amount of the disclosed isolated cell. In yet another aspect, the invention provides an inventive cell for use in transplantation in a patient in need thereof, whereby the cell is administered to the patient in an effective amount, wherein

- a. the cell is a differentiated cell;
- b. the patient is human and the cell is a human cell; and/or
- c. the cell further expresses a single chain fusion HLA class I protein.

In certain disclosed embodiments, the patient is immune competent. In certain particular embodiments, the patient is a primate and preferably a human. In certain preferred embodiments, the patient is a human and the cell is a human cell. In further embodiments the cell is a stem cell or a differentiated cell, optionally expressing a single chain fusion HLA class I protein.

[0014] Furthermore a method of treating a disease condition in a patient in need thereof is disclosed comprising the step of administering to the patient an effective amount of the disclosed *B2M*^{-/-} cells, wherein the disease condition includes without limitation an endocrine disorder, diabetes, an autoimmune disease, cancer, infection, anemia, a platelet disorder, immunodeficiency, cytopenia, myocardial infarction, heart failure, liver failure, skeletal or joint condition, a neurological condition, stroke, paralysis, blindness or another visual disorder, muscular dystrophy, osteogenesis imperfecta, pulmonary disease, skin condition, or burns. In yet another aspect, the invention provides an inventive cell for use in treating a disease condition in a patient in need thereof, whereby the cell is administered to the patient in an effective amount, and wherein the disease condition is diabetes, an autoimmune disease, cancer, infection, anemia, cytopenia, myocardial infarction, heart failure, skeletal or joint condition, osteogenesis imperfecta or burns. Preferably,

- a. the cell is a differentiated cell;
- b. the patient is a human and the cell is a human cell;
- c. the disease condition is diabetes and the cell is a pancreatic islet cell; and/or
- d. the cell further expresses a single chain fusion HLA class I protein.

In certain embodiments, the patient is immune competent. In certain particular embodiments, the patient is a primate and preferably a human. In certain preferred embodiments, the patient is a human and the cell is a human cell. In further embodiments the cell is a stem cell or a differentiated cell, optionally expressing a single chain fusion HLA class I protein. In certain particular embodiments, the disease condition is diabetes and the cell is a differentiated pancreatic islet cell. In further embodiments the differentiated pancreatic islet cell expresses a single chain fusion HLA class I protein.

[0015] In another aspect, the invention provides a kit comprising the isolated primate cells, preferably human cells, of the invention. In certain embodiments, the kit is for use in transplantation or for use in treating a disease condition. In certain other embodiments, the kit comprises an implant comprising the isolated primate cells, preferably human cells, of the invention.

[0016] Specific embodiments of the present invention will become evident from the following more detailed description of certain preferred embodiments and the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0017]

Figure 1. Creation of *B2M*^{-/-} ESCs. **Figure 1A** is an illustration of the AAV *B2M* targeting vectors with exons shown in large boxes. **Figure 1B** presents Southern blots showing the results of gene targeting and Cre-mediated transgene excision (Cre-out). **Figure 1C** presents results of flow cytometry showing a lack of HLA class I expression after gene targeting (with isotype controls).

Figure 2. Tissue sections of teratoma developed from *B2M*^{-/-} Cre-out human ESCs transplanted in immune-deficient mice. The sections were stained with DAPI, hematoxylin and eosin, or lineage-specific markers MAP-2 (microtubule associated protein-2) for ectoderm, α -SAM (α -smooth muscle actin) for mesoderm or FoxA2 (forkhead box protein A2) for endoderm. Scale bar = 100 microns.

Figure 3. Single chain fusion HLA class I constructs. **Figure 3A** shows the foamy viral vector design for expressing single chain fusion HLA class I proteins. **Figure 3B** illustrates the linear protein structure of single chain fusion HLA class I proteins. Sequences for exemplary single chain fusion HLA class I proteins are provided for HLA-bGBE (SEQ ID NOs: 19 and 20, DNA and protein sequences, respectively), HLA-gBE (SEQ ID NOs: 17 and 18) and HLA-bBA0201 (SEQ ID NOs: 15 and 16). **Figure 3C** presents results of flow cytometry showing single chain fusion HLA-E expression in *B2M*^{-/-} ESCs (isotype controls). **Figure 3D** presents results of flow cytometry showing single chain fusion HLA-A0201 expression in *B2M*^{-/-} ESCs (isotype controls).

Figure 4 outlines the experimental design for each differentiated cell type.

Figure 5 shows differentiation of keratinocytes from *B2M*^{-/-} ESCs.

DETAILED DESCRIPTION OF THE INVENTION

[0018] Within this application, unless otherwise stated, the techniques utilized may be found in any of several well-known references such as: Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press) and PCR Protocols: A Guide to Methods and Applications (Innis, et al. 1990. Academic Press, San Diego,

CA).

[0019] As used herein, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise. For example, reference to "an isolated cell" means one or more isolated cells.

[0020] All embodiments disclosed herein can be combined unless the context clearly dictates otherwise.

[0021] In one aspect, the invention provides *B2M* deficient cells. In particular, the invention provides isolated primate cells, preferably human cells, comprising a genetically engineered disruption in a *B2M* gene. In certain preferred embodiments, the cell is a human cell comprising a genetically engineered disruption in the *B2M* gene. In a related aspect, the cell comprises genetically engineered disruptions of all copies of the *B2M* gene. In certain embodiments, the genetic disruptions in the *B2M* gene result in defective or no expression of the B2M protein. Since B2M is a common component of all HLA class I proteins, the disruptions preclude the expression of all natural HLA class I proteins on the cell surface. The *B2M* coding sequence is shown in SEQ ID NO:1 (GenBank Accession Number NM_004048) and the *B2M* protein sequence is shown in SEQ ID NO:2. There may be many single nucleotide polymorphisms (SNPs) in the gene; as will be understood by those of skill in the art, the human cells and methods of the invention are applicable to any such *B2M* gene and SNPs.

[0022] The cells of these embodiments of the invention can be used, for example, as donor cells for transplantation in a recipient in need thereof. *B2M* deficient cells encompass cells that comprise a *B2M*^{-/-} genetic background (referred to as *B2M*^{-/-} cells). The term "*B2M*^{-/-} cells" refers to primate cells, preferably human cells, that comprise genetically engineered disruptions in all copies of the *B2M* gene. The *B2M*^{-/-} cells can serve as "universal donor cells" in that they are immunologically compatible to all or a significant percentage of recipients in a population. As used herein, a recipient or patient refers to a primate, and preferably a human. In certain particular embodiments, the cell is a human cell and the patient is a human.

[0023] The cells of the invention can be engineered to disrupt the *B2M* gene such that no functional endogenous B2M protein is produced from the disrupted genetic loci. In certain embodiments, the disruption results in expression of non-functional B2M proteins, including but not limited to truncations, deletions, point mutations and insertions. In other embodiments, the disruption results in no protein expression from the *B2M* gene.

[0024] Cells deficient in B2M expression are unable to express HLA class I proteins on the cell surface. HLA class I deficiency provides further benefits; for example, cells without HLA class I expression cannot present auto-antigens that would otherwise prevent successful cell therapies for autoimmune diseases such as diabetes and rheumatoid arthritis. Similarly, therapeutic gene products introduced by the inventive cell therapies (e.g., dystrophin) that are missing in patients with certain genetic diseases (e.g., muscular dystrophy) will not be presented and recognized by the immune system as neo-antigens in replacement therapies.

[0025] Any suitable technique for disrupting one, two or all copies of the *B2M* gene can be used; exemplary techniques are disclosed throughout the application and are within the level of skill in the art based on the teachings herein and the teachings known in the art. Exemplary other techniques can be found, for example, in U.S. Patent Application Publication Number US2008/0219956, published September 11, 2008. These techniques may optionally include steps to remove non-human DNA sequences from the cells after *B2M* gene disruption.

[0026] An exemplary embodiment of this method is as disclosed throughout the application, using an adeno-associated virus gene targeting vector, optionally including removing the transgene used for targeting via techniques such as those described below, or by removing the transgene used for targeting by Cre-mediated loxP recombination, or other suitable recombination techniques. See Khan et al. 2011, Protocol, 6:482-501. Exemplary targeting vectors and exemplary vector diagrams are also disclosed herein. It is within the level of those of skill in the art, based on the teachings herein and known in the art, to utilize a variety of techniques for making the *B2M*^{-/-} cells, preferably human cells, of the invention.

[0027] In certain embodiments, the cell genome of the *B2M*^{-/-} cells may comprise no more than 100, no more than 50 or no more than 30 nucleotides of non-human DNA sequences. In certain other embodiments, the cell genome may comprise 6, 5, 4, 3, 2, 1, or 0 nucleotides of non-human DNA sequences. An exemplary technique for removing any non-human DNA introduced in disrupting the *B2M* gene is provided in Figure 1A. The non-human DNA sequences can be removed by a second round of targeting to delete the HyTK or TKNeo transgenes in the first vectors or by the Cre-mediated loxP recombination.

[0028] In other embodiments, the cells instead can be engineered to recombinantly express a single chain fusion HLA class I protein in a *B2M*^{-/-} genetic background. Thus, the *B2M*^{-/-} cells as used herein also encompass primate, preferably human, cells that express one or more single chain fusion HLA class I proteins in a *B2M*^{-/-} genetic background. The *B2M*^{-/-} cells recombinantly expressing a single chain fusion HLA class I protein are nevertheless deficient in normal B2M function in that the cells do not express wild type B2M protein that form a non-covalently associated heterodimer with any HLA class I α chain on the cell surface.

[0029] . The term "single chain fusion HLA class I protein," "single chain fusion HLA class I molecule" or "single chain fusion HLA class I antigen" refers to a fusion protein comprising at least a portion of the B2M protein covalently linked, either directly or via a linker sequence, to at least a portion of an HLA-I α chain. On the other hand, the term "HLA class I protein," "HLA class I molecule" or "HLA class I antigen" refers to a non-covalently associated heterodimer of B2M and

an HLA α chain expressed on the surface of a wild type cell.

[0030] As used herein, the term "HLA class I α chain" or "HLA-I heavy chain" refers to the α chain of the HLA class I heterodimer. HLA class I heavy chain includes without limitation HLA class I α chains HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G. Representative DNA and protein sequences are provided for HLA-A (GenBank No. K02883.1, SEQ ID NO:3; UniProt No. P01892, SEQ ID NO:4), HLA-B (NM_005514, SEQ ID NO:5; NP_005505; SEQ ID NO:6), HLA-C (NM_002117, SEQ ID NO:7; NP_002108, SEQ ID NO:8), HLA-E (NM_005516, SEQ ID NO:9; NP_005507, SEQ ID NO:10), HLA-F (NM_018950, SEQ ID NO:11; NP_061823, SEQ ID NO:12), and HLA-G (NM_002127, SEQ ID NO:13; NP_002118, SEQ ID NO: 14).

[0031] In addition, although the term "HLA class I protein/molecule" is known to refer to the MHC class I protein/molecule in human, the terms HLA and MHC are sometimes used interchangeably throughout this application: for example, the term HLA class I protein can also be used to refer to the primate equivalent to the HLA class I protein in a primate. One of skill in the art will be able to discern the meaning of the term based on the content.

[0032] The term *B2M*^{-/-} cells as used herein also encompasses cells having genetically engineered disruptions in all copies of the *B2M* gene, wherein one *B2M* allele is genetically engineered to express, instead of the wild type *B2M* protein, a single chain fusion HLA class I protein (*i.e.*, genetically targeted knockin in one *B2M* allele). *B2M*^{-/-} cells with such genetic background express *B2M* only in the context of the single chain fusion HLA class I protein from a *B2M* genetic locus. In certain advantageous embodiments, the expression of the single chain fusion HLA class I protein is regulated by the endogenous *B2M* regulatory sequence located at the *B2M* locus.

[0033] In related embodiments, *B2M*^{-/-} cells further encompass cells having genetically engineered disruptions in all copies of the *B2M* gene, wherein all *B2M* alleles are genetically engineered to express, instead of the wild type *B2M* protein, single chain fusion HLA class I proteins (*i.e.*, genetically targeted knockin in all *B2M* alleles). *B2M*^{-/-} cells with such genetic disruptions express *B2M* only in the context of single chain fusion HLA class I proteins from the genetic loci of all the alleles of the *B2M* gene. In certain embodiments, the cells are genetically engineered to express the same type of single chain fusion HLA class I protein from the genetic loci of all alleles of the *B2M* gene; while in other embodiments, the cells are genetically engineered to express different types of single chain fusion HLA class I proteins from different genetic loci of different alleles of the *B2M* gene.

[0034] Throughout the application, the "cells of the invention," "isolated cells of the invention," "*B2M*^{-/-} cells," "*B2M*^{-/-} cells of the invention" or "stem cells or differentiated cells of the invention" sometimes can be used interchangeably to encompass all the *B2M*^{-/-} cells described herein. In certain particular embodiments, the *B2M*^{-/-} cells of the invention express a single chain fusion HLA class I protein as defined herein, in a *B2M*^{-/-} background. The *B2M*^{-/-} cells can be genetically engineered to express a single chain HLA class I protein either from the *B2M* locus or from other location of the genome. In certain particular embodiments, the cells of the invention comprise genetically engineered disruptions in all alleles of the *B2M* gene that preclude the expression of wild type *B2M* protein, and nevertheless express a single chain fusion HLA class I protein from a *B2M* genetic locus. In certain other particular embodiments, the cells of the invention comprise genetically engineered disruptions in all alleles of the *B2M* gene that preclude the expression of wild type *B2M* protein, and nevertheless express single chain fusion HLA class I proteins from all *B2M* genetic loci. The term "gene," "allele," and "genetic locus" may be used interchangeably throughout the application.

[0035] The "isolated cell" can be any suitable cell type for a given purpose. For example, the cell can be a pluripotent stem cell or a differentiated cell. "A stem cell" broadly encompasses any cells that are capable of further differentiation. "A pluripotent stem cell" refers to a stem cell that has the potential to differentiate into any of the three germ layers: endoderm, mesoderm or ectoderm. "An adult stem cell," on the other hand, is multipotent in that it can produce only a limited number of cell types.. "Induced pluripotent stem cells (iPS cells)" are pluripotent stem cell artificially derived from a non-pluripotent cell, typically an adult somatic cell, by artificially inducing expression of certain genes.

[0036] In certain embodiments, the single chain fusion HLA class I protein comprises at least a portion of *B2M* and at least a portion of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F or HLA-G (also referred to as a dimeric construct). In certain preferred embodiments, the HLA α chain contained in the single chain fusion HLA class I protein does not contain the leader sequence (or signal sequence) of the HLA class I α chain (leaderless HLA α chain). In certain other embodiments, the single chain fusion HLA class I protein comprises at least a portion of *B2M* and at least a portion of HLA-C, HLA-E or HLA-G. In certain further embodiments, the single chain fusion HLA class I protein comprises at least a portion of *B2M* and at least a portion of HLA-A, HLA-E or HLA-G. In certain preferred embodiments, the single chain fusion HLA class I protein comprises a leader sequence (or signal peptide) covalently linked to the at least a portion of *B2M* and at least a portion of an HLA α chain to ensure proper folding of the single chain fusion on the cell surface. The leader sequence can be the leader sequence of the *B2M* protein, the leader sequence of an HLA α chain protein or the leader sequence of other secretory proteins. In certain particular embodiments, the single chain fusion HLA class I protein comprises a *B2M* protein with its leader sequence removed. In certain other particular embodiments, the single chain fusion HLA class I protein comprises an HLA α chain protein with its leader sequence removed. Certain HLA class I α chains are highly polymorphic. As will be understood by those of skill in the art, the human cells and methods of the invention are applicable to any such HLA α chains and polymorphism thereof.

[0037] Single chain fusion HLA class I proteins comprising sequence variants and fragments of B2M and/or HLA α chains are contemplated by the instant invention, wherein such single chain fusion constructs nevertheless possess normal HLA class I functions, e.g., forming proper secondary structure of the heterodimer on the cell surface, presenting peptides in the peptide binding cleft and engaging the inhibitory receptors on the surface of NK cells. In certain embodiments, the variants share at least 75%, 80%, 81%, 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or complete sequence homology with the naturally occurring HLA heavy chains and B2M sequences, wherein the variants possess normal HLA class I functions. In certain other embodiments, the variants share at least 75%, 80%, 81%, 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or complete sequence homology with the sequences of B2M or HLA heavy chains as shown in SEQ ID NOs:2, 4, 6, 8, 10, 12 or 14.

[0038] In certain particular embodiments, the HLA-A variants share at least 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or complete sequence homology with SEQ ID NO:4. In certain other particular embodiments, the HLA-B variants share at least 81%, 83%, 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or complete sequence homology with SEQ ID NO:6. In certain further embodiments, the HLA-C variants share at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or complete sequence homology with SEQ ID NO:8. In yet other embodiments, the HLA-E variants share at least 97%, 98%, 99%, or complete sequence homology with SEQ ID NO:10. In certain particular embodiments, the HLA-F variants share at least 99%, or complete sequence homology with SEQ ID NO:12. In certain other embodiments, the HLA-G variants share at least 98%, 99%, or complete sequence homology with SEQ ID NO:14.

[0039] In certain other embodiments, the single chain fusion HLA class I protein comprises a full length B2M (including its leader sequence) and an HLA α chain without the leader sequence (leaderless HLA α chain); while in certain other embodiments, the single chain fusion HLA class I protein comprises a B2M protein without the leader sequence. It is understood that *B2M*^{-/-} cells expressing two, three or more different types of single chain fusion HLA class I protein in any combination, for example, expressing SC fusion comprising HLA-A (or a leaderless HLA-A) and SC fusion comprising HLA-C (or a leaderless HLA-C), expressing SC fusion comprising HLA-A (or a leaderless HLA-A) and SC fusion comprising HLA-E (or a leaderless HLA-E), or expressing SC fusion comprising HLA-B (or a leaderless HLA-B), SC fusion comprising HLA-E (or a leaderless HLA-E) and SC fusion comprising HLA-G (or a leaderless HLA-G), etc., are all contemplated by the invention.

[0040] Natural killer (NK) cells are part of the innate immune response. Several pathogens can down regulate HLA class I protein expression in infected cells. The NK cells monitor infection by recognizing and inducing apoptosis in cells that do not express HLA class I proteins. The inhibitory receptors on the NK cell surface recognize HLA class I α chain alleles thereby preventing NK-mediated apoptosis in uninfected normal cells. Thus, in certain particular embodiments, the single chain fusion HLA-I protein inhibits NK cell-mediated killing of cells that do not express endogenous HLA class I proteins by binding to the inhibitory receptors on the NK cells. For example, HLA-E is a ligand for the CD94/NKG2 receptor of NK cells that inhibits NK cell-mediated apoptosis. Thus, in certain particular embodiments, the *B2M*^{-/-} cell expresses the single chain fusion HLA class I protein comprising at least a portion of B2M and at least a portion of HLA-E. In addition, HLA-G is normally expressed on the surface of placental cytotrophoblasts that do not express HLA-A, B or C, and it protects these cells from NK cell-mediated lysis by interacting with the inhibitory ILT2(LIR1) receptor on NK cells (Pazmany et al., 1996, Science 274, 792-795). Thus, in certain other preferred embodiments, the *B2M*^{-/-} cell expresses the single chain fusion HLA class I protein comprising at least a portion of B2M and at least a portion of HLA-G.

[0041] In certain particular embodiments, the single chain fusion HLA class I protein comprises at least a portion of B2M and at least a portion of HLA-A0201, an allele of HLA-A. HLA-A0201 (SEQ ID NO:4) is a common HLA class I allele found in a large percentage of the population in the United States. Thus, in certain advantageous embodiments, the isolated cell expresses the single chain fusion HLA class I protein comprising at least a portion of B2M and at least a portion of HLA-A0201 in a *B2M*^{-/-} genetic background, wherein the isolated cell is immune compatible with a large percentage of the human population in the United States. Other suitable common alleles that can be used include without limitation HLA-A0101, HLA-A0301, HLA-B0702, HLA-B0801, HLA-C0401, HLA-C0701, and HLA-C0702. In certain preferred embodiments, the HLA allele comprises at least a portion of HLA-A0201 (SEQ ID NO:4), HLA-B0702 (SEQ ID NO:6) or HLA-C0401 (SEQ ID NO:8).

[0042] In certain further embodiments, the single chain fusion HLA class I protein also comprises a specific peptide antigen that occupies the peptide binding cleft of the single chain fusion HLA class I protein, wherein the peptide antigen is covalently linked to the single chain fusion HLA class I protein (also referred to as a trimeric construct). An example of the trimeric construct is shown in Figure 3B. The HLA-bGBE construct of Figure 3B comprises B2M and HLA-E covalently linked to a peptide antigen (such as, but not limited to, the HLA-G peptide antigen as illustrated in the figure) (SEQ ID NO:23) designed to occupy the peptide binding cleft of the single chain fusion HLA class I protein. In certain other embodiments, the covalently linked peptide antigen is cleaved via a built in protease cleavage site, and the cleaved peptide antigen can bind to the peptide binding cleft of the single chain fusion HLA-I protein for presentation. In certain alternative embodiments, the peptide antigen occupying the peptide binding cleft of the single chain fusion HLA class I protein is produced by the intracellular antigen processing pathway, in which the peptide antigen is produced by pro-

teasome, transported to and loaded onto the single chain fusion HLA class I protein in the endoplasmic reticulum. In certain particular embodiments, the peptide antigen comprises a peptide of a tumor antigen. In certain other embodiments, the peptide antigen comprises a peptide of a protein from a pathogen including without limitation a bacterium, a virus, a fungus and a parasite. In further embodiments, the peptide antigen comprises a peptide of a tumor antigen. In certain particular embodiments, the *B2M*^{-/-} cell expresses a single chain fusion HLA class I protein that is covalently linked to a peptide that does not comprise an auto-antigen or neo-antigen to the patient. It is within the ability of a skilled person to design the single chain fusion HLA class I protein and the peptide antigen presented thereon to modulate the immune response that may be elicited in a recipient.

[0043] The isolated *B2M*^{-/-} cell expressing a single chain fusion HLA class I protein comprising a specific peptide antigen either covalently or non-covalently bound to the single chain fusion HLA class I protein can be used, for example, for administration to a recipient to elicit an immune response. Accordingly, in a related aspect, the invention provides a vaccine comprising the isolated cell of the invention, wherein the vaccine is capable of eliciting in a recipient an immune response specific for the target peptide antigen. The immune response includes without limitation a cellular immune response and/or a humoral immune response. The vaccine may comprise a stem cell or a differentiated cell; in certain particular embodiments, the cell is a differentiated dendritic cell. In certain other embodiments, the cell further expresses a cytokine. Any suitable cytokine can be used; in certain particular embodiments, the cytokine is IL2 or IFN- γ . In certain preferred embodiments, the cell is a human cell and the recipient is a human.

[0044] The single chain fusion HLA class I protein can be expressed from an expression vector that allows either transient or more preferably, stable expression of the protein in a *B2M*^{-/-} cell. Exemplary suitable expression vectors are known in the art. One such example is a retroviral vector, which is capable of integrating into the cellular genome to provide long-term, stable expression of an exogenous gene. In certain particular embodiments, the viral vector is derived from human foamy virus, a type of retrovirus. Other suitable viral vectors include without limitation vectors derived from retrovirus, adenoviral virus, adeno-associated virus, lentivirus, herpes simplex virus, vaccinia virus, and pox virus.

[0045] In certain preferred embodiments, the polynucleotide capable of encoding a single chain fusion HLA class I protein is integrated into the chromosome of the cells, preferably into the *B2M* or the *HLA* loci, for stable expression. Thus, in certain preferred embodiments, the *B2M* loci are disrupted by inserting in the *B2M* loci the polynucleotide capable of encoding a single chain fusion HLA class I protein to replace the expression of the endogenous wild type *B2M* protein. The result of such gene targeting disrupts normal *B2M* expression and precludes formation of wild type HLA class I proteins but permits expression of a predetermined single chain fusion HLA class I protein of choice on the surface of the otherwise *B2M* deficient cells. Other expression vectors are also contemplated and the selection of suitable expression vector is within the ability of one ordinary skill in the art.

[0046] According to the vector design, the polynucleotide capable of expressing a single chain fusion HLA class I protein is delivered to a cell by viral infection (when a viral vector is used) or by other delivery methods including without limitation transfection, electroporation, gene targeting or liposome-mediated DNA delivery.

[0047] Any immune effects of the single chain fusion HLA class I protein expressing *B2M*^{-/-} cells can be studied by various means. For example, *B2M*^{-/-} cells expressing a SC fusion HLA class I protein can be differentiated into antigen-presenting dendritic cells (iDCs). Suppression of NK cell-mediated lysis can be measured by chromium release assays after incubating iDCs with normal human NK cells and NKL cell lines. A variety of controls (untransduced *B2M*^{-/-} iDCs, *B2M*^{+/+} iDCs, the 721.221 class I-negative cell line, and anti-receptor and anti-HLA antibodies) can be used to establish the specificity of the interactions. Additional characterization can be done with Elispot assays by incubating the cells with T cells.

[0048] In a related aspect, the invention provides an HLA class I-typed *B2M*^{-/-} cell bank, wherein the cells of the cell bank comprise a *B2M*^{-/-} genetic background and are engineered to express one or more types of single chain fusion HLA class I proteins in which the HLA α chain is selected from the group consisting of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F and HLA-G. In certain embodiments, the cell bank comprises a population of cells that expresses a single chain fusion HLA class I protein in which the HLA α chain comprises HLA-A. In certain other embodiments, the cell bank comprises a population of cells that expresses a single chain fusion HLA class I protein in which the HLA α chain comprises HLA-B. In certain further embodiments, the cell bank comprises a population of cells that expresses a single chain fusion HLA class I protein in which the HLA α chain comprises HLA-C. In yet other embodiments, the cell bank comprises a population of cells that expresses a single chain fusion HLA class I protein in which the HLA α chain comprises HLA-E. In certain other embodiments, the cell bank comprises a population of cells that expresses a single chain fusion HLA class I protein in which the HLA α chain comprises HLA-F. In certain particular embodiments, the cell bank comprises a population of cells that expresses a single chain fusion HLA class I protein in which the HLA α chain comprises HLA-G. In certain particular embodiments, the cell bank comprises the above-described one or more or preferably all populations of cells.

[0049] The cells of the cell bank can be pluripotent stem cells or differentiated cells. In certain particular embodiments, the cell bank comprises different types of differentiated cells, such as skin cells, pancreatic beta islet cells, etc., that express the same single chain fusion HLA class I protein. While in other particular embodiments, the cell bank comprises

different types of differentiated cells, such as skin cells, pancreatic beta islet cells, etc., that each express different single chain fusion HLA class I proteins. It can be determined by a skilled researcher or clinician to choose suitable donor cells from the cell bank for a given patient. In certain other embodiments, some of the cells of the cell bank express the HLA class I allele that matches the HLA class I allele of the patient to whom the cells are administered. In certain preferred

embodiments, the cell is a human cell and the patient is a human. In certain particular embodiments, the cells express a single chain fusion HLA class I protein comprising B2M and HLA-A0201 that matches the HLA allele of a large portion of the population in the United States.

[0050] Furthermore, a method of transplantation in a patient in need thereof is disclosed comprising the step of administering to the patient an effective amount of the disclosed cells for transplantation. In yet another aspect, the invention provides an inventive cell for use in transplantation in a patient in need thereof, whereby the cell is administered to the patient in an effective amount, wherein

- a. the cell is a differentiated cell;
- b. the patient is human and the cell is a human cell; and/or
- c. the cell further expresses a single chain fusion HLA class I protein.

Because the *B2M*^{-/-} cells do not express wild type HLA class I protein on the cell surface, the cells when administered to a patient elicit minimal or no immune responses in the patient. Thus, transplantation using the *B2M*^{-/-} cells limits the need for taking immune suppressant therapies. Thus, in disclosed preferred embodiments, the patient is immune competent. In certain other embodiments, the cell is an isogeneic cell; while in other embodiments, the cell is an allogeneic cell.

[0051] In certain further embodiments, the cells of the invention are pluripotent stem cells; while in other embodiments, the cells of the invention are differentiated cells. In certain preferred embodiments, the cell is a human cell and the patient is a human patient. In certain particular embodiments, the inventive cell for use in transplantation comprises administering to a human an effective amount of the pluripotent stem cells or differentiated cells. In certain preferred embodiments, the cells of the invention further express one or more engineered single chain fusion HLA class I proteins. In certain other embodiments, the cells are able to escape NK cell-mediated killing and elicit minimal or no immune response in the recipient after transplantation.

[0052] Transplantation therapy, replacement therapy or regenerative therapy refers to therapies for a disease condition by administering to a patient cells or tissues to replenish or replace defective cellular functions in a target organ. In certain particular embodiments, the need for transplantation arises as a result of physical or pathological injuries to a tissue or organ. In certain other particular embodiments, the need for transplantation arises as a result of one or more genetic defect or mutation in the patient and the inventive cell for use in transplantation replenishes or replaces defective cellular functions in the patient without the need for gene therapy to correct the underlying genetic mutation of the patient. In certain further embodiments, inventive cell for use in the transplantation includes without limitation hematopoietic stem cell for use in transplantation, or cells for use in transplantation that are incorporated into an organ such as liver, kidney, pancreas, lung, brain, muscle, heart, gastrointestinal tract, nervous system, skin, bones, bone marrow, fat, connective tissue, immune system, or blood vessels. In certain particular embodiments, the target organ is a solid organ.

[0053] In certain particular embodiments, the cells administered to the recipient may or may not be incorporated into an organ in need of such therapy. In certain embodiments, the cells of the invention for use in transplantation are differentiated into the desired cell type, either before or after their use in transplantation, and provide the necessary cellular function without itself being incorporated into the tissue at the site of transplantation. For example, in certain embodiments for treating diabetes, the cells of the invention for use in transplantation either as pluripotent stem cells or differentiated pancreatic beta islet cells are used to be transplanted to a diabetic patient. The transplanted cells need not reconstitute a functioning pancreas: they just need to secrete insulin in response to glucose levels. In certain particular embodiments, the cells for use in transplantation are transplanted into an ectopic location and are not fully incorporated into the pancreas. Pluripotent cells of the invention for use in transplantation, differentiated cells of the invention for use in transplantation, or a tissue differentiated and developed *ex vivo* from the cells of the invention for use in transplantation are all contemplated by the invention. In certain preferred embodiments, the cell is a human cell and the patient is a human patient. In certain other preferred embodiments, the cells of the invention express one or more single chain fusion HLA class I proteins.

[0054] In a further aspect, the invention provides a cell for use in treating a disease condition in a patient in need thereof comprising the step of administering to the patient an effective amount of the cell of the invention to treat the disease condition, wherein the disease condition is diabetes, an autoimmune disease, cancer, infection, anemia, cytopenia, myocardial infarction, heart failure, skeletal or joint condition, osteogenesis imperfecta or burns. In certain particular embodiments, the disease condition results from pathological or physical injuries to a tissue or organ. In certain embodiments, the cells of the invention are stem cells; while in other embodiments, the cells of the invention are differentiated cells. In certain preferred embodiments, the cell is a human cell and the patient is a human patient. In certain particular embodiments, the human cell is a differentiated cell. A tissue developed *ex vivo* from the cells of the invention for use

in transplantation is also contemplated by the invention. In certain preferred embodiments, the cells of the invention further express one or more single chain fusion HLA class I proteins. In certain embodiments, the cell is an isogeneic cell; while in other embodiments, the cell is an allogeneic cell.

[0055] In certain particular embodiments, the cell is a differentiated cell including without limitation a dendritic cell, lymphocyte, red blood cell, platelet, hematopoietic cell, pancreatic islet cell, liver cell, muscle cell, keratinocyte, cardiomyocyte, neuronal cell, skeletal muscle cell, ocular cell, mesenchymal cell, fibroblast, lung cell, GI tract cell, vascular cell, endocrine cell and adipocyte. In certain other particular embodiments, the invention provides a cell of the invention for use in treating a disease condition in a solid organ. In certain embodiments, the cells of the invention used in treating a disease condition express one or more single chain fusion HLA class I proteins.

[0056] "Treating" a patient having a disease or disorder means accomplishing one or more of the following: (a) reducing the severity of the disease; (b) arresting the development of the disease or disorder; (c) inhibiting worsening of the disease or disorder; (d) limiting or preventing recurrence of the disease or disorder in patients that have previously had the disease or disorder; (e) causing regression of the disease or disorder; (f) improving or eliminating the symptoms of the disease or disorder; and (f) improving survival. In certain preferred embodiments, the disease or disorder is a disease or disorder that can be treated by a cell of the invention for use in transplantation.

[0057] The effective amount of the isolated cells of the invention for use in transplantation or for use in treating a disease condition depends on a number of factors, such as the type of tissue, the severity of the disease condition, the transplantation reaction, the reason for transplantation, and the age and general health of the patient. The effective amount can be determined by a skilled researcher or clinician by routine practice. Due to the reduced immunogenicity of the transplanted cells, relative large amount of cells can be tolerated by a patient to achieve the desired therapeutic effects. Alternatively, the cells can be repeatedly transplanted at intervals until a desired therapeutic effect is achieved.

[0058] The route for administration of the cells of the invention is not limited in any particular way. Exemplary delivery routes include without limitation intravenous, intramuscular, subdermal, intraperitoneal, transcutaneous, intracutaneous, and subcutaneous route. The cells of the present invention can also be administered topically by injection. For example, the cells can be injected into an injured joint, a fractured bone, an infarct site, an ischemic site or their periphery.

[0059] In certain particular embodiments, the cells are administered via a delivery device including without limitation a syringe. For example, the cells can be suspended in a solution or a pharmaceutical composition contained in such a delivery device. The "solution" or "pharmaceutical composition" comprises a physiological compatible buffer and optionally a pharmaceutically acceptable carrier or diluent in which the cells of the invention remain viable. The use of such carriers and diluents is well known in the art. The solution includes without limitation physiologically compatible buffers such as Hank's solution, Ringer' solution, or physiologically buffered saline. The cells can be kept in the solution or pharmaceutical composition for short term storage without losing viability. In certain particular embodiments, the cells are frozen for long term storage without losing viability according to cryopreservation methods well-known in the art.

[0060] Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran, but still fluid to the extent that can be easily delivered by syringe injection. The solution is preferably sterile, stable under the conditions of manufacture and storage and is free of micro-organism contamination through the use of, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. The cells contained in the solution can be stem cells or differentiated cells as described herein, in a pharmaceutically acceptable carrier or diluent and, as required, other ingredients indicated above.

[0061] The cells may be administered systemically (e.g., intravenously) or locally (e.g., directly into a myocardial defect under the guidance of echocardiogram, or by direct application to damaged tissues or organs accessible during open surgery). For injections, the cells may be in an injectable liquid suspension preparation or in a biocompatible medium which is injectable in liquid form and becomes semi-solid at the site of damaged tissue. A syringe, a controllable endoscopic delivery device or other similar devices can be used so long as the needle lumen is of sufficient diameter (e.g. at least 30 gauge or larger) to avoid physical damages to the cells during delivery.

[0062] In certain other embodiments, the cells for use in transplantation can be transplanted via a solid support, e.g., a planar surface or three-dimensional matrix. The matrix or planar surface is surgically implanted into the appropriate site in a patient. For example, a patient needing a pancreatic graft can have differentiated cells on a solid support surgically implanted in the pancreas tissue. Exemplary solid support includes without limitation a patch, a gel matrix (such as GELFOAM® from Pharmacia-Upjohn), polyvinyl alcohol sponge (PVA)-collagen gel implants (such as IVALON, Unipoint Industries, High Point, NC) and other similar or equivalent devices. A variety of other encapsulation technologies can be used with the cells of the invention, for example, WO 91/10470; WO 91/10425; U.S. Pat. No. 5,837,234; U.S. Pat. No. 5,011,472; U.S. Pat. No. 4,892,538).

[0063] The cells of the invention can be differentiated into various cell types of all three lineages, including without limitation hematopoietic, mesenchymal, pancreatic endoderm, cardiac and keratinocytes cells. In certain embodiments, the differentiated cell further expresses a single chain fusion HLA class I protein. In general, each cell type can be analyzed for HLA class I protein expression, reactivity with human T cells and NK cells, appropriate differentiation markers, and xenotransplantation in immunodeficient mice to examine *in vivo* developmental potential. See Figure 4. A

brief discussion of each differentiated cell type follows.

[0064] In certain embodiments, the cells of the invention can be differentiated to hematopoietic cells for the use in treating various hematopoietic diseases currently treated by bone marrow transplantation. Patients receiving transfusion can become refractory to platelet transfusions due to HLA mismatches. Anemic or cytopenic patients can be treated by

delivering the cells of the invention-derived erythrocytes, platelets or neutrophils to treat bleeding or infection.

[0065] Further, stem cells of the invention-derived dendritic cells are antigen-presenting cells that can be used as cellular vaccines when properly engineered. In certain embodiments, the cells of the invention engineered to express a single chain fusion HLA class I protein and a unique peptide antigen are used to vaccinate against specific pathogen or tumor antigens. In certain other embodiments, differentiated *B2M*^{-/-} cytotoxic lymphocytes with HLA-restricted reactivity against specific antigens are used to eliminate infected cells or tumor cells.

[0066] To obtain hematopoietic cells, the pluripotent cells are first allowed to form embryoid bodies, thereafter non-adherent cells were cultured in the presence of hematopoietic cytokines to develop into specific cell lineages. The differentiation of hematopoietic cells from the cells of the invention that express a single chain fusion HLA class I protein expressers can be analyzed by flow cytometry and colony assays. The different cell populations are sorted based on their surface markers, and used to monitor the expression of HLA genes and reactivity with human NK cells and T cells as measured by Elispot, mixed lymphocyte reactions, and cytotoxicity assays. The effectiveness of the single chain fusion HLA constructs on suppression of NK cell-mediated killing can be examined at different stages of differentiation and transplantation. See Bix et al., 1991, *Nature* 349, 329-331. The hematopoietic stem cells can also be assayed using xenotransplantation models in, for example, immunodeficient mice (SCID-repopulating cells or SRCs).

[0067] The cells of the invention can be differentiated into hematopoietic cell either before or after the cells are administered to a patient. In certain preferred embodiments, the cell is a human cell and the patient is a human. *In vitro* hematopoietic differentiation can be performed according to established protocols. See for example, Slukvin et al., 2006, *J Immunol* 176:2924-32, and Chang et al., 2006, *Blood* 108:1515-23.

[0068] In certain other embodiments, the cells of the invention can be differentiated into mesenchymal stem cells. In certain embodiments, the cells of the invention express one or more single chain fusion HLA class I proteins. MSCs have the potential to form several differentiated cell types, including marrow stromal cells, adipocytes, osteoblasts, and chondrocytes. Thus, inducing pluripotent stem cells to form MSCs (iMSCs) is useful in treating skeletal and joint conditions. The iMSCs can be further differentiated into osteoblasts and formed bone *in vivo*. Deyle et al., 2012, *Mol Ther.* 20(1):204-13. Cellular responses of T cells and NK cells to ESCs, iMSCs, and their more terminally differentiated derivatives such as osteoblasts can be examined.

[0069] In certain particular embodiments, the mesenchymal stem cells are capable of differentiating into non-limiting examples of cell types such as marrow stromal cells, adipocytes, osteoblasts, osteocytes and chondrocytes. The cells of the invention are differentiated into mesenchymal stem cells either before or after the cells are administered to a patient. In certain preferred embodiments, the cell is a human cell and the patient is a human. *In vitro* mesenchymal differentiation can be performed according to established protocols. See for example, Deyle et al., *supra*.

[0070] In yet other particular embodiments, the cells of the invention can be differentiated into insulin-producing pancreatic islet cells. In certain embodiments, the cells of the invention express one or more single chain fusion HLA class I proteins. The cells of the invention can be used to treat insulin-dependent diabetes mellitus. Advantageously, the transplanted cells do not need to reconstitute a functioning pancreas: they just need to secrete insulin in response to glucose levels. Therefore the treatment can succeed with different cell doses, with cells that are not perfectly differentiated into adult cell types, and when cells are transplanted into an ectopic location. Specific auto-antigens such as those derived from GAD65 or Insulin can cause autoimmune destruction of β cells in diabetes (Di Lorenzo et al., 2007, *Clin Exp Immunol* 148, 1-16). Thus, *B2M*^{-/-} cells or *B2M*^{-/-} cells expressing a single chain fusion HLA class I protein presenting a predetermined peptide antigen provide additional advantages in that they do not present these auto-antigens and can avoid autoimmune rejection and prevent a relapse of diabetes after transplantation.

[0071] The cells of the invention can be differentiated into pancreatic cells as described previously, which employs exposure of cells to different cytokines and drugs to promote sequential formation of mesendoderm, definitive endoderm, and pancreatic progenitors (Kroon et al., 2008, *Nat Biotechnol* 26, 443-452). These cells can be further cultured in implants in immunodeficient mice. The cells of the invention with or without expressing a single chain fusion HLA class I protein and wild-type cell lines can be analyzed at different developmental stages for their reactivity with T cells and NK cells.

[0072] The cells of the invention are differentiated into pancreatic islet cell either before or after patient administration. In certain preferred embodiments, the cell is a human cell and the patient is a human. *In vitro* hematopoietic differentiation can be performed according to established protocols. See for example, Kroon et al., 2008, *Nat Biotechnol* 26, 443-452.

[0073] In certain other particular embodiments, the cells of the invention can be differentiated into cardiomyocytes. In certain embodiments, the cells of the invention further express one or more single chain fusion HLA class I proteins. The common clinical problems of myocardial infarction and congestive heart failure can be treated by transplanting healthy stem cell-derived cardiomyocytes that engraft and re-establish functional myocardium. The use of cells of the

invention-derived cardiomyocytes allow these treatments to proceed with pre-packaged cells and avoid the immunosuppression currently required for allogeneic heart transplants. Physiologically relevant tests can be performed on the cardiomyocytes derived from the cells of the invention, such as electrical conduction and contraction studies. *B2M*^{-/-} stem cells or differentiated cardiomyocytes with or without expressing a single chain fusion HLA class I protein can be tested to determine their immunological reactivity when expressing cardiomyocyte genes, and to establish which HLA modifications minimize these immune responses.

[0074] The cells of the invention can be differentiated into cardiomyocytes either before or after the cells are administered to a patient. In certain preferred embodiments, the cell is a human cell and the patient is a human. In certain embodiments, the cells of the invention are differentiated into cardiomyocytes for the use in treating diseases including without limitation myocardial infarction and congestive heart failure. *In vitro* cardiomyocyte differentiation can be performed according to established protocols. See for example, Laflamme et al., 2007, Nat Biotechnol 25, 1015-1024.

[0075] In yet other particular embodiments, the cells of the invention can be differentiated into keratinocytes. In certain embodiments, the cells of the invention used for differentiation into keratinocytes express one or more single chain fusion HLA class I proteins. Severe burns and genetic skin conditions require treatment with skin grafts, and this is currently done with a variety of cell sources such as porcine skin grafts and cultured autologous human keratinocytes. Keratinocytes derived from the cells of the invention can provide a major clinical advance, since burns could be treated as an emergency with pre-packaged cells, and genetic diseases such as epidermolysis bullosa can be treated with normal cells (albeit with the *B2M*^{-/-} background in the cellular chromosome) that do not require correction of the responsible genetic mutations. In many cases the cells only need to engraft long enough for neighboring host cells to repopulate the affected area. Figure 5 shows *in vitro* differentiation of Keratin 5+ and Keratin 14+ keratinocyte colonies from the cells of the invention. The cells of the invention were cultured in matrigel cultures, followed by expansion in serum-free keratinocyte medium containing all-trans retinoic acid and BMP4 as described previously (Itoh et al., 2011, PNAS USA 108, 8797-8802). For *in vivo* differentiation, the cells of the invention for use in transplantation can be embedded in polyvinyl alcohol sponge (PVA)-collagen gel implants for transplantation into a recipient. The cells of the invention can be differentiated into keratinocytes either before or after transplantation. In certain preferred embodiments, the cell is a human cell and the patient is a human.

[0076] In yet another aspect, the invention provides a use of the cells of the invention for the preparation for a medicament for transplantation. In a related aspect, the invention provides a use of the cells of the invention for the preparation for a medicament for treating a disease condition.

[0077] Further, the cells of the invention can serve as a research tool to provide a system for studying the functions of immunoregulatory proteins in a *B2M*^{-/-} genetic background. In certain embodiments, the cells of the invention further express one or more single chain fusion HLA class I proteins. Accordingly, in a related aspect, the invention provides a method of determining the function of an immunoregulatory protein comprising the steps of introducing one or more immunoregulatory genes into the cells of the invention and assaying for the activities of the immunoregulatory genes. In certain preferred embodiments, the cell is a human cell. For example, the cells of the invention can be used to study the function of an immune regulatory gene, or to study an immune response, in the absence of unwanted class I antigens. In certain embodiments, the cells of the invention express HLA-F or a single chain fusion HLA class I protein comprising B2M and HLA-F, wherein the function of the HLA-F can be studied in the *B2M*^{-/-} background. In a further related aspect, the invention provides a method of identifying a compound or molecule that modulates the function of the immunoregulatory protein comprising the steps of contacting the *B2M*^{-/-} cells comprising the one or more immunoregulatory genes with a compound or molecule of interest and assaying for the activities of the immunoregulatory genes. In certain preferred embodiments, the cell is a human cell.

[0078] In yet another related aspect, the invention provides an *in vivo* research tool in a mammal, particular in a non-human primate, that are administered the cells of the invention, for studying the functions of immunoregulatory genes, or identifying a compound that modulates the function of an immunoregulatory gene in the administered cells in a *B2M*^{-/-} genetic background. In certain embodiments, the cells of the invention further express one or more single chain fusion HLA class I proteins.

[0079] Mice, especially immune deficient mice, have been used as a model system for studying human cells *in vivo*. Human stem cells can behave differently in mice. In addition, the mouse and human immune systems have different NK cell receptors and non-classical MHC class I genes (e.g. HLA-E, F and G). Therefore, a *Macaca nemestrina* (Mn, pigtailed macaque) model can be developed to study the cells of the invention. The *Macaca mulatta* genome has been sequenced, which is highly homologous to the *nemestrina* genome. Further, the organization of macaque MHC loci is similar to human HLA, including the non-classical genes. Homologs of the human HLA-E and HLA-G genes have been identified in macaques. The macaque MHC loci also contain homologs of many human NK cell receptors. Human *B2M*^{-/-} ESCs as well as Mn *B2M*^{-/-} ESCs can be used for transplantation in macaques.

[0080] MHC class I-deficient (*B2M*^{-/-}) macaque ESCs can be developed using the same AAV-mediated gene targeting strategy described for human cells. Mn versions of the single-chain HLA class I fusion proteins are expressed in the *B2M*^{-/-} macaques ESCs using the analogous viral vectors as described above.

[0081] Cells can be expanded *in vitro* and labeled with a vector expressing GFP for subsequent identification of transplanted cells. The cells can be embedded in polyvinyl alcohol sponge (PVA)-collagen gel implants, and placed subdermally into macaques. The implants can be harvested, sectioned and stained to determine the cell types that are present. Specific antibodies can be used to identify the differentiated cell types formed by the transplanted cells.

[0082] Any and every embodiment described above applies to any and every aspect of the invention, unless the context clearly indicates otherwise. All embodiments within and between different aspects can be combined unless the context clearly dictates otherwise.

[0083] The Examples, which follow, are illustrative of specific embodiments of the invention, and various uses thereof. They are set forth for explanatory purposes only, and are not to be taken as limiting the invention.

EXAMPLES

Reference Example 1 Construction of Human Pluripotent Stem Cells with Knockout Mutations in B2M Genes

[0084] Human pluripotent stem cells were created with knockout mutations in both alleles of the beta-2 microglobulin (*B2M*) genes that encodes the common subunit required for surface expression of all HLA class I heterodimers (HLA-A, B, C, E, F and G). Adeno-associated virus (AAV) gene targeting vectors were used to construct *B2M*^{-/-} (class I-negative) H1 human ESCs (University of Wisconsin). Human pluripotent stem cells were infected with AAV gene targeting vectors and the *B2M* gene was inactivated by homologous recombination. AAV mediated gene targeting methodology has been described previously in for example, Khan et al., 2011, Protocol, 482:482-501 and Khan et al., 1990, Science 248:1227-30.

[0085] Figure 1 describes the construction of HLA class I-negative human H1 ESCs cells using the adeno-associated virus (AAV) gene targeting vectors. The two AAV vectors used contain homologous arms surrounding exon 1 of the human *B2M* gene, and are designed to insert either a *TKNeo* or *HyTK* fusion gene encoding G418 or hygromycin resistance respectively into exon 1 (Figure 1A). The H1 ESCs were infected with the AAV-B2M-ETKNpA vector and 30% of G418-resistant cells were targeted at one *B2M* allele based on Southern blot analysis. One of these clones was then infected with the AAV-B2M-EHyTKpA vector and 10% of hygromycin-resistant cells were targeted at *B2M*. Southern blot analysis of a representative clone that had deletions in both *B2M* alleles (*B2M*^{-/-}) is shown in Figure 1B (HyTK/TKN). None of the targeted clones analyzed contained random integrants. The sequences of the targeting vector plasmid pA2-B2METKmpA and pA2-B2MEHuTKpA are shown in SEQ ID NO:21 and SEQ ID NO:22, respectively.

[0086] Cre recombinase was then used to remove the floxed *TKNeo* and *HyTK* transgenes from the *B2M* loci. Cre was delivered transiently by a non-integrating foamy virus vector, which is a type of retroviral vector previously described that efficiently infects human ESCs. See Deyle, et al., 2010, J. Virol 84, 9341-9 and Gharwan et al., 2007, Mol Ther 15, 1827-1833. Four clones lacking the *TKNeo* and *HyTK* transgenes were selected by gancyclovir selection that kills cells expressing thymidine kinase (TK). The results shown by Southern blot analysis demonstrated transgene-free double knockouts (Figure 1B).

[0087] Karyotypes were checked on two of these clones and found to be normal (data not shown), and teratoma assays conducted in immunodeficient mice showed that these cells had trilineage developmental potential (Figure 2). Flow cytometry with antibodies against B2M (anti-B2M-01- PE from SantaCruz Biotechnology) and pan-HLA class I antigens (W6/32 from Sigma-Aldrich) confirmed that these cells did not express HLA class I proteins on the cell surface (Figure 1C).

Reference Example 2 Expression of Single Chain Fusion HLA class I Proteins in B2M Knockout Cells

[0088] In mice, HLA class I-negative cells can be destructed by Natural Killer (NK) cells through the "missing self" mechanism. Bix et al., 1991, Nature 349, 329-331. Human NK cells have different receptors, but an analogous inhibition of NK cell killing is mediated through interactions of NK cell receptors with HLA-C, E and G. The "missing self" phenomenon has largely been described for class I-deficient hematopoietic cells, and the mouse transplantation data reported previously showing that many types of *B2M*^{-/-} organs survived in *B2M*^{+/+} hosts suggests that it may be less important when transplanting cells form solid organs. However, given that it could significantly affect donor cell survival in some settings, specific HLA class I genes as single chain fusion proteins that suppress NK cell killing were introduced to the *B2M*^{-/-} cells.

[0089] The strategy for expressing specific HLA class I genes in a *B2M*^{-/-} background is shown in Figure 3. The B2M chain was fused to the specific HLA class I heavy chain, thereby allowing surface expression of the class I chain even in *B2M*^{-/-} cells. Integrating foamy virus vectors were used to express these single chain fusion proteins. Foamy virus vectors are a type of retroviral vector with a large packaging capacity that can efficiently infect human pluripotent stem cells (Gharwan *et al.*, *supra*). One such representative single chain fusion HLA class I protein foamy virus construct is shown in Figure 3A. The Δ P-EGP-PHLA-SC foamy vectors included a GFP-Puro fusion protein gene driven by an EF1 alpha promoter to allow for puromycin selection and GFP expression in transduced cells, and a separate expression

cassette with a ubiquitously expressed PGK promoter driving an HLA single chain fusion (HLA-SC) construct (Figure 3A). The vector design produced constitutive expression of both transgenes, but many other vector designs and internal promoters can also be used. For example, the GFP-Pur gene can be driven by the pGK promoter, and the EF1 alpha promoter controls the expression of the SC HLA gene.

[0090] As shown in Figure 3B, the HLA-bGBE trimeric single chain fusion construct included a covalently attached HLA-G peptide (SEQ ID NO:23) in the HLA-E peptide binding cleft, while the HLA-gBE dimeric construct included an HLA-G signal peptide that was cleaved off but still bound non-covalently to the HLA-E molecule. See Crew et al., 2005, Mol Immunol 42, 1205-1214. *B2M*^{-/-} cells were transduced with these vectors. Puromycin-resistant clones were selected and HLA-E surface expression was analyzed by flow cytometry in pluripotent cells expressing these constructs (Figure 3C).

[0091] Further, a specific classical HLA class I allele single chain fusion protein was constructed and expressed in *B2M*^{-/-} H1 ESCs to create a "semi-universal" donor cell to facilitate compatibility with recipients. For example, in the U.S. the HLA-A0201 allele is present in 48% of Caucasians, 46% of Hispanics, and 24% of African-Americans, all of which should accept HLA-A0201+ stem cells. See www.allelfrequencies.net and Storkus et al., 1989, PNAS USA 86:2361-2364. The HLA-bBA0201 dimeric single chain fusion construct was introduced in *B2M*^{-/-} H1 ESCs by foamy virus vectors (Figure 3B) and the expression of the single chain fusion protein was analyzed by flow cytometry (Figure 3D).

SEQUENCE LISTING

[0092]

<110> University of Washington Russell, David W

<120> Beta-2 Microglobulin-Deficient Cells

<130> 11-442-PCT

<150> 61/477474

<151> 2011-04-20

<160> 23

<170> PatentIn version 3.5

<210> 1

<211> 987

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (61)..(420)

<400> 1

EP 2 699 593 B1

	aatataagtg gaggcgtcgc gctggcgggc attcctgaag ctgacagcat tcgggccgag	60
5	atg tct cgc tcc gtg gcc tta gct gtg ctc gcg cta ctc tct ctt tct Met Ser Arg Ser Val Ala Leu Ala Val Leu Ala Leu Leu Ser Leu Ser 1 5 10 15	108
10	ggc ctg gag gct atc cag cgt act cca aag att cag gtt tac tca cgt Gly Leu Glu Ala Ile Gln Arg Thr Pro Lys Ile Gln Val Tyr Ser Arg 20 25 30	156
15	cat cca gca gag aat gga aag tca aat ttc ctg aat tgc tat gtg tct His Pro Ala Glu Asn Gly Lys Ser Asn Phe Leu Asn Cys Tyr Val Ser 35 40 45	204
20	ggg ttt cat cca tcc gac att gaa gtt gac tta ctg aag aat gga gag Gly Phe His Pro Ser Asp Ile Glu Val Asp Leu Leu Lys Asn Gly Glu 50 55 60	252
25	aga att gaa aaa gtg gag cat tca gac ttg tct ttc agc aag gac tgg Arg Ile Glu Lys Val Glu His Ser Asp Leu Ser Phe Ser Lys Asp Trp 65 70 75 80	300
30	tct ttc tat ctc ttg tac tac act gaa ttc acc ccc act gaa aaa gat Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu Lys Asp 85 90 95	348
35	gag tat gcc tgc cgt gtg aac cat gtg act ttg tca cag ccc aag ata Glu Tyr Ala Cys Arg Val Asn His Val Thr Leu Ser Gln Pro Lys Ile 100 105 110	396
40	gtt aag tgg gat cga gac atg taa gcagcatcat ggaggtttga agatgccgca Val Lys Trp Asp Arg Asp Met 115	450
45	tttggattgg atgaattcca aattctgctt gcttgctttt taatattgat atgcttatac	510
50	acttacactt tatgcacaaa atgtaggggtt ataataatgt taacatggac atgatcttct	570
55	ttataattct actttgagtg ctgtctccat gtttgatgta tctgagcagg ttgctccaca	630
60	ggtagctcta ggagggctgg caacttagag gtggggagca gagaattctc ttatccaaca	690
65	tcaacatctt ggtcagattht gaactcttca atctcttgca ctcaaagctt gttaagatag	750
70	ttaagcgtgc ataagttaac ttccaattta catactctgc ttagaatttg ggggaaaatt	810
75	tagaaatata attgacagga ttattggaaa tttgttataa tgaatgaaac attttgtcat	870
80	ataagattca tatttacttc ttatacattt gataaagtaa ggcatggttg tgggttaatct	930
85	ggtttatttt tgttccacaa gttaaataaaa tcataaaaact tgatgtgtta tctctta	987
90	<210> 2	
95	<211> 119	
100	<212> PRT	
105	<213> Homo sapiens	
110	<400> 2	

EP 2 699 593 B1

	Met	Ser	Arg	Ser	Val	Ala	Leu	Ala	Val	Leu	Ala	Leu	Leu	Ser	Leu	Ser
	1				5					10					15	
5	Gly	Leu	Glu	Ala	Ile	Gln	Arg	Thr	Pro	Lys	Ile	Gln	Val	Tyr	Ser	Arg
				20					25					30		
10	His	Pro	Ala	Glu	Asn	Gly	Lys	Ser	Asn	Phe	Leu	Asn	Cys	Tyr	Val	Ser
			35					40					45			
15	Gly	Phe	His	Pro	Ser	Asp	Ile	Glu	Val	Asp	Leu	Leu	Lys	Asn	Gly	Glu
		50					55					60				
20	Arg	Ile	Glu	Lys	Val	Glu	His	Ser	Asp	Leu	Ser	Phe	Ser	Lys	Asp	Trp
	65					70					75					80
25	Ser	Phe	Tyr	Leu	Leu	Tyr	Tyr	Thr	Glu	Phe	Thr	Pro	Thr	Glu	Lys	Asp
					85					90					95	
30	Glu	Tyr	Ala	Cys	Arg	Val	Asn	His	Val	Thr	Leu	Ser	Gln	Pro	Lys	Ile
				100					105					110		
35	Val	Lys	Trp	Asp	Arg	Asp	Met									
				115												
40	<210> 3 <211> 1611 <212> DNA <213> Homo sapiens <220> <221> CDS <222> (85)..(1182) <400> 3															

EP 2 699 593 B1

	gagaagccaa tcagtgtcgt cgcggtcgct gttctaaagt ccgcacgcac ccaccgggac	60
5	tcagattctc cccagacgcc gagg atg gcc gtc atg gcg ccc cga acc ctc Met Ala Val Met Ala Pro Arg Thr Leu 1 5	111
10	ctc ctg cta ctc tcg ggg gcc ctg gcc ctg acc cag acc tgg gcg ggc Leu Leu Leu Leu Ser Gly Ala Leu Ala Leu Thr Gln Thr Trp Ala Gly 10 15 20 25	159
15	tcc cac tcc atg agg tat ttc ttc aca tcc gtg tcc cgg ccc ggc cgc Ser His Ser Met Arg Tyr Phe Phe Thr Ser Val Ser Arg Pro Gly Arg 30 35 40	207
20	ggg gag ccc cgc ttc atc gcc gtg ggc tac gtg gac gac acg cag ttc Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln Phe 45 50 55	255
25	gtg cgg ttc gac agc gac gcc gcg agc cag aag atg gag ccg ccg gcg Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Lys Met Glu Pro Arg Ala 60 65 70	303
30	ccg tgg ata gag cag gag ggg ccg gag tat tgg gac cag gag aca ccg Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Gln Glu Thr Arg 75 80 85	351
35	aat atg aag gcc cac tca cag act gac cga gcg aac ctg ggg acc ctg Asn Met Lys Ala His Ser Gln Thr Asp Arg Ala Asn Leu Gly Thr Leu 90 95 100 105	399
40	cgc ggc tac tac aac cag agc gag gac ggt tct cac acc atc cag ata Arg Gly Tyr Tyr Asn Gln Ser Glu Asp Gly Ser His Thr Ile Gln Ile 110 115 120	447
45	atg tat ggc tgc gac gtg ggg ccg gac ggg cgc ttc ctc cgc ggg tac Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Phe Leu Arg Gly Tyr 125 130 135	495
50	cgg cag gac gcc tac gac ggc aag gat tac atc gcc ctg aac gag gac Arg Gln Asp Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu Asp 140 145 150	543
55	ctg cgc tct tgg acc gcg gcg gac atg gca gct cag atc acc aag cgc Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr Lys Arg 155 160 165	591
60	aag tgg gag gcg gtc cat gcg gcg gag cag ccg aga gtc tac ctg gag Lys Trp Glu Ala Val His Ala Ala Glu Gln Arg Arg Val Tyr Leu Glu 170 175 180 185	639
65	ggc cgg tgc gtg gac ggg ctc cgc aga tac ctg gag aac ggg aag gag Gly Arg Cys Val Asp Gly Leu Arg Arg Tyr Leu Glu Asn Gly Lys Glu 190 195 200	687
70	acg ctg cag cgc acg gac ccc ccc aag aca cat atg acc cac cac ccc Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His His Pro 205 210 215	735
75	atc tct gac cat gag gcc acc ctg agg tgc tgg gcc ctg ggc ttc tac	783

EP 2 699 593 B1

	Ile	Ser	Asp	His	Glu	Ala	Thr	Leu	Arg	Cys	Trp	Ala	Leu	Gly	Phe	Tyr	
			220					225					230				
5	cct	gcg	gag	atc	aca	ctg	acc	tgg	cag	cgg	gat	ggg	gag	gac	cag	acc	831
	Pro	Ala	Glu	Ile	Thr	Leu	Thr	Trp	Gln	Arg	Asp	Gly	Glu	Asp	Gln	Thr	
		235					240					245					
10	cag	gac	acg	gag	ctc	gtg	gag	acc	agg	cct	gca	ggg	gat	gga	acc	ttc	879
	Gln	Asp	Thr	Glu	Leu	Val	Glu	Thr	Arg	Pro	Ala	Gly	Asp	Gly	Thr	Phe	
	250					255					260					265	
15	cag	aag	tgg	gcg	gct	gtg	gtg	gtg	cct	tct	gga	gag	gag	cag	aga	tac	927
	Gln	Lys	Trp	Ala	Ala	Val	Val	Val	Pro	Ser	Gly	Glu	Glu	Gln	Arg	Tyr	
					270					275					280		
20	acc	tgc	cat	gtg	cag	cat	gag	ggt	ctg	ccc	aag	ccc	ctc	acc	ctg	aga	975
	Thr	Cys	His	Val	Gln	His	Glu	Gly	Leu	Pro	Lys	Pro	Leu	Thr	Leu	Arg	
					285				290					295			
25	tgg	gag	ctg	tct	tcc	cag	ccc	acc	atc	ccc	atc	gtg	ggc	atc	att	gct	1023
	Trp	Glu	Leu	Ser	Ser	Gln	Pro	Thr	Ile	Pro	Ile	Val	Gly	Ile	Ile	Ala	
			300					305					310				
30	ggc	ctg	gtt	ctc	ctt	gga	gct	gtg	atc	act	gga	gct	gtg	gtc	gct	gcc	1071
	Gly	Leu	Val	Leu	Leu	Gly	Ala	Val	Ile	Thr	Gly	Ala	Val	Val	Ala	Ala	
			315				320					325					
35	gtg	atg	tgg	agg	agg	aag	agc	tca	gat	aga	aaa	gga	ggg	agt	tac	act	1119
	Val	Met	Trp	Arg	Arg	Lys	Ser	Ser	Asp	Arg	Lys	Gly	Gly	Ser	Tyr	Thr	
	330					335					340					345	
40	cag	gct	gca	agc	agt	gac	agt	gcc	cag	ggc	tct	gat	gtg	tct	ctc	aca	1167
	Gln	Ala	Ala	Ser	Ser	Asp	Ser	Ala	Gln	Gly	Ser	Asp	Val	Ser	Leu	Thr	
					350					355					360		
45	gct	tgt	aaa	gtg	tga	gacagctgcc	ttgtgtggga	ctgagaggca	agagttgttc								1222
	Ala	Cys	Lys	Val													
				365													
50	ctgcccttcc	ctttgtgact	tgaagaaccc	tgactttgtt	tctgcaaagg	cacctgcatg											1282
55	tgtctgtgtt	cgtgtaggca	taatgtgagg	aggtggggag	agcaccacccac	ccccatgtcc											1342
	accatgaccc	tcttcccacg	ctgacctgtg	ctccctctcc	aatcatcttt	cctgttccag											1402
	agagggtgggg	ctgagggtgtc	tccatctctg	tctcaacttc	atgggtgcact	gagctgtaac											1462
	ttcttcccttc	cctattataaaa	ttagaacctg	agtataaatt	tacttttctca	aattcttgcc											1522
	atgagagggtt	gatgagttaa	ttaaaggaga	agattcctaa	aatttgagag	acaaaattaa											1582
	tggaacgcat	gagaaccttc	cagagtcca														1611
	<210>	4															
	<211>	365															
	<212>	PRT															
	<213>	Homo sapiens															
	<400>	4															

EP 2 699 593 B1

Met Ala Val Met Ala Pro Arg Thr Leu Leu Leu Leu Leu Ser Gly Ala
1 5 10 15

5

10

15

20

25

30

35

40

45

50

55

EP 2 699 593 B1

	Leu	Ala	Leu	Thr	Gln	Thr	Trp	Ala	Gly	Ser	His	Ser	Met	Arg	Tyr	Phe	
				20					25					30			
5	Phe	Thr	Ser	Val	Ser	Arg	Pro	Gly	Arg	Gly	Glu	Pro	Arg	Phe	Ile	Ala	
			35					40					45				
10	Val	Gly	Tyr	Val	Asp	Asp	Thr	Gln	Phe	Val	Arg	Phe	Asp	Ser	Asp	Ala	
		50					55					60					
15	Ala	Ser	Gln	Lys	Met	Glu	Pro	Arg	Ala	Pro	Trp	Ile	Glu	Gln	Glu	Gly	
	65					70					75					80	
20	Pro	Glu	Tyr	Trp	Asp	Gln	Glu	Thr	Arg	Asn	Met	Lys	Ala	His	Ser	Gln	
					85					90					95		
25	Thr	Asp	Arg	Ala	Asn	Leu	Gly	Thr	Leu	Arg	Gly	Tyr	Tyr	Asn	Gln	Ser	
				100					105					110			
30	Glu	Asp	Gly	Ser	His	Thr	Ile	Gln	Ile	Met	Tyr	Gly	Cys	Asp	Val	Gly	
			115					120					125				
35	Pro	Asp	Gly	Arg	Phe	Leu	Arg	Gly	Tyr	Arg	Gln	Asp	Ala	Tyr	Asp	Gly	
		130					135					140					
40	Lys	Asp	Tyr	Ile	Ala	Leu	Asn	Glu	Asp	Leu	Arg	Ser	Trp	Thr	Ala	Ala	
	145					150					155					160	
45	Asp	Met	Ala	Ala	Gln	Ile	Thr	Lys	Arg	Lys	Trp	Glu	Ala	Val	His	Ala	
					165					170					175		
50	Ala	Glu	Gln	Arg	Arg	Val	Tyr	Leu	Glu	Gly	Arg	Cys	Val	Asp	Gly	Leu	
				180					185					190			
55	Arg	Arg	Tyr	Leu	Glu	Asn	Gly	Lys	Glu	Thr	Leu	Gln	Arg	Thr	Asp	Pro	
			195				200						205				
60	Pro	Lys	Thr	His	Met	Thr	His	His	Pro	Ile	Ser	Asp	His	Glu	Ala	Thr	
		210					215					220					
65	Leu	Arg	Cys	Trp	Ala	Leu	Gly	Phe	Tyr	Pro	Ala	Glu	Ile	Thr	Leu	Thr	
	225					230					235					240	
70	Trp	Gln	Arg	Asp	Gly	Glu	Asp	Gln	Thr	Gln	Asp	Thr	Glu	Leu	Val	Glu	
				245						250					255		
75	Thr	Arg	Pro	Ala	Gly	Asp	Gly	Thr	Phe	Gln	Lys	Trp	Ala	Ala	Val	Val	

EP 2 699 593 B1

260

265

270

5

Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln His Glu
275 280 285

10

Gly Leu Pro Lys Pro Leu Thr Leu Arg Trp Glu Leu Ser Ser Gln Pro
290 295 300

15

Thr Ile Pro Ile Val Gly Ile Ile Ala Gly Leu Val Leu Leu Gly Ala
305 310 315 320

20

Val Ile Thr Gly Ala Val Val Ala Ala Val Met Trp Arg Arg Lys Ser
325 330 335

Ser Asp Arg Lys Gly Gly Ser Tyr Thr Gln Ala Ala Ser Ser Asp Ser
340 345 350

25

Ala Gln Gly Ser Asp Val Ser Leu Thr Ala Cys Lys Val
355 360 365

<210> 5
<211> 1578
<212> DNA
<213> Homo sapiens

30

<220>
<221> CDS
<222> (55)..(1143)

35

<400> 5

40

45

50

55

EP 2 699 593 B1

	agttctaaag tccccacgca cccacccgga ctcagagtct cctcagacgc cgag atg	57
	Met	
	1	
5	ctg gtc atg gcg ccc cga acc gtc ctc ctg ctg ctc tcg gcg gcc ctg	105
	Leu Val Met Ala Pro Arg Thr Val Leu Leu Leu Leu Ser Ala Ala Leu	
	5 10 15	
10	gcc ctg acc gag acc tgg gcc ggc tcc cac tcc atg agg tat ttc tac	153
	Ala Leu Thr Glu Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe Tyr	
	20 25 30	
15	acc tcc gtg tcc cgg ccc ggc cgc ggg gag ccc cgc ttc atc tca gtg	201
	Thr Ser Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ser Val	
	35 40 45	
20	ggc tac gtg gac gac acc cag ttc gtg agg ttc gac agc gac gcc gcg	249
	Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ala Ala	
	50 55 60 65	
25	agt ccg aga gag gag ccg cgg gcg ccg tgg ata gag cag gag ggg ccg	297
	Ser Pro Arg Glu Glu Pro Arg Ala Pro Trp Ile Glu Gln Glu Gly Pro	
	70 75 80	
30	gag tat tgg gac cgg aac aca cag atc tac aag gcc cag gca cag act	345
35		
40		
45		
50		
55		

EP 2 699 593 B1

	Glu	Tyr	Trp	Asp	Arg	Asn	Thr	Gln	Ile	Tyr	Lys	Ala	Gln	Ala	Gln	Thr	
				85					90					95			
5	gac	cga	gag	agc	ctg	cgg	aac	ctg	cgc	ggc	tac	tac	aac	cag	agc	gag	393
	Asp	Arg	Glu	Ser	Leu	Arg	Asn	Leu	Arg	Gly	Tyr	Tyr	Asn	Gln	Ser	Glu	
			100					105					110				
10	gcc	ggg	tct	cac	acc	ctc	cag	agc	atg	tac	ggc	tgc	gac	gtg	ggg	ccg	441
	Ala	Gly	Ser	His	Thr	Leu	Gln	Ser	Met	Tyr	Gly	Cys	Asp	Val	Gly	Pro	
			115				120					125					
15	gac	ggg	cgc	ctc	ctc	cgc	ggg	cat	gac	cag	tac	gcc	tac	gac	ggc	aag	489
	Asp	Gly	Arg	Leu	Leu	Arg	Gly	His	Asp	Gln	Tyr	Ala	Tyr	Asp	Gly	Lys	
	130					135					140					145	
20	gat	tac	atc	gcc	ctg	aac	gag	gac	ctg	cgc	tcc	tgg	acc	gcc	gcg	gac	537
	Asp	Tyr	Ile	Ala	Leu	Asn	Glu	Asp	Leu	Arg	Ser	Trp	Thr	Ala	Ala	Asp	
					150					155					160		
25	acg	gcg	gct	cag	atc	acc	cag	cgc	aag	tgg	gag	gcg	gcc	cgt	gag	gcg	585
	Thr	Ala	Ala	Gln	Ile	Thr	Gln	Arg	Lys	Trp	Glu	Ala	Ala	Arg	Glu	Ala	
				165					170					175			
30	gag	cag	cgg	aga	gcc	tac	ctg	gag	ggc	gag	tgc	gtg	gag	tgg	ctc	cgc	633
	Glu	Gln	Arg	Arg	Ala	Tyr	Leu	Glu	Gly	Glu	Cys	Val	Glu	Trp	Leu	Arg	
			180				185						190				
35	aga	tac	ctg	gag	aac	ggg	aag	gac	aag	ctg	gag	cgc	gct	gac	ccc	cca	681
	Arg	Tyr	Leu	Glu	Asn	Gly	Lys	Asp	Lys	Leu	Glu	Arg	Ala	Asp	Pro	Pro	
		195					200					205					
40	aag	aca	cac	gtg	acc	cac	cac	ccc	atc	tct	gac	cat	gag	gcc	acc	ctg	729
	Lys	Thr	His	Val	Thr	His	His	Pro	Ile	Ser	Asp	His	Glu	Ala	Thr	Leu	
	210					215					220					225	
45	agg	tgc	tgg	gcc	ctg	ggt	ttc	tac	cct	gcg	gag	atc	aca	ctg	acc	tgg	777
	Arg	Cys	Trp	Ala	Leu	Gly	Phe	Tyr	Pro	Ala	Glu	Ile	Thr	Leu	Thr	Trp	
				230					235						240		
50	cag	cgg	gat	ggc	gag	gac	caa	act	cag	gac	act	gag	ctt	gtg	gag	acc	825
	Gln	Arg	Asp	Gly	Glu	Asp	Gln	Thr	Gln	Asp	Thr	Glu	Leu	Val	Glu	Thr	
				245				250						255			
55	aga	cca	gca	gga	gat	aga	acc	ttc	cag	aag	tgg	gca	gct	gtg	gtg	gtg	873
	Arg	Pro	Ala	Gly	Asp	Arg	Thr	Phe	Gln	Lys	Trp	Ala	Ala	Val	Val	Val	
			260				265						270				
60	cct	tct	gga	gaa	gag	cag	aga	tac	aca	tgc	cat	gta	cag	cat	gag	ggg	921
	Pro	Ser	Gly	Glu	Glu	Gln	Arg	Tyr	Thr	Cys	His	Val	Gln	His	Glu	Gly	
		275				280						285					
65	ctg	ccg	aag	ccc	ctc	acc	ctg	aga	tgg	gag	ccg	tct	tcc	cag	tcc	acc	969
	Leu	Pro	Lys	Pro	Leu	Thr	Leu	Arg	Trp	Glu	Pro	Ser	Ser	Gln	Ser	Thr	
	290					295					300					305	
70	gtc	ccc	atc	gtg	ggc	att	gtt	gct	ggc	ctg	gct	gtc	cta	gca	gtt	gtg	1017
	Val	Pro	Ile	Val	Gly	Ile	Val	Ala	Gly	Leu	Ala	Val	Leu	Ala	Val	Val	
				310					315						320		
75	gtc	atc	gga	gct	gtg	gtc	gct	gct	gtg	atg	tgt	agg	agg	aag	agt	tca	1065
	Val	Ile	Gly	Ala	Val	Val	Ala	Ala	Val	Met	Cys	Arg	Arg	Lys	Ser	Ser	
			325					330						335			

EP 2 699 593 B1

	ggt gga aaa gga ggg agc tac tct cag gct gcg tgc agc gac agt gcc	1113
	Gly Gly Lys Gly Gly Ser Tyr Ser Gln Ala Ala Cys Ser Asp Ser Ala	
	340 345 350	
5	cag ggc tct gat gtg tct ctc aca gct tga aaagcctgag acagctgtct	1163
	Gln Gly Ser Asp Val Ser Leu Thr Ala	
	355 360	
10	tgtgagggac tgagatgcag gatttcttca cgcctcccct ttgtgacttc aagagcctct	1223
	ggcatctctt tctgcaaagg cacctgaatg tgtctgcgtc cctgttagca taatgtgagg	1283
	aggtggagag acagcccacc cttgtgtcca ctgtgacccc tgttcccatg ctgacctgtg	1343
15	tttcctcccc agtcatcttt cttgttccag agaggtgggg ctggatgtct ccatctctgt	1403
	ctcaacttta cgtgcactga gctgcaactt cttacttccc tactgaaaat aagaatctga	1463
	atataaattt gttttctcaa atatttgcta tgagaggttg atggattaat taaataagtc	1523
20	aattcctgga atttgagaga gcaaataaag acctgagaac cttccagaaa aaaaa	1578
	<210> 6	
	<211> 362	
	<212> PRT	
25	<213> Homo sapiens	
	<400> 6	
30		
35		
40		
45		
50		
55		

EP 2 699 593 B1

	Met	Leu	Val	Met	Ala	Pro	Arg	Thr	Val	Leu	Leu	Leu	Leu	Ser	Ala	Ala		
	1				5					10					15			
5		Leu	Ala	Leu	Thr	Glu	Thr	Trp	Ala	Gly	Ser	His	Ser	Met	Arg	Tyr	Phe	
					20					25					30			
	Tyr	Thr	Ser	Val	Ser	Arg	Pro	Gly	Arg	Gly	Glu	Pro	Arg	Phe	Ile	Ser		
10			35					40					45					
	Val	Gly	Tyr	Val	Asp	Asp	Thr	Gln	Phe	Val	Arg	Phe	Asp	Ser	Asp	Ala		
		50					55					60						
15																		
	Ala	Ser	Pro	Arg	Glu	Glu	Pro	Arg	Ala	Pro	Trp	Ile	Glu	Gln	Glu	Gly		
	65					70					75					80		
20	Pro	Glu	Tyr	Trp	Asp	Arg	Asn	Thr	Gln	Ile	Tyr	Lys	Ala	Gln	Ala	Gln		
					85					90					95			
	Thr	Asp	Arg	Glu	Ser	Leu	Arg	Asn	Leu	Arg	Gly	Tyr	Tyr	Asn	Gln	Ser		
25				100					105					110				
	Glu	Ala	Gly	Ser	His	Thr	Leu	Gln	Ser	Met	Tyr	Gly	Cys	Asp	Val	Gly		
			115					120					125					
30																		
	Pro	Asp	Gly	Arg	Leu	Leu	Arg	Gly	His	Asp	Gln	Tyr	Ala	Tyr	Asp	Gly		

35

40

45

50

55

EP 2 699 593 B1

	130		135		140												
5	Lys	Asp	Tyr	Ile	Ala	Leu	Asn	Glu	Asp	Leu	Arg	Ser	Trp	Thr	Ala	Ala	
	145					150					155					160	
	Asp	Thr	Ala	Ala	Gln	Ile	Thr	Gln	Arg	Lys	Trp	Glu	Ala	Ala	Arg	Glu	
10					165					170					175		
	Ala	Glu	Gln	Arg	Arg	Ala	Tyr	Leu	Glu	Gly	Glu	Cys	Val	Glu	Trp	Leu	
				180					185					190			
15	Arg	Arg	Tyr	Leu	Glu	Asn	Gly	Lys	Asp	Lys	Leu	Glu	Arg	Ala	Asp	Pro	
			195					200					205				
20	Pro	Lys	Thr	His	Val	Thr	His	His	Pro	Ile	Ser	Asp	His	Glu	Ala	Thr	
	210						215					220					
	Leu	Arg	Cys	Trp	Ala	Leu	Gly	Phe	Tyr	Pro	Ala	Glu	Ile	Thr	Leu	Thr	
25	225					230					235					240	
	Trp	Gln	Arg	Asp	Gly	Glu	Asp	Gln	Thr	Gln	Asp	Thr	Glu	Leu	Val	Glu	
					245					250					255		
30	Thr	Arg	Pro	Ala	Gly	Asp	Arg	Thr	Phe	Gln	Lys	Trp	Ala	Ala	Val	Val	
				260					265					270			
35	Val	Pro	Ser	Gly	Glu	Glu	Gln	Arg	Tyr	Thr	Cys	His	Val	Gln	His	Glu	
			275					280					285				
	Gly	Leu	Pro	Lys	Pro	Leu	Thr	Leu	Arg	Trp	Glu	Pro	Ser	Ser	Gln	Ser	
40	290						295					300					
	Thr	Val	Pro	Ile	Val	Gly	Ile	Val	Ala	Gly	Leu	Ala	Val	Leu	Ala	Val	
	305					310					315					320	
45	Val	Val	Ile	Gly	Ala	Val	Val	Ala	Ala	Val	Met	Cys	Arg	Arg	Lys	Ser	
					325					330					335		
50	Ser	Gly	Gly	Lys	Gly	Gly	Ser	Tyr	Ser	Gln	Ala	Ala	Cys	Ser	Asp	Ser	
				340					345					350			
55	Ala	Gln	Gly	Ser	Asp	Val	Ser	Leu	Thr	Ala							
			355					360									

<210> 7

<211> 1586

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

5 <222> (66)..(1166)

<400> 7

10

15

20

25

30

35

40

45

50

55

EP 2 699 593 B1

	tccgcagttcc	cggtttctaaa	gtccccagtc	acccacccgg	actcacattc	tccccagagg	60										
	ccgag	atg	cgg	gtc	atg	gcg	ccc	cga	gcc	ctc	ctc	ctg	ctg	ctc	tcg	gga	110
5		Met	Arg	Val	Met	Ala	Pro	Arg	Ala	Leu	Leu	Leu	Leu	Leu	Ser	Gly	
	1					5				10					15		
	ggc	ctg	gcc	ctg	acc	gag	acc	tgg	gcc	tgc	tcc	cac	tcc	atg	agg	tat	158
	Gly	Leu	Ala	Leu	Thr	Glu	Thr	Trp	Ala	Cys	Ser	His	Ser	Met	Arg	Tyr	
					20					25					30		
10	ttc	gac	acc	gcc	gtg	tcc	cgg	ccc	ggc	cgc	gga	gag	ccc	cgc	ttc	atc	206
	Phe	Asp	Thr	Ala	Val	Ser	Arg	Pro	Gly	Arg	Gly	Glu	Pro	Arg	Phe	Ile	
				35					40					45			
15	tca	gtg	ggc	tac	gtg	gac	gac	acg	cag	ttc	gtg	cgg	ttc	gac	agc	gac	254
	Ser	Val	Gly	Tyr	Val	Asp	Asp	Thr	Gln	Phe	Val	Arg	Phe	Asp	Ser	Asp	
			50					55					60				
	gcc	gcg	agt	ccg	aga	ggg	gag	ccg	cgg	gcg	ccg	tgg	gtg	gag	cag	gag	302
20	Ala	Ala	Ser	Pro	Arg	Gly	Glu	Pro	Arg	Ala	Pro	Trp	Val	Glu	Gln	Glu	
		65					70					75					
	ggg	ccg	gag	tat	tgg	gac	cgg	gag	aca	cag	aag	tac	aag	cgc	cag	gca	350
	Gly	Pro	Glu	Tyr	Trp	Asp	Arg	Glu	Thr	Gln	Lys	Tyr	Lys	Arg	Gln	Ala	
	80					85					90					95	
25	cag	gct	gac	cga	gtg	agc	ctg	cgg	aac	ctg	cgc	ggc	tac	tac	aac	cag	398
	Gln	Ala	Asp	Arg	Val	Ser	Leu	Arg	Asn	Leu	Arg	Gly	Tyr	Tyr	Asn	Gln	
					100					105					110		
30	agc	gag	gac	ggg	tct	cac	acc	ctc	cag	agg	atg	tct	ggc	tgc	gac	ctg	446
	Ser	Glu	Asp	Gly	Ser	His	Thr	Leu	Gln	Arg	Met	Ser	Gly	Cys	Asp	Leu	
				115					120					125			
	ggg	ccc	gac	ggg	cgc	ctc	ctc	cgc	ggg	tat	gac	cag	tcc	gcc	tac	gac	494
35	Gly	Pro	Asp	Gly	Arg	Leu	Leu	Arg	Gly	Tyr	Asp	Gln	Ser	Ala	Tyr	Asp	
			130					135					140				
	ggc	aag	gat	tac	atc	gcc	ctg	aac	gag	gac	ctg	cgc	tcc	tgg	acc	gcc	542
	Gly	Lys	Asp	Tyr	Ile	Ala	Leu	Asn	Glu	Asp	Leu	Arg	Ser	Trp	Thr	Ala	
		145					150					155					
40	gcg	gac	acc	gcg	gct	cag	atc	acc	cag	cgc	aag	ttg	gag	gcg	gcc	cgt	590
	Ala	Asp	Thr	Ala	Ala	Gln	Ile	Thr	Gln	Arg	Lys	Leu	Glu	Ala	Ala	Arg	
		160					165				170					175	
45	gcg	gcg	gag	cag	ctg	aga	gcc	tac	ctg	gag	ggc	acg	tgc	gtg	gag	tgg	638
	Ala	Ala	Glu	Gln	Leu	Arg	Ala	Tyr	Leu	Glu	Gly	Thr	Cys	Val	Glu	Trp	
					180					185					190		
	ctc	cgc	aga	tac	ctg	gag	aac	ggg	aag	gag	acg	ctg	cag	cgc	gca	gaa	686
50	Leu	Arg	Arg	Tyr	Leu	Glu	Asn	Gly	Lys	Glu	Thr	Leu	Gln	Arg	Ala	Glu	
				195					200					205			
	ccc	cca	aag	aca	cac	gtg	acc	cac	cac	ccc	ctc	tct	gac	cat	gag	gcc	734
	Pro	Pro	Lys	Thr	His	Val	Thr	His	His	Pro	Leu	Ser	Asp	His	Glu	Ala	

EP 2 699 593 B1

	210	215	220	
5	acc ctg agg tgc tgg gcc ctg ggc ttc tac cct gcg gag atc aca ctg Thr Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Thr Leu 225 230 235			782
10	acc tgg cag cgg gat ggg gag gac cag acc cag gac acc gag ctt gtg Thr Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Thr Glu Leu Val 240 245 250 255			830
15	gag acc agg cca gca gga gat gga acc ttc cag aag tgg gca gct gtg Glu Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val 260 265 270			878
20	gtg gtg cct tct gga caa gag cag aga tac acg tgc cat atg cag cac Val Val Pro Ser Gly Gln Glu Gln Arg Tyr Thr Cys His Met Gln His 275 280 285			926
25	gag ggg ctg caa gag ccc ctc acc ctg agc tgg gag cca tct tcc cag Glu Gly Leu Gln Glu Pro Leu Thr Leu Ser Trp Glu Pro Ser Ser Gln 290 295 300			974
30	ccc acc atc ccc atc atg ggc atc gtt gct ggc ctg gct gtc ctg gtt Pro Thr Ile Pro Ile Met Gly Ile Val Ala Gly Leu Ala Val Leu Val 305 310 315			1022
35	gtc cta gct gtc ctt gga gct gtg gtc acc gct atg atg tgt agg agg Val Leu Ala Val Leu Gly Ala Val Val Thr Ala Met Met Cys Arg Arg 320 325 330 335			1070
40	aag agc tca ggt gga aaa gga ggg agc tgc tct cag gct gcg tgc agc Lys Ser Ser Gly Gly Lys Gly Gly Ser Cys Ser Gln Ala Ala Cys Ser 340 345 350			1118
45	aac agt gcc cag ggc tct gat gag tct ctc atc act tgt aaa gcc tga Asn Ser Ala Gln Gly Ser Asp Glu Ser Leu Ile Thr Cys Lys Ala 355 360 365			1166
50	gacagctgcc tgtgtgggac tgagatgcag gatttcttca cacctctcct ttgtgacttc			1226
55	aagagcctct ggcatctctt tctgcaaagg cacctgaatg tgtctgcgtt cctgttagca			1286
60	taatgtgagg aggtggagag acagcccacc cccgtgtcca ccgtgacccc tgtccccaca			1346
65	ctgacctgtg ttccctcccc gatcatcttt cctgttccag agaggtgggg ctggatgtct			1406
70	ccatctctgt ctcaaattca tgggtgactg agctgcaact tcttacttcc ctaatgaagt			1466
75	taagaacctg aatataaatt tgtgttctca aatatttgct atgaagcgtt gatggattaa			1526
80	ttaaataagt caattcctag aagttgagag agcaaataaa gacctgagaa ccttccagaa			1586
85	<210> 8			
90	<211> 366			
95	<212> PRT			
100	<213> Homo sapiens			
105	<400> 8			
110	Met Arg Val Met Ala Pro Arg Ala Leu Leu Leu Leu Leu Ser Gly Gly			
115	1 5 10 15			

EP 2 699 593 B1

	Leu	Ala	Leu	Thr	Glu	Thr	Trp	Ala	Cys	Ser	His	Ser	Met	Arg	Tyr	Phe	
				20					25					30			
5	Asp	Thr	Ala	Val	Ser	Arg	Pro	Gly	Arg	Gly	Glu	Pro	Arg	Phe	Ile	Ser	
			35					40					45				
	Val	Gly	Tyr	Val	Asp	Asp	Thr	Gln	Phe	Val	Arg	Phe	Asp	Ser	Asp	Ala	
10		50					55					60					
	Ala	Ser	Pro	Arg	Gly	Glu	Pro	Arg	Ala	Pro	Trp	Val	Glu	Gln	Glu	Gly	
	65					70					75					80	
15	Pro	Glu	Tyr	Trp	Asp	Arg	Glu	Thr	Gln	Lys	Tyr	Lys	Arg	Gln	Ala	Gln	
					85					90					95		
	Ala	Asp	Arg	Val	Ser	Leu	Arg	Asn	Leu	Arg	Gly	Tyr	Tyr	Asn	Gln	Ser	
20				100					105					110			
	Glu	Asp	Gly	Ser	His	Thr	Leu	Gln	Arg	Met	Ser	Gly	Cys	Asp	Leu	Gly	
25			115					120					125				
	Pro	Asp	Gly	Arg	Leu	Leu	Arg	Gly	Tyr	Asp	Gln	Ser	Ala	Tyr	Asp	Gly	
		130					135					140					
30	Lys	Asp	Tyr	Ile	Ala	Leu	Asn	Glu	Asp	Leu	Arg	Ser	Trp	Thr	Ala	Ala	
	145					150					155					160	
	Asp	Thr	Ala	Ala	Gln	Ile	Thr	Gln	Arg	Lys	Leu	Glu	Ala	Ala	Arg	Ala	
35					165					170					175		
	Ala	Glu	Gln	Leu	Arg	Ala	Tyr	Leu	Glu	Gly	Thr	Cys	Val	Glu	Trp	Leu	
				180					185					190			
40	Arg	Arg	Tyr	Leu	Glu	Asn	Gly	Lys	Glu	Thr	Leu	Gln	Arg	Ala	Glu	Pro	
			195					200					205				
	Pro	Lys	Thr	His	Val	Thr	His	His	Pro	Leu	Ser	Asp	His	Glu	Ala	Thr	
45		210					215					220					
	Leu	Arg	Cys	Trp	Ala	Leu	Gly	Phe	Tyr	Pro	Ala	Glu	Ile	Thr	Leu	Thr	
50	225					230					235					240	
	Trp	Gln	Arg	Asp	Gly	Glu	Asp	Gln	Thr	Gln	Asp	Thr	Glu	Leu	Val	Glu	
					245					250					255		
55	Thr	Arg	Pro	Ala	Gly	Asp	Gly	Thr	Phe	Gln	Lys	Trp	Ala	Ala	Val	Val	
				260					265					270			

EP 2 699 593 B1

	Val Pro Ser Gly Gln Glu Gln Arg Tyr Thr Cys His Met Gln His Glu	
	275 280 285	
5	Gly Leu Gln Glu Pro Leu Thr Leu Ser Trp Glu Pro Ser Ser Gln Pro	
	290 295 300	
10	Thr Ile Pro Ile Met Gly Ile Val Ala Gly Leu Ala Val Leu Val Val	
	305 310 315 320	
	Leu Ala Val Leu Gly Ala Val Val Thr Ala Met Met Cys Arg Arg Lys	
	325 330 335	
15	Ser Ser Gly Gly Lys Gly Gly Ser Cys Ser Gln Ala Ala Cys Ser Asn	
	340 345 350	
20	Ser Ala Gln Gly Ser Asp Glu Ser Leu Ile Thr Cys Lys Ala	
	355 360 365	
	<210> 9	
	<211> 2679	
25	<212> DNA	
	<213> Homo sapiens	
	<220>	
	<221> CDS	
30	<222> (127)..(1203)	
	<400> 9	
35	gcagactcag ttctcattcc caatgggtgt cgggtttcta gagaagccaa tcagcgtcgc	60
	cacgactccc gactataaag tccccatccg gactcaagaa gttctcagga ctgagaggct	120
	gggatac atg gta gat gga acc ctc ctt tta ctc ctc tcg gag gcc ctg	168
40	Met Val Asp Gly Thr Leu Leu Leu Leu Leu Ser Glu Ala Leu	
	1 5 10	
	gcc ctt acc cag acc tgg gcg ggc tcc cac tcc ttg aag tat ttc cac	216
	Ala Leu Thr Gln Thr Trp Ala Gly Ser His Ser Leu Lys Tyr Phe His	
	15 20 25 30	
45	act tcc gtg tcc cgg ccc ggc cgc ggg gag ccc cgc ttc atc tct gtg	264
	Thr Ser Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ser Val	
	35 40 45	
50	ggc tac gtg gac gac acc cag ttc gtg cgc ttc gac aac gac gcc gcg	312
	Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Asn Asp Ala Ala	
	50 55 60	
	agt ccg agg atg gtg ccg cgg gcg ccg tgg atg gag cag gag ggg tca	360
55	Ser Pro Arg Met Val Pro Arg Ala Pro Trp Met Glu Gln Glu Gly Ser	
	65 70 75	
	gag tat tgg gac cgg gag aca cgg agc gcc agg gac acc gca cag att	408
	Glu Tyr Trp Asp Arg Glu Thr Arg Ser Ala Arg Asp Thr Ala Gln Ile	

EP 2 699 593 B1

	80				85				90								
5	ttc Phe 95	cga Arg Val	gtg Asn Leu	aat Leu Arg	ctg Leu Arg	cgg Arg Thr	acg Thr Leu	ctg Leu Arg	cgc Arg Gly	ggc Gly Tyr	tac Tyr Tyr	tac Asn Gln	aat Gln Ser	cag Ser Glu	agc Ser Glu	gag Glu 110	456
	gcc Ala	ggg Gly	tct Ser	cac His	acc Thr	ctg Leu	cag Gln	tgg Trp	atg Met	cat His	ggc Gly	tgc Cys	gag Glu	ctg Leu	ggg Gly	ccc Pro	504
10	gac Asp	ggg Gly	cgc Arg	ttc Phe	ctc Leu	cgc Arg	ggg Gly	tat Tyr	gaa Glu	cag Gln	ttc Phe	gcc Ala	tac Tyr	gac Asp	ggc Gly	aag Lys	552
15	gat Asp	tat Tyr	ctc Leu	acc Thr	ctg Leu	aat Asn	gag Glu	gac Asp	ctg Leu	cgc Arg	tcc Ser	tgg Trp	acc Thr	gcg Ala	gtg Val	gac Asp	600
	acg Thr	gcg Ala	gct Ala	cag Gln	atc Ile	tcc Ser	gag Glu	caa Gln	aag Lys	tca Ser	aat Asn	gat Asp	gcc Ala	tct Ser	gag Glu	gcg Ala	648
20	gag Glu	cac His	cag Gln	aga Arg	gcc Ala	tac Tyr	ctg Leu	gaa Glu	gac Asp	aca Thr	tgc Cys	gtg Val	gag Glu	tgg Trp	ctc Leu	cac His	696
25	aaa Lys	tac Tyr	ctg Leu	gag Glu	aag Lys	ggg Gly	aag Lys	gag Glu	acg Thr	ctg Leu	ctt Leu	cac His	ctg Leu	gag Glu	ccc Pro	cca Pro	744
	aag Lys	aca Thr	cac His	gtg Val	act Thr	cac His	cac His	ccc Pro	atc Ile	tct Ser	gac Asp	cat His	gag Glu	gcc Ala	acc Thr	ctg Leu	792
30	agg Arg	tgc Cys	tgg Trp	gcc Ala	ctg Leu	ggc Gly	ttc Phe	tac Tyr	cct Pro	gcg Ala	gag Glu	atc Ile	aca Thr	ctg Leu	acc Thr	tgg Trp	840
35	cag Gln	cag Gln	gat Asp	ggg Gly	gag Glu	ggc Gly	cat His	acc Thr	cag Gln	gac Asp	acg Thr	gag Glu	ctc Leu	gtg Val	gag Glu	acc Thr	888
	agg Arg	cct Pro	gca Ala	ggg Gly	gat Asp	gga Gly	acc Thr	ttc Phe	cag Gln	aag Lys	tgg Trp	gca Ala	gct Ala	gtg Val	gtg Val	gtg Val	936
40	cct Pro	tct Ser	gga Gly	gag Glu	gag Glu	cag Gln	aga Arg	tac Tyr	acg Thr	tgc Cys	cat His	gtg Val	cag Gln	cat His	gag Glu	ggg Gly	984
45	cta Leu	ccc Pro	gag Glu	ccc Pro	gtc Val	acc Thr	ctg Leu	aga Arg	tgg Trp	aag Lys	ccg Pro	gct Ala	tcc Ser	cag Gln	ccc Pro	acc Thr	1032
50	atc Ile	ccc Pro	atc Ile	gtg Val	ggc Gly	atc Ile	att Ile	gct Ala	ggc Gly	ctg Leu	gtt Val	ctc Leu	ctt Leu	gga Gly	tct Ser	gtg Val	1080
	gtc Val	tct Ser	gga Gly	gct Ala	gtg Val	gtt Val	gct Ala	gct Ala	gtg Val	ata Ile	tgg Trp	agg Arg	aag Lys	aag Lys	agc Ser	tca Ser	1128
55	ggt Gly	gga Gly	aaa Ser	gga Ala	ggg Val	agc Val	tac Ala	tct Ala	aag Val	gct Val	gag Trp	tgg Arg	agc Lys	gac Lys	agt Ser	gcc Ser	1176

EP 2 699 593 B1

Gly Gly Lys Gly Gly Ser Tyr Ser Lys Ala Glu Trp Ser Asp Ser Ala
335 340 345 350

5 cag ggg tct gag tct cac agc ttg taa agcctgagac agctgccttg 1223
Gln Gly Ser Glu Ser His Ser Leu 355

10 tgtgcgactg agatgcacag ctgccttgtg tgcgactgag atgcaggatt tcctcacgcc 1283

15 tccccatatgt gtcttagggg actctggctt ctctttttgc aagggcctct gaatctgtct 1343

20 gtgtccctgt tagcacaatg tgaggaggta gagaaacagt ccacctctgt gtctaccatg 1403

25 acccccttcc tcacactgac ctgtgttcct tccctgttct cttttctatt aaaaataaga 1463

30 acctggggcag agtgcggcag ctcatgcctg taatcccagc acttagggag gccgaggagg 1523

35 gcagatcacg aggtcaggag atcgaaacca tcctggctaa cacggtgaaa ccccgctctct 1583

40 actaaaaaat acaaaaaatt agctgggagc agaggcacgg gcctgtagtc ccagctactc 1643

45 aggaggcgga ggcaggagaa tggcgtcaac ccgggaggcg gaggttgagc tgagccagga 1703

50 ttgtgcgact gcactccagc ctgggtgaca gggtgaaacg ccatctcaaa aaataaaaat 1763

55 tgaaaaataa aaaaagaacc tggatctcaa tttaattttt catattcttg caatgaaatg 1823

60 gacttgagga agctaagatc atagctagaa atacagataa ttccacagca catctctagc 1883

65 aaatttagcc tattcctatt ctctagccta ttccttacca cctgtaatct tgaccatata 1943

70 ccttggagtt gaatattgtt ttcatactgc tgtggtttga atgttccctc caacactcat 2003

75 gttgagactt aatccctaata gtggcaatac tgaaagggtg gccctttgag atgtgattgg 2063

80 atcgtaaggc tgtgccttca ttcattgggtt aatggattaa tgggttatca caggaatggg 2123

85 actggtggct ttataagaag aggaaaagag aactgagcta gcatgccag cccacagaga 2183

90 gcctccacta gagtgatgct aagtggaaat gtgagggtga gctgccacag agggccccc 2243

95 ccagggaat gtctagtgtc tagtgatcc aggccacagg agagagtgcc ttgtggagcg 2303

100 ctgggagcag gacctgacca ccaccaggac ccagaaactg tggagtcagt ggcagcatgc 2363

105 agcgccttct tgggaaagct ttaggcacca gcctgcaacc cattcgagca gccacgtagg 2423

110 ctgcacccag caaagccaca ggcacggggc tacctgaggc cttggggggc caatccctgc 2483

115 tccagtgtgt ccgtgaggca gcacacgaag tcaaaagaga ttattctctt cccacagata 2543

120 ccttttctct cccatgacct tttaacagca tctgcttcat tcccctcacc ttcccaggct 2603

125 gatctgaggt aaactttgaa gtaaaataaa agctgtgttt gagcatcatt tgtatttcaa 2663

130 aaaaaaaaaa aaaaaa 2679

55 <210> 10
<211> 358
<212> PRT
<213> Homo sapiens

<400> 10

5

10

15

20

25

30

35

40

45

50

55

EP 2 699 593 B1

	Met	Val	Asp	Gly	Thr	Leu	Leu	Leu	Leu	Leu	Ser	Glu	Ala	Leu	Ala	Leu	
	1				5					10					15		
5	Thr	Gln	Thr	Trp	Ala	Gly	Ser	His	Ser	Leu	Lys	Tyr	Phe	His	Thr	Ser	
				20					25					30			
10	Val	Ser	Arg	Pro	Gly	Arg	Gly	Glu	Pro	Arg	Phe	Ile	Ser	Val	Gly	Tyr	
			35					40					45				
15	Val	Asp	Asp	Thr	Gln	Phe	Val	Arg	Phe	Asp	Asn	Asp	Ala	Ala	Ser	Pro	
		50					55					60					
20	Arg	Met	Val	Pro	Arg	Ala	Pro	Trp	Met	Glu	Gln	Glu	Gly	Ser	Glu	Tyr	
	65					70					75					80	
25	Trp	Asp	Arg	Glu	Thr	Arg	Ser	Ala	Arg	Asp	Thr	Ala	Gln	Ile	Phe	Arg	
					85					90					95		
30	Val	Asn	Leu	Arg	Thr	Leu	Arg	Gly	Tyr	Tyr	Asn	Gln	Ser	Glu	Ala	Gly	
				100					105					110			
35	Ser	His	Thr	Leu	Gln	Trp	Met	His	Gly	Cys	Glu	Leu	Gly	Pro	Asp	Gly	
			115					120					125				
40	Arg	Phe	Leu	Arg	Gly	Tyr	Glu	Gln	Phe	Ala	Tyr	Asp	Gly	Lys	Asp	Tyr	
		130					135					140					
45	Leu	Thr	Leu	Asn	Glu	Asp	Leu	Arg	Ser	Trp	Thr	Ala	Val	Asp	Thr	Ala	
	145					150					155					160	
50	Ala	Gln	Ile	Ser	Glu	Gln	Lys	Ser	Asn	Asp	Ala	Ser	Glu	Ala	Glu	His	
					165					170					175		
55	Gln	Arg	Ala	Tyr	Leu	Glu	Asp	Thr	Cys	Val	Glu	Trp	Leu	His	Lys	Tyr	
				180					185					190			
60	Leu	Glu	Lys	Gly	Lys	Glu	Thr	Leu	Leu	His	Leu	Glu	Pro	Pro	Lys	Thr	
			195					200					205				
65	His	Val	Thr	His	His	Pro	Ile	Ser	Asp	His	Glu	Ala	Thr	Leu	Arg	Cys	
		210					215					220					
70	Trp	Ala	Leu	Gly	Phe	Tyr	Pro	Ala	Glu	Ile	Thr	Leu	Thr	Trp	Gln	Gln	
	225					230					235					240	
75	Asp	Gly	Glu	Gly	His	Thr	Gln	Asp	Thr	Glu	Leu	Val	Glu	Thr	Arg	Pro	

EP 2 699 593 B1

	245	250	255
5	Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser 260 265 270		
10	Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln His Glu Gly Leu Pro 275 280 285		
15	Glu Pro Val Thr Leu Arg Trp Lys Pro Ala Ser Gln Pro Thr Ile Pro 290 295 300		
20	Ile Val Gly Ile Ile Ala Gly Leu Val Leu Leu Gly Ser Val Val Ser 305 310 315 320		
25	Gly Ala Val Val Ala Ala Val Ile Trp Arg Lys Lys Ser Ser Gly Gly 325 330 335		
30	Lys Gly Gly Ser Tyr Ser Lys Ala Glu Trp Ser Asp Ser Ala Gln Gly 340 345 350		
35	Ser Glu Ser His Ser Leu 355		

<210> 11
 <211> 1301
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (125)..(1165)

<400> 11

EP 2 699 593 B1

	tttctcactc ccattgggcg tcgcgtttct agagaagcca atcagtgtcg ccgcagttcc	60
	caggttctaa agtcccacgc accccgcggg actcatatct ttcccagacg cggaggttgg	120
5	ggtc atg gcg ccc cga agc ctc ctc ctg ctg ctc tca ggg gcc ctg gcc	169
	Met Ala Pro Arg Ser Leu Leu Leu Leu Leu Ser Gly Ala Leu Ala	
	1 5 10 15	
	ctg acc gat act tgg gcg ggc tcc cac tcc ttg agg tat ttc agc acc	217
10	Leu Thr Asp Thr Trp Ala Gly Ser His Ser Leu Arg Tyr Phe Ser Thr	
	20 25 30	
	gct gtg tcg cgg ccc ggc cgc ggg gag ccc cgc tac atc gcc gtg gag	265
	Ala Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Tyr Ile Ala Val Glu	
15	35 40 45	
	tac gta gac gac acg caa ttc ctg cgg ttc gac agc gac gcc gcg att	313
	Tyr Val Asp Asp Thr Gln Phe Leu Arg Phe Asp Ser Asp Ala Ala Ile	
	50 55 60	
20	ccg agg atg gag ccg cgg gag ccg tgg gtg gag caa gag ggg ccg cag	361

25

30

35

40

45

50

55

EP 2 699 593 B1

	Pro	Arg	Met	Glu	Pro	Arg	Glu	Pro	Trp	Val	Glu	Gln	Glu	Gly	Pro	Gln	
	65						70					75					
5	tat	tgg	gag	tgg	acc	aca	ggg	tac	gcc	aag	gcc	aac	gca	cag	act	gac	409
	Tyr	Trp	Glu	Trp	Thr	Thr	Gly	Tyr	Ala	Lys	Ala	Asn	Ala	Gln	Thr	Asp	
	80					85					90					95	
10	cga	gtg	gcc	ctg	agg	aac	ctg	ctc	cgc	cgc	tac	aac	cag	agc	gag	gct	457
	Arg	Val	Ala	Leu	Arg	Asn	Leu	Leu	Arg	Arg	Tyr	Asn	Gln	Ser	Glu	Ala	
					100					105					110		
15	ggg	tct	cac	acc	ctc	cag	gga	atg	aat	ggc	tgc	gac	atg	ggg	ccc	gac	505
	Gly	Ser	His	Thr	Leu	Gln	Gly	Met	Asn	Gly	Cys	Asp	Met	Gly	Pro	Asp	
				115					120					125			
20	gga	cgc	ctc	ctc	cgc	ggg	tat	cac	cag	cac	gcg	tac	gac	ggc	aag	gat	553
	Gly	Arg	Leu	Leu	Arg	Gly	Tyr	His	Gln	His	Ala	Tyr	Asp	Gly	Lys	Asp	
			130					135					140				
25	tac	atc	tcc	ctg	aac	gag	gac	ctg	cgc	tcc	tgg	acc	gcg	gcg	gac	acc	601
	Tyr	Ile	Ser	Leu	Asn	Glu	Asp	Leu	Arg	Ser	Trp	Thr	Ala	Ala	Asp	Thr	
		145					150					155					
30	gtg	gct	cag	atc	acc	cag	cgc	ttc	tat	gag	gca	gag	gaa	tat	gca	gag	649
	Val	Ala	Gln	Ile	Thr	Gln	Arg	Phe	Tyr	Glu	Ala	Glu	Glu	Tyr	Ala	Glu	
	160					165					170					175	
35	gag	ttc	agg	acc	tac	ctg	gag	ggc	gag	tgc	ctg	gag	ttg	ctc	cgc	aga	697
	Glu	Phe	Arg	Thr	Tyr	Leu	Glu	Gly	Glu	Cys	Leu	Glu	Leu	Leu	Arg	Arg	
					180					185					190		
40	tac	ttg	gag	aat	ggg	aag	gag	acg	cta	cag	cgc	gca	gat	cct	cca	aag	745
	Tyr	Leu	Glu	Asn	Gly	Lys	Glu	Thr	Leu	Gln	Arg	Ala	Asp	Pro	Pro	Lys	
				195					200					205			
45	gca	cac	gtt	gcc	cac	cac	ccc	atc	tct	gac	cat	gag	gcc	acc	ctg	agg	793
	Ala	His	Val	Ala	His	His	Pro	Ile	Ser	Asp	His	Glu	Ala	Thr	Leu	Arg	
			210					215					220				
50	tgc	tgg	gcc	ctg	ggc	ttc	tac	cct	gcg	gag	atc	acg	ctg	acc	tgg	cag	841
	Cys	Trp	Ala	Leu	Gly	Phe	Tyr	Pro	Ala	Glu	Ile	Thr	Leu	Thr	Trp	Gln	
		225				230						235					
55	cgg	gat	ggg	gag	gaa	cag	acc	cag	gac	aca	gag	ctt	gtg	gag	acc	agg	889
	Arg	Asp	Gly	Glu	Glu	Gln	Thr	Gln	Asp	Thr	Glu	Leu	Val	Glu	Thr	Arg	
	240					245					250					255	
60	cct	gca	ggg	gat	gga	acc	ttc	cag	aag	tgg	gcc	gct	gtg	gtg	gtg	cct	937
	Pro	Ala	Gly	Asp	Gly	Thr	Phe	Gln	Lys	Trp	Ala	Ala	Val	Val	Val	Pro	
					260					265					270		
65	cct	gga	gag	gaa	cag	aga	tac	aca	tgc	cat	gtg	cag	cac	gag	ggg	ctg	985
	Pro	Gly	Glu	Glu	Gln	Arg	Tyr	Thr	Cys	His	Val	Gln	His	Glu	Gly	Leu	
				275					280					285			
70	ccc	cag	ccc	ctc	atc	ctg	aga	tgg	gag	cag	tct	ccc	cag	ccc	acc	atc	1033
	Pro	Gln	Pro	Leu	Ile	Leu	Arg	Trp	Glu	Gln	Ser	Pro	Gln	Pro	Thr	Ile	
			290					295					300				
75	ccc	atc	gtg	ggc	atc	gtt	gct	ggc	ctt	gtt	gtc	ctt	gga	gct	gtg	gtc	1081
	Pro	Ile	Val	Gly	Ile	Val	Ala	Gly	Leu	Val	Val	Leu	Gly	Ala	Val	Val	
		305					310					315					

EP 2 699 593 B1

	act gga gct gtg gtc gct gct gtg atg tgg agg aag aag agc tca gat	1129
	Thr Gly Ala Val Val Ala Ala Val Met Trp Arg Lys Lys Ser Ser Asp	
	320 325 330 335	
5	aga aac aga ggg agc tac tct cag gct gca gtg tga gacagcttcc	1175
	Arg Asn Arg Gly Ser Tyr Ser Gln Ala Ala Val	
	340 345	
10	ttgtgtggga ctgagaagca agatatcaat gtagcagaat tgcacttgtg cctcacgaac	1235
	atacataaat tttaaaaata aagaataaaa atatatcttt ttatagataa aaaaaaaaaa	1295
	aaaaaa	1301
15	<210> 12	
	<211> 346	
	<212> PRT	
	<213> Homo sapiens	
20	<400> 12	
25		
30		
35		
40		
45		
50		
55		

EP 2 699 593 B1

	Met	Ala	Pro	Arg	Ser	Leu	Leu	Leu	Leu	Leu	Ser	Gly	Ala	Leu	Ala	Leu	
	1				5					10					15		
5	Thr	Asp	Thr	Trp	Ala	Gly	Ser	His	Ser	Leu	Arg	Tyr	Phe	Ser	Thr	Ala	
				20					25					30			
10	Val	Ser	Arg	Pro	Gly	Arg	Gly	Glu	Pro	Arg	Tyr	Ile	Ala	Val	Glu	Tyr	
			35					40					45				
15	Val	Asp	Asp	Thr	Gln	Phe	Leu	Arg	Phe	Asp	Ser	Asp	Ala	Ala	Ile	Pro	
		50					55					60					
20	Arg	Met	Glu	Pro	Arg	Glu	Pro	Trp	Val	Glu	Gln	Glu	Gly	Pro	Gln	Tyr	
	65					70					75					80	
25	Trp	Glu	Trp	Thr	Thr	Gly	Tyr	Ala	Lys	Ala	Asn	Ala	Gln	Thr	Asp	Arg	
					85					90					95		
30	Val	Ala	Leu	Arg	Asn	Leu	Leu	Arg	Arg	Tyr	Asn	Gln	Ser	Glu	Ala	Gly	
				100					105					110			
35	Ser	His	Thr	Leu	Gln	Gly	Met	Asn	Gly	Cys	Asp	Met	Gly	Pro	Asp	Gly	
			115					120					125				
40	Arg	Leu	Leu	Arg	Gly	Tyr	His	Gln	His	Ala	Tyr	Asp	Gly	Lys	Asp	Tyr	
		130					135					140					
45	Ile	Ser	Leu	Asn	Glu	Asp	Leu	Arg	Ser	Trp	Thr	Ala	Ala	Asp	Thr	Val	
	145					150					155					160	
50	Ala	Gln	Ile	Thr	Gln	Arg	Phe	Tyr	Glu	Ala	Glu	Glu	Tyr	Ala	Glu	Glu	
55																	

EP 2 699 593 B1

	165								170				175			
5	Phe	Arg	Thr	Tyr	Leu	Glu	Gly	Glu	Cys	Leu	Glu	Leu	Leu	Arg	Arg	Tyr
				180					185					190		
10	Leu	Glu	Asn	Gly	Lys	Glu	Thr	Leu	Gln	Arg	Ala	Asp	Pro	Pro	Lys	Ala
			195					200					205			
15	His	Val	Ala	His	His	Pro	Ile	Ser	Asp	His	Glu	Ala	Thr	Leu	Arg	Cys
		210					215					220				
20	Trp	Ala	Leu	Gly	Phe	Tyr	Pro	Ala	Glu	Ile	Thr	Leu	Thr	Trp	Gln	Arg
	225					230					235					240
25	Asp	Gly	Glu	Glu	Gln	Thr	Gln	Asp	Thr	Glu	Leu	Val	Glu	Thr	Arg	Pro
					245					250					255	
30	Ala	Gly	Asp	Gly	Thr	Phe	Gln	Lys	Trp	Ala	Ala	Val	Val	Val	Pro	Pro
				260					265					270		
35	Gly	Glu	Glu	Gln	Arg	Tyr	Thr	Cys	His	Val	Gln	His	Glu	Gly	Leu	Pro
			275					280					285			
40	Gln	Pro	Leu	Ile	Leu	Arg	Trp	Glu	Gln	Ser	Pro	Gln	Pro	Thr	Ile	Pro
		290					295					300				
45	Ile	Val	Gly	Ile	Val	Ala	Gly	Leu	Val	Val	Leu	Gly	Ala	Val	Val	Thr
	305					310					315					320
50	Gly	Ala	Val	Val	Ala	Ala	Val	Met	Trp	Arg	Lys	Lys	Ser	Ser	Asp	Arg
					325					330					335	
55	Asn	Arg	Gly	Ser	Tyr	Ser	Gln	Ala	Ala	Val						
				340					345							
60	<210> 13															
	<211> 1578															
	<212> DNA															
	<213> Homo sapiens															
65	<220>															
	<221> CDS															
	<222> (179)..(1195)															
70	<400> 13															

EP 2 699 593 B1

	agtgtggtac tttgtcttga ggagatgtcc tggactcaca cggaaactta gggctacgga	60
	atgaagttct cactcccatt aggtgacagg tttttagaga agccaatcag cgtcgccgcg	120
5	gtcctgggtc taaagtcctc gtcacccac ccggactcat tctccccaga cgccaagg	178
10		
15		
20		
25		
30		
35		
40		
45		
50		
55		

EP 2 699 593 B1

	atg	gtg	gtc	atg	gcg	ccc	cga	acc	ctc	ttc	ctg	ctg	ctc	tcg	ggg	gcc	226
	Met	Val	Val	Met	Ala	Pro	Arg	Thr	Leu	Phe	Leu	Leu	Leu	Ser	Gly	Ala	
	1				5				10					15			
5	ctg	acc	ctg	acc	gag	acc	tgg	gcg	ggc	tcc	cac	tcc	atg	agg	tat	ttc	274
	Leu	Thr	Leu	Thr	Glu	Thr	Trp	Ala	Gly	Ser	His	Ser	Met	Arg	Tyr	Phe	
				20					25					30			
10	agc	gcc	gcc	gtg	tcc	cgg	ccc	ggc	cgc	ggg	gag	ccc	cgc	ttc	atc	gcc	322
	Ser	Ala	Ala	Val	Ser	Arg	Pro	Gly	Arg	Gly	Glu	Pro	Arg	Phe	Ile	Ala	
				35				40					45				
15	atg	ggc	tac	gtg	gac	gac	acg	cag	ttc	gtg	cgg	ttc	gac	agc	gac	tcg	370
	Met	Gly	Tyr	Val	Asp	Asp	Thr	Gln	Phe	Val	Arg	Phe	Asp	Ser	Asp	Ser	
		50					55					60					
20	gcg	tgt	ccg	agg	atg	gag	ccg	cgg	gcg	ccg	tgg	gtg	gag	cag	gag	ggg	418
	Ala	Cys	Pro	Arg	Met	Glu	Pro	Arg	Ala	Pro	Trp	Val	Glu	Gln	Glu	Gly	
	65				70						75					80	
25	ccg	gag	tat	tgg	gaa	gag	gag	aca	cgg	aac	acc	aag	gcc	cac	gca	cag	466
	Pro	Glu	Tyr	Trp	Glu	Glu	Glu	Thr	Arg	Asn	Thr	Lys	Ala	His	Ala	Gln	
					85					90					95		
30	act	gac	aga	atg	aac	ctg	cag	acc	ctg	cgc	ggc	tac	tac	aac	cag	agc	514
	Thr	Asp	Arg	Met	Asn	Leu	Gln	Thr	Leu	Arg	Gly	Tyr	Tyr	Asn	Gln	Ser	
				100					105					110			
35	gag	gcc	agt	tct	cac	acc	ctc	cag	tgg	atg	att	ggc	tgc	gac	ctg	ggg	562
	Glu	Ala	Ser	Ser	His	Thr	Leu	Gln	Trp	Met	Ile	Gly	Cys	Asp	Leu	Gly	
			115					120					125				
40	tcc	gac	gga	cgc	ctc	ctc	cgc	ggg	tat	gaa	cag	tat	gcc	tac	gat	ggc	610
	Ser	Asp	Gly	Arg	Leu	Leu	Arg	Gly	Tyr	Glu	Gln	Tyr	Ala	Tyr	Asp	Gly	
			130				135					140					
45	aag	gat	tac	ctc	gcc	ctg	aac	gag	gac	ctg	cgc	tcc	tgg	acc	gca	gcg	658
	Lys	Asp	Tyr	Leu	Ala	Leu	Asn	Glu	Asp	Leu	Arg	Ser	Trp	Thr	Ala	Ala	
						150					155					160	
50	gac	act	gcg	gct	cag	atc	tcc	aag	cgc	aag	tgt	gag	gcg	gcc	aat	gtg	706
	Asp	Thr	Ala	Ala	Gln	Ile	Ser	Lys	Arg	Lys	Cys	Glu	Ala	Ala	Asn	Val	
					165					170					175		
55	gct	gaa	caa	agg	aga	gcc	tac	ctg	gag	ggc	acg	tgc	gtg	gag	tgg	ctc	754
	Ala	Glu	Gln	Arg	Arg	Ala	Tyr	Leu	Glu	Gly	Thr	Cys	Val	Glu	Trp	Leu	
				180					185					190			
60	cac	aga	tac	ctg	gag	aac	ggg	aag	gag	atg	ctg	cag	cgc	gcg	gac	ccc	802
	His	Arg	Tyr	Leu	Glu	Asn	Gly	Lys	Glu	Met	Leu	Gln	Arg	Ala	Asp	Pro	
				195				200					205				
65	ccc	aag	aca	cac	gtg	acc	cac	cac	cct	gtc	ttt	gac	tat	gag	gcc	acc	850
	Pro	Lys	Thr	His	Val	Thr	His	His	Pro	Val	Phe	Asp	Tyr	Glu	Ala	Thr	
			210				215					220					
70	ctg	agg	tgc	tgg	gcc	ctg	ggc	ttc	tac	cct	gcg	gag	atc	ata	ctg	acc	898
	Leu	Arg	Cys	Trp	Ala	Leu	Gly	Phe	Tyr	Pro	Ala	Glu	Ile	Ile	Leu	Thr	
					230						235					240	
75	tgg	cag	cgg	gat	ggg	gag	gac	cag	acc	cag	gac	gtg	gag	ctc	gtg	gag	946
	Trp	Gln	Arg	Asp	Gly	Glu	Asp	Gln	Thr	Gln	Asp	Val	Glu	Leu	Val	Glu	

EP 2 699 593 B1

	245	250	255	
5	acc agg cct gca ggg gat gga acc ttc cag aag tgg gca gct gtg gtg Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val 260 265 270			994
10	gtg cct tct gga gag gag cag aga tac acg tgc cat gtg cag cat gag Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln His Glu 275 280 285			1042
15	ggg ctg ccg gag ccc ctc atg ctg aga tgg aag cag tct tcc ctg ccc Gly Leu Pro Glu Pro Leu Met Leu Arg Trp Lys Gln Ser Ser Leu Pro 290 295 300			1090
20	acc atc ccc atc atg ggt atc gtt gct ggc ctg gtt gtc ctt gca gct Thr Ile Pro Ile Met Gly Ile Val Ala Gly Leu Val Val Leu Ala Ala 305 310 315 320			1138
25	gta gtc act gga gct gcg gtc gct gct gtg ctg tgg aga aag aag agc Val Val Thr Gly Ala Ala Val Ala Ala Val Leu Trp Arg Lys Lys Ser 325 330 335			1186
30	tca gat tga aaaggaggga gctactctca ggctgcaatg tgaaacagct Ser Asp			1235
35	gccctgtgtg ggactgagtg gcaagtcctt ttgtgacttc aagaaccctg actcctcttt gtgcagagac cagcccaccc ctgtgcccac catgaccctc ttcctcatgc tgaactgcat tccttcccca atcacctttc ctgttccaga aaaggggctg ggatgtctcc gtctctgtct caaatttgtg gtccactgag ctataactta cttctgtatt aaaattagaa tctgagtata aatttacttt ttcaaattat ttccaagaga gattgatggg ttaattaaag gagaagattc ctgaaatttg agagacaaaa taaatggaag acatgagaac ttt			1295 1355 1415 1475 1535 1578
40	<210> 14 <211> 338 <212> PRT <213> Homo sapiens			
45	<400> 14			
50				
55				

EP 2 699 593 B1

Met Val Val Met Ala Pro Arg Thr Leu Phe Leu Leu Leu Ser Gly Ala
1 5 10 15

5 Leu Thr Leu Thr Glu Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe
20 25 30

10 Ser Ala Ala Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala
35 40 45

15 Met Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ser
50 55 60

Ala Cys Pro Arg Met Glu Pro Arg Ala Pro Trp Val Glu Gln Glu Gly

20

25

30

35

40

45

50

55

EP 2 699 593 B1

	65					70									75				80
5	Pro	Glu	Tyr	Trp	Glu	Glu	Glu	Thr	Arg	Asn	Thr	Lys	Ala	His	Ala	Gln			
					85					90					95				
	Thr	Asp	Arg	Met	Asn	Leu	Gln	Thr	Leu	Arg	Gly	Tyr	Tyr	Asn	Gln	Ser			
				100					105					110					
10	Glu	Ala	Ser	Ser	His	Thr	Leu	Gln	Trp	Met	Ile	Gly	Cys	Asp	Leu	Gly			
			115					120					125						
15	Ser	Asp	Gly	Arg	Leu	Leu	Arg	Gly	Tyr	Glu	Gln	Tyr	Ala	Tyr	Asp	Gly			
		130					135					140							
	Lys	Asp	Tyr	Leu	Ala	Leu	Asn	Glu	Asp	Leu	Arg	Ser	Trp	Thr	Ala	Ala			
20		145				150					155							160	
	Asp	Thr	Ala	Ala	Gln	Ile	Ser	Lys	Arg	Lys	Cys	Glu	Ala	Ala	Asn	Val			
					165					170					175				
25	Ala	Glu	Gln	Arg	Arg	Ala	Tyr	Leu	Glu	Gly	Thr	Cys	Val	Glu	Trp	Leu			
				180					185					190					
30	His	Arg	Tyr	Leu	Glu	Asn	Gly	Lys	Glu	Met	Leu	Gln	Arg	Ala	Asp	Pro			
			195					200					205						
	Pro	Lys	Thr	His	Val	Thr	His	His	Pro	Val	Phe	Asp	Tyr	Glu	Ala	Thr			
35		210					215					220							
	Leu	Arg	Cys	Trp	Ala	Leu	Gly	Phe	Tyr	Pro	Ala	Glu	Ile	Ile	Leu	Thr			
		225				230					235					240			
40	Trp	Gln	Arg	Asp	Gly	Glu	Asp	Gln	Thr	Gln	Asp	Val	Glu	Leu	Val	Glu			
					245					250					255				
	Thr	Arg	Pro	Ala	Gly	Asp	Gly	Thr	Phe	Gln	Lys	Trp	Ala	Ala	Val	Val			
45				260					265					270					
	Val	Pro	Ser	Gly	Glu	Glu	Gln	Arg	Tyr	Thr	Cys	His	Val	Gln	His	Glu			
			275					280					285						
50	Gly	Leu	Pro	Glu	Pro	Leu	Met	Leu	Arg	Trp	Lys	Gln	Ser	Ser	Leu	Pro			
		290					295					300							
55	Thr	Ile	Pro	Ile	Met	Gly	Ile	Val	Ala	Gly	Leu	Val	Val	Leu	Ala	Ala			
		305				310					315					320			

EP 2 699 593 B1

Val Val Thr Gly Ala Ala Val Ala Ala Val Leu Trp Arg Lys Lys Ser
325 330 335

5 Ser Asp

<210> 15

<211> 9232

<212> DNA

10 <213> Artificial Sequence

<220>

<223> Vector sequence for human B2M-HLA-A0201 fusion protein

15 <400> 15

20

25

30

35

40

45

50

55

EP 2 699 593 B1

	ctcgaggagc ttggcccatt gcatacgttg tatccatatac ataatatgta cttttatatt	60
	ggctcatgtc caacattacc gccatgttga cattgattat tgactagtta ttaatagtaa	120
5	tcaattacgg ggtcattagt tcatagccca tatatggagt tccgcgttac ataacttacg	180
	gtaaatggcc cgcctggctg accgcccac gacccccgcc cattgacgtc aataatgacg	240
10	tatgttccca tagtaacgcc aatagggact ttccattgac gtcaatgggt ggagtattta	300
	cgctaaactg cccacttggc agtacatcaa gtgtatcata tgccaagtac gccccctatt	360
	gacgtcaatg acggtaaatg gcccgcctgg cattatgccc agtacatgac cttatgggac	420
15	tttctactt ggagtagcat ctacgtatta gtcacgcta ttaccatgggt gatgcgggtt	480
	tggcagtaca tcaatgggagc tggatagcgg ttgactcac ggggatttcc aagtctccac	540
	cccattgacg tcaatgggagc tttgttttgg caccaaaatc aacgggactt tccaaaatgt	600
20	cgtaacaact ccgcccatt gacgcaaatg ggcggtaggc gtgtacgggtg ggaggtctat	660
	ataagcagag cttctagatt gtacgggagc tcttcactac tcgctgcgtc gagagtgtac	720
	gagactctcc aggttttgta agaaatattt tatattgtta taatgttact atgatccatt	780
25	aacactctgc ttatagattg taagggtgat tgcaatgctt tctgcataaa acttttggtt	840
	tcttggtaat caataaacgc acttgattcg agaacctact catatattat tgtctctttt	900
30	atactttatt aagtaaaaagg atttgtatat tagccttgct aaggagaca tctagtata	960
	taagtgtgaa ctacacttat cttaaatgat gtaactcctt aggataatca atatacaaaa	1020
	ttccatgaca attggcgccc aacgtggggc tcgaatataa gtcgggttta tttgtaaatt	1080
35	atccctaggg acctccgagc aagcgagcat agcgggaggc atataaaagc caatagacaa	1140
	tggctagcag gaagtaatgt tgaagaatat gaacttgatg ttgaagctct ggttgtaatt	1200
	ttaagagata gaaatatacc aagaaatcct ttacatggag aagttatagg tcttcgcctt	1260
40	actgaaggat ggtggggaca aattgagaga ttccagatgg tacgttgatc taaggctatg	1320
	gatttggtcca tgggacaaga aatattagtt tatagtccca ttgtatctat gactaaaata	1380

45

50

55

EP 2 699 593 B1

	caaaaaactc	cactaccaga	aagaaaagct	ttacccatta	gatggataac	atggatgact	1440
	tatttagaag	atccaagaat	ccaatttcat	tatgataaaa	ccttaccaga	acttaagcat	1500
5	attccagatg	tatatacatc	tagtcagtct	cctgttaaac	atccttctca	atatgaagga	1560
	gtgtttttata	ctgatggctc	ggccatcaaa	agtcctgatc	ctacaaaaag	caataatgct	1620
	ggcatgggaa	tagtacatgc	cacatacaaa	cctgaatatc	aagttttgaa	tcaatgggtca	1680
10	ataccactag	gtaatcatac	tgctcagatg	gctgaaatag	ctgcagttga	atttgcctgt	1740
	aaaaaagctt	taaaaatacc	tggtcctgta	ttagttataa	ctgatagttt	ctatgtagca	1800
	gaaagtgcta	ataaagaatt	accatactgg	aaatctaata	ggttttgttaa	taataagaaa	1860
15	aagcctctta	aacatatctc	caaattggaaa	tctattgctg	agtgtttatc	tatgaaacca	1920
	gacattacta	ttcaacatga	aaaaggcatc	agcctacaaa	taccagtatt	catactgaaa	1980
	ggcaatgccc	tagcagataa	gcttgccacc	caaggaaagt	atgtgggttaa	ttgtaatacc	2040
20	aaaaaaccaa	acctggatgc	agagttggat	caattattac	agggtcatta	tataaaagga	2100
	tatcccaaac	aataacata	tttttttagaa	gatggcaaag	taaaagtttc	cagacctgaa	2160
25	ggggttaaaa	ttattccccc	tcagtcagac	agacaaaaaa	ttgtgcttca	agcccacaat	2220
	ttggctcaca	ccggacgtga	agccactctt	ttaaaaattg	ccaaccttta	ttggtggcca	2280
	aatatgagaa	aggatgtggt	taaacaacta	ggacgctgtc	aacagtgttt	aatcacaaat	2340
30	gcttccaaca	aagcctctgg	tcctattcta	agaccagata	ggcctcaaaa	accttttgat	2400
	aaattcttta	ttgactatat	tggacctttg	ccaccttcac	agggatacct	atatgtatta	2460
	gtagttgttg	atggaatgac	aggattcact	tggttatacc	ccactaaggc	tccttctact	2520
35	agcgcaactg	ttaaatctct	caatgtactc	actagtattg	caattccaaa	ggtgattcac	2580
	tctgatcaag	gtgcagcatt	cacttcttca	acctttgctg	aatgggcaaa	ggaaagaggt	2640
	atacatttgg	aattcagtac	tccttatcac	ccccaaagtg	gtagtaaggt	ggaaaggaaa	2700
40	aatagtgata	taaaacgact	tttaactaaa	ctgctagtag	gaagaccac	aaagtgggat	2760
	gacctattgc	ctgttgtaga	acttgcttta	aacaacacct	atagccctgt	attaaaatat	2820
	actccacatc	aactcttatt	tggtatagat	tcaaatactc	catttgcaaa	tcaagataca	2880
45	cttgacttga	ccagagaaga	agaactttct	cttttacagg	aaattcgtac	ttctttatac	2940
	catccatcca	cccctccagc	ctcctctcgt	tcctgggtctc	ctgttggttg	ccaattgggtc	3000
	caggagaggg	tggttagggc	tgcttctttg	agacctcggt	ggcataaacc	gtctactgta	3060
50	cttaaggtgt	tgaatccaag	gactgttggt	attttggtacc	atcttggtgaa	caacagaact	3120
	gtaagtatag	ataattttaa	acctacttct	catcagaatg	gcaccaccaa	tgacactgca	3180
55	acaatggatc	attttgaaaa	aatgaataa	agcgcatgag	gcacttcaaa	atacaacaac	3240
	tgtgactgaa	cagcagaagg	aacaaattat	actggacatt	caaaatgaag	aagtacaacc	3300

EP 2 699 593 B1

	aactaggaga	gataaattta	gatatctgct	ttatacttgt	tgtgctacta	gctcaagagt	3360
	attggcctgg	atgttttttag	tttgtatatt	gttaatcatt	gttttggttt	catgctttgt	3420
5	gactatatcc	agaataacaat	ggaataagga	tattcaggta	ttaggacctg	taatagactg	3480
	gaatgttact	caaagagctg	tttatcaacc	cttacagact	agaaggattg	cacgttccct	3540
	tagaatgcag	catcctgttc	caaaatatgt	ggaggtaa	atgactagta	ttccacaagg	3600
10	tgtatactat	gaaccccatc	cggcctcgac	ggatcgcg	gtaccggtat	cgataagctt	3660
	gataacctcg	agagatctaa	ttctaccggg	taggggaggg	gcttttccca	aggcagtctg	3720
	gagcatgcgc	tttagcagcc	ccgctggcac	ttggcgctac	acaagtggcc	tctggcctcg	3780
15	cacacattcc	acatccaccg	gtagcgccaa	ccggctccgt	tctttggtgg	ccccttcgcg	3840
	ccacttctac	tctctcccta	gtcaggaagt	ttcccccagc	aagctcgcg	cgtgcaggac	3900
20	gtgacaaatg	gaagtagcac	gtctcactag	tctcgtgcag	atggacagca	ccgctgagca	3960
	atggaagcgg	gtaggccttt	ggggcagcgg	ccaatagcag	ctttgttcct	tcgctttctg	4020
	ggctcagagg	ctgggaaggg	gtgggtccgg	ggcggggctc	aggggcgggc	tcaggggcgg	4080
25	gcgggcgccc	gaaggtcctc	ccgaggcccg	gcattctgca	cgcttcaaaa	gcgcacgtct	4140
	gccgcgctgt	tctcctcttc	ctcatctccg	ggcctttcga	cctgcagccc	gggggatcga	4200
	tcctaggtga	tttaaatacca	ccatgaccga	gtacaagccc	acggtgcgcc	tcgccaccgc	4260
30	cgacgacgtc	ccccgggccc	tacgcaccct	cgccgcccgc	ttcgccgact	accccgccac	4320
	gcgccacacc	gtcgaccg	accgccacat	cgagcgggtc	accgagctgc	aagaactctt	4380
35	cctcacgcgc	gtcgggctcg	acatcgga	ggtgtgggtc	gcggacgacg	gcgccgcggt	4440
	ggcgggtctg	accacgccg	agagcgtcga	agcggggg	gtgttcgccc	agatcgcccc	4500
	gcgcatggcc	gagttgagcg	gttcccggct	ggccgcgcag	caacagatgg	aaggcctcct	4560
40	ggcgccgcac	cggcccaagg	agcccgcgtg	gttcctggcc	accgtcggcg	tctcgcccga	4620
	ccaccagggc	aagggctctg	gcagcgccgt	cgtgctcccc	ggagtggagg	cggccgagcg	4680
	cgccggggtg	cccgccttcc	tggagacctc	cgcgccccgc	aacctcccct	tctacgagcg	4740
45	gctcggcttc	accgtcaccg	ccgacgtcga	gtgcccgaag	gaccgcgcga	cctggtgcat	4800
	gacccgcaag	cccgggtgcct	gacggatcca	tcgctccggt	gcccgtcagt	gggcagagcg	4860
	cacatcgccc	acagtccccg	agaagttggg	gggaggggtc	ggcaattgaa	ccggtgccta	4920
50	gagaaggtgg	cgcggggtaa	actgggaaag	tgatgtcgtg	tactggctcc	gcctttttcc	4980
	cgaggggtgg	ggagaaccgt	atataagtgc	agtagtcgcc	gtgaacgttc	tttttcgcaa	5040
55	cgggtttgcc	gccagaacac	agctgcggcc	gcgccgccac	catgtctcgc	tccgtggcct	5100
	tagctgtgct	cgcgctactc	tctctttctg	gcctggaggg	tatccagcgt	actccaaaga	5160

EP 2 699 593 B1

	ttcaggttta	ctcacgtcat	ccagcagaga	atggaaagtc	aaatttcctg	aattgctatg	5220
	tgtctgggtt	tcatccatcc	gacattgaag	ttgacttact	gaagaatgga	gagagaattg	5280
5	aaaaagtgga	gcattcagac	ttgtctttca	gcaaggactg	gtctttctat	ctcttgact	5340
	acactgaatt	cacccccact	gaaaaagatg	agtatgcctg	ccgtgtgaac	catgtgactt	5400
	tgtcacagcc	caagatagtt	aagtgggatc	gagacatggg	cggaggcgga	agcgggggcg	5460
10	gcggatccgg	cggaggcgga	agcggcgggc	ggggaagcgg	ctctcactcc	atgaggtatt	5520
	tcttcacatc	cgtgtcccgg	cccggccgcg	gggagccccg	cttcatcgca	gtgggctacg	5580
	tggaagacac	gcagttcgtg	cggttcgaca	gcgacgccgc	gagccagagg	atggagccgc	5640
15	gggcgcctg	gatagagcag	gaggggtccg	agtattggga	cggggagaca	cggaaagtga	5700
	aggccctc	acagactcac	cgagtggacc	tggggaccct	gcgcggctac	tacaaccaga	5760
	gcgaggccgg	ttctcacacc	gtccagagga	tgtatggctg	cgacgtgggg	tcggactggc	5820
20	gcttcctccg	cgggtaccac	cagtacgcct	acgacggcaa	ggattacatc	gccctgaaag	5880
	aggacctgcg	ctcttgacc	gcggcgga	tggcagctca	gaccaccaag	cacaagtggg	5940
	aggcgccca	tgtggcgag	cagttgagag	cctacctgga	gggcacgtgc	gtggagtggc	6000
25	tccgcagata	cctggagaac	gggaaggaga	cgctgcagcg	cacggacgcc	cccaaacgc	6060
	atatgactca	ccacgctgtc	tctgaccatg	aagccaccct	gaggtgctgg	gccctgagct	6120
	tctaccctgc	ggagatcaca	ctgacctggc	agcgggatgg	ggaggaccag	accaggaca	6180
30	cggagctcgt	ggagaccagg	cctgcagggg	atggaacctt	ccagaagtgg	gcggctgtgg	6240
	tgggtgccttc	tggacaggag	cagagataca	cctgccatgt	gcagcatgag	ggtttgccca	6300
35	agccctcac	cctgagatgg	gagccgtctt	cccagcccac	catccccatc	gtgggcatca	6360
	ttgctggcct	ggttctcttt	ggagctgtga	tactggagc	tgtggtcgct	gctgtgatgt	6420
	ggaggaggaa	gagctcagat	agaaaaggag	ggagctactc	tcaggctgca	agcagtgaca	6480
40	gtgcccagg	ctctgatgtg	tctctcacag	cttgtaaagt	gtgagcgcc	gcgactctag	6540
	atcaggcgcg	ccgttaccaa	gcagctatgg	aagcttatgg	acctcagaga	ggaagtaacg	6600
	aggagaggg	gtggtggaat	gtcactagaa	accagggaaa	acaaggagga	gagtattaca	6660
45	gggaaggagg	tgaagaacct	cattacccaa	atactcctgc	tcctcataga	cgtacctggg	6720
	atgagagaca	caaggttctt	aaattgtcct	cattcgctac	tcctctgac	atccaacgct	6780
	gggctactaa	ctctagattg	tacgggagct	ctcttacta	ctcgctgcgt	cgagagtgt	6840
50	cgagactctc	caggtttgg	aagaaatatt	ttatattgtt	ataatgttac	tatgatccat	6900
	taacactctg	cttatagatt	gtaaggggtga	ttgcaatgct	ttctgcataa	aactttggtt	6960
55	ttcttgtaa	tcaataaacc	gacttgattc	gagaacctac	tcataatatta	ttgtctcttt	7020
	tatactttat	taagtaaaag	gatttgtata	ttagccttgc	taaggagagac	atctagtgat	7080

EP 2 699 593 B1

	ataagtgtga	actacactta	tcttaaata	tgtaactcct	taggataatc	aataatacaaa	7140
	attccatgac	aattggcgat	accgtcgacc	gttcagctgc	attaatgaat	cggccaacgc	7200
5	gcggggagag	gcggtttgcg	tattgggagc	tcttccgctt	cctcgctcac	tgactcgctg	7260
	cgctcggtcg	ttcggtgctg	gcgagcggtg	tcagctcact	caaaggcggt	aatacgggtta	7320
	tccacagaat	caggggataa	cgcaggaaag	aacatgtgag	caaaaggcca	gcaaaaaggcc	7380
10	aggaaccgta	aaaaggccgc	gttgctggcg	tttttccata	ggctccgccc	ccctgacgag	7440
	catcacaaaa	atcgacgctc	aagtcagagg	tggcgaaacc	cgacaggact	ataaagatac	7500
	caggcgtttc	cccctggaag	ctccctcgctg	cgctctcctg	ttccgaccct	gccgcttacc	7560
15	ggatacctgt	ccgcctttct	cccttcggga	agcgtggcgc	tttctcaatg	ctcacgctgt	7620
	aggtatctca	gttcggtgta	ggtcgttcgc	tccaagctgg	gctgtgtgca	cgaaccccccc	7680
20	gttcagcccg	accgctgcgc	cttatccggt	aactatcgtc	ttgagtccaa	cccggtaaga	7740
	cacgacttat	cgccactggc	agcagccact	ggtaacagga	ttagcagagc	gaggtatgta	7800
	ggcgggtgcta	cagagttctt	gaagtgggtg	cctaactacg	gctacactag	aaggacagta	7860
25	tttggtatct	gcgctctgct	gaagccagtt	accttcggaa	aaagagttgg	tagctcttga	7920
	tccggcaaac	aaaccaccgc	tggtagcggg	ggttttttttg	tttgcaagca	gcagattacg	7980
	cgcagaaaaa	aaggatctca	agaagatcct	ttgatctttt	ctacggggtc	tgacgctcag	8040
30	tggaacgaaa	actcacgtta	agggattttg	gtcatgagat	tatcaaaaag	gatcttcacc	8100
	tagatccttt	taaattaaaa	atgaagtttt	aatcaatct	aaagtatata	tgagtaaact	8160
35	tggtctgaca	gttaccaatg	cttaatcagt	gaggcaccta	tctcagcgat	ctgtctattt	8220
	cgttcatcca	tagttgcctg	actccccgtc	gtgtagataa	ctacgatacg	ggagggctta	8280
	ccatctggcc	ccagtgcctg	aatgataccg	cgagaccac	gctcaccggc	tccagattta	8340
40	tcagcaataa	accagccagc	cgggaagggc	gagcgcagaa	gtggtcctgc	aactttatcc	8400
	gcctccatcc	agtctattaa	ttgttgccgg	gaagctagag	taagtagttc	gccagttaat	8460
	agtttgcgca	acgttggtgc	cattgctaca	ggcatcgtgg	tgtcacgctc	gtcgtttggt	8520
45	atggcttcat	tcagctccgg	ttcccaacga	tcaaggcgag	ttacatgatc	ccccatgttg	8580
	tgcaaaaaag	cggttagctc	cttcggtcct	ccgatcgttg	tcagaagtaa	gttggccgca	8640
	gtgttatcac	tcattggttat	ggcagcactg	cataattctc	ttactgtcat	gccatccgta	8700
50	agatgctttt	ctgtgactgg	tgagtactca	accaagtcac	tctgagaata	gtgtatgcgg	8760
	cgaccgagtt	gctcttgccc	ggcgtcaata	cgggataata	ccgcgccaca	tagcagaact	8820
55	ttaaaagtgc	tcattcattgg	aaaacgttct	tcggggcgaa	aactctcaag	gatcttaccg	8880
	ctgttgagat	ccagttcgat	gtaaccact	cgtgcaccca	actgatcttc	agcatctttt	8940

EP 2 699 593 B1

	actttcacca gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc aaaaaagga	9000
	ataagggcga cacggaaatg ttgaatactc atactcttcc tttttcaata ttattgaagc	9060
5	atttatcagg gttattgtct catgagcggg tacatatattg aatgtattta gaaaaataaa	9120
	caaatagggg ttccgcgcac atttccccga aaagtgccac ctgacgtcta agaaaccatt	9180
10	attatcatga cattaaccta taaaaatagg cgtatcacga ggccctttcg tc	9232
	<210> 16	
	<211> 480	
	<212> PRT	
	<213> Artificial Sequence	
15	<220>	
	<223> HLA-bBA0201 (human B2M-HLA-A0201 fusion peptide)	
20	<400> 16	
25		
30		
35		
40		
45		
50		
55		

EP 2 699 593 B1

	Met	Ser	Arg	Ser	Val	Ala	Leu	Ala	Val	Leu	Ala	Leu	Leu	Ser	Leu	Ser	
	1				5					10					15		
5	Gly	Leu	Glu	Ala	Ile	Gln	Arg	Thr	Pro	Lys	Ile	Gln	Val	Tyr	Ser	Arg	
				20					25					30			
10	His	Pro	Ala	Glu	Asn	Gly	Lys	Ser	Asn	Phe	Leu	Asn	Cys	Tyr	Val	Ser	
			35					40					45				
15	Gly	Phe	His	Pro	Ser	Asp	Ile	Glu	Val	Asp	Leu	Leu	Lys	Asn	Gly	Glu	
		50					55					60					
20	Arg	Ile	Glu	Lys	Val	Glu	His	Ser	Asp	Leu	Ser	Phe	Ser	Lys	Asp	Trp	
	65					70					75					80	
25	Ser	Phe	Tyr	Leu	Leu	Tyr	Tyr	Thr	Glu	Phe	Thr	Pro	Thr	Glu	Lys	Asp	
					85					90					95		
30	Glu	Tyr	Ala	Cys	Arg	Val	Asn	His	Val	Thr	Leu	Ser	Gln	Pro	Lys	Ile	
				100					105					110			
35	Val	Lys	Trp	Asp	Arg	Asp	Met	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	
			115					120					125				
40	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Ser	His	Ser	Met	
		130					135					140					
45	Arg	Tyr	Phe	Phe	Thr	Ser	Val	Ser	Arg	Pro	Gly	Arg	Gly	Glu	Pro	Arg	
	145					150					155					160	
50	Phe	Ile	Ala	Val	Gly	Tyr	Val	Asp	Asp	Thr	Gln	Phe	Val	Arg	Phe	Asp	
					165					170					175		
55																	

EP 2 699 593 B1

	Ser	Asp	Ala	Ala	Ser	Gln	Arg	Met	Glu	Pro	Arg	Ala	Pro	Trp	Ile	Glu	
				180					185					190			
5	Gln	Glu	Gly	Pro	Glu	Tyr	Trp	Asp	Gly	Glu	Thr	Arg	Lys	Val	Lys	Ala	
			195					200					205				
10	His	Ser	Gln	Thr	His	Arg	Val	Asp	Leu	Gly	Thr	Leu	Arg	Gly	Tyr	Tyr	
		210					215					220					
15	Asn	Gln	Ser	Glu	Ala	Gly	Ser	His	Thr	Val	Gln	Arg	Met	Tyr	Gly	Cys	
	225					230					235					240	
20	Asp	Val	Gly	Ser	Asp	Trp	Arg	Phe	Leu	Arg	Gly	Tyr	His	Gln	Tyr	Ala	
					245				250						255		
25	Tyr	Asp	Gly	Lys	Asp	Tyr	Ile	Ala	Leu	Lys	Glu	Asp	Leu	Arg	Ser	Trp	
				260					265					270			
30	Thr	Ala	Ala	Asp	Met	Ala	Ala	Gln	Thr	Thr	Lys	His	Lys	Trp	Glu	Ala	
			275					280					285				
35	Ala	His	Val	Ala	Glu	Gln	Leu	Arg	Ala	Tyr	Leu	Glu	Gly	Thr	Cys	Val	
		290					295					300					
40	Glu	Trp	Leu	Arg	Arg	Tyr	Leu	Glu	Asn	Gly	Lys	Glu	Thr	Leu	Gln	Arg	
	305					310					315					320	
45	Thr	Asp	Ala	Pro	Lys	Thr	His	Met	Thr	His	His	Ala	Val	Ser	Asp	His	
					325					330					335		
50	Glu	Ala	Thr	Leu	Arg	Cys	Trp	Ala	Leu	Ser	Phe	Tyr	Pro	Ala	Glu	Ile	
				340					345					350			
55	Thr	Leu	Thr	Trp	Gln	Arg	Asp	Gly	Glu	Asp	Gln	Thr	Gln	Asp	Thr	Glu	
			355					360					365				
60	Leu	Val	Glu	Thr	Arg	Pro	Ala	Gly	Asp	Gly	Thr	Phe	Gln	Lys	Trp	Ala	
		370					375					380					
65	Ala	Val	Val	Val	Pro	Ser	Gly	Gln	Glu	Gln	Arg	Tyr	Thr	Cys	His	Val	
	385					390					395					400	
70	Gln	His	Glu	Gly	Leu	Pro	Lys	Pro	Leu	Thr	Leu	Arg	Trp	Glu	Pro	Ser	
					405					410					415		
75	Ser	Gln	Pro	Thr	Ile	Pro	Ile	Val	Gly	Ile	Ile	Ala	Gly	Leu	Val	Leu	

EP 2 699 593 B1

420

425

430

5

Phe Gly Ala Val Ile Thr Gly Ala Val Val Ala Ala Val Met Trp Arg
435 440 445

10

Arg Lys Ser Ser Asp Arg Lys Gly Gly Ser Tyr Ser Gln Ala Ala Ser
450 455 460

Ser Asp Ser Ala Gln Gly Ser Asp Val Ser Leu Thr Ala Cys Lys Val
465 470 475 480

15

<210> 17
<211> 9224
<212> DNA
<213> Artificial Sequence

20

<220>
<223> Vector sequence for HLA-gBE

<400> 17

25

30

35

40

45

50

55

EP 2 699 593 B1

	ctcgaggagc ttggcccatt gcatacgttg tatccatatac ataatatgta catttatatt	60
	ggctcatgtc caacattacc gccatgttga cattgattat tgactagtta ttaatagtaa	120
5	tcaattacgg ggtcattagt tcatagccca tatatggagt tccgcgttac ataacttacg	180
	gtaaatggcc cgcctggctg accgcccac gacccccgcc cattgacgtc aataatgacg	240
	tatgttccca tagtaacgcc aatagggact ttccattgac gtcaatgggt ggagtattta	300
10	cgctaaaactg cccacttggc agtacatcaa gtgtatcata tgccaagtac gccccctatt	360
	gacgtcaatg acggtaaatg gcccgcttg cattatgccc agtacatgac cttatgggac	420
15	tttcctactt ggcagtacat ctacgtatta gtcacgcta ttaccatgggt gatgcggttt	480
	tggcagtaca tcaatgggcg tggatagcgg tttgactcac ggggatttcc aagtctccac	540
	cccattgacg tcaatgggag tttgttttg caccaaaatc aacgggactt tccaaaatgt	600
20	cgtaacaact ccgcccatt gacgcaaag ggcggtaggc gtgtacgggt ggaggtctat	660
	ataagcagag cttctagatt gtacgggagc tcttactac tcgctgcgtc gagagtgtac	720
	gagactctcc aggtttggta agaaatattt tatattgtta taatgttact atgatccatt	780
25	aacactctgc ttatagattg taagggtgat tgcaatgctt tctgcataaa actttggttt	840
	tcttgttaat caataaaccg acttgattcg agaactact catatattat tgtctctttt	900
30	atactttatt aagtaaaagg atttgtatat tagccttgct aaggagaca tctagtata	960
	taagtgtgaa ctacacttat cttaaagat gtaactcctt aggataatca atatacaaaa	1020
	ttccatgaca attggcgccc aacgtggggc tcgaatataa gtcgggttta tttgtaaatt	1080
35	atccctaggg acctccgagc atagcgggag gcatataaaa gccaatagac aatggctagc	1140
	aggaagtaat gttgaagaat atgaacttga tggtgaagct ctggttgtaa ttttaagaga	1200

40

45

50

55

EP 2 699 593 B1

	tagaaatata ccaagaaatc ctttacatgg agaagttata ggtcttcgcc ttactgaagg	1260
	atgggtgggga caaattgaga gatttcagat ggtacgttga tctaaggcta tggattttggc	1320
5	catgggacaa gaaatattag tttatagtcc cattgtatct atgactaaaa tacaaaaaac	1380
	tccactacca gaaagaaaag ctttaccat tagatggata acatggatga cttattttaga	1440
	agatccaaga atccaatttc attatgataa aaccttacca gaacttaagc atattccaga	1500
10	tgtatatata tctagtcagt ctccctgttaa acatccttct caatatgaag gagtgtttta	1560
	tactgatggc tcggccatca aaagtcctga tcctacaaaa agcaataatg ctggcatggg	1620
	aatagtacat gccacataca aacctgaata tcaagttttg aatcaatggc caataccact	1680
15	aggtaatcat actgctcaga tggctgaaat agctgcagtt gaatttgcct gtaaaaaagc	1740
	tttaaaaata cctggctcctg tattagttat aactgatagt ttctatgtag cagaaagtgc	1800
20	taataaagaa ttaccatact ggaaatctaa tgggtttgtt aataataaga aaaagcctct	1860
	taaacatatc tccaaatgga aatctattgc tgagtgttta tctatgaaac cagacattac	1920
	tattcaacat gaaaaaggca tcagcctaca aataccagta ttcatactga aaggcaatgc	1980
25	cctagcagat aagcttgcca cccaagggaag ttatgtgggt aattgtaata ccaaaaaacc	2040
	aaacctggat gcagagttgg atcaattatt acagggctcat tatataaaaag gatatcccaa	2100
	acaatatata tatttttttag aagatggcaa agtaaaagtt tccagacctg aaggggttaa	2160
30	aattattccc cctcagtcag acagacaaaa aattgtgctt caagcccaca atttggctca	2220
	caccggacgt gaagccactc ttttaaaaaat tgccaacctt tattggtggc caaatatgag	2280
35	aaaggatgtg gttaaacaac taggacgctg tcaacagtg ttaatcacia atgcttccaa	2340
	caaagcctct ggtcctattc taagaccaga taggcctcaa aaaccttttg ataaattcctt	2400
	tattgactat attggacctt tgccaccttc acagggatac ctatatgtat tagtagttgt	2460
40	tgatggaatg acaggattca cttgggtata cccactaag gctccttcta ctagcgcaac	2520
	tgttaaatct ctcaatgtac tcactagtat tgcaattcca aaggtgattc actctgatca	2580
	aggtgcagca ttcacttctt caacctttgc tgaatgggca aaggaaagag gtatacattt	2640
45	ggaattcagt actccttatt acccccaaag tggtagtaag gtggaaagga aaaatagtga	2700
	tataaaacga cttttaacta aactgctagt aggaagaccc acaaagtggc atgacctatt	2760
50	gcctgttgta caacttgctt taaacaacac ctatagccct gtattaaaaat atactccaca	2820
	tcaactctta tttggatatag attcaaatac tccatttgca aatcaagata cacttgactt	2880
	gaccagagaa gaagaacttt ctcttttaca ggaaattcgt acttctttat accatccatc	2940
55	caccctcca gcctcctctc gttcctgggc tcctgttggt ggccaattgg tccaggagag	3000
	ggtggctagg cctgcttctt tgagacctcg ttggcataaa ccgtctactg tacttaaggt	3060

EP 2 699 593 B1

	gttgaatcca	aggactgttg	ttatTTTTgga	ccatcttggc	aacaacagaa	ctgtaagtat	3120
	agataattta	aaacctactt	ctcatcagaa	tggcaccacc	aatgacactg	caacaatgga	3180
5	tcatttggaa	aaaaatgaat	aaagcgcgatg	aggcacttca	aaatacaaca	actgtgactg	3240
	aacagcagaa	ggaacaaatt	atactggaca	ttcaaaatga	agaagtacaa	ccaactagga	3300
	gagataaatt	tagatatctg	ctttatactt	gttgtgtctac	tagctcaaga	gtattggcct	3360
10	ggatgttttt	agtttgtata	ttgttaaatca	ttgttttggg	ttcatgcttt	gtgactatat	3420
	ccagaataca	atggaataag	gatattcagg	tattaggacc	tgtaatagac	tggaatgtta	3480
	ctcaaagagc	tgtttatcaa	cccttacaga	ctagaaggat	tgcacgttcc	cttagaatgc	3540
15	agcatcctgt	tccaaaatat	gtggaggtaa	atatgactag	tattccacaa	gggtgtatact	3600
	atgaacccca	tccggcctcg	acggtatcga	tggtagccgt	atcgataagc	ttgataacct	3660
	cgagagatct	aattctaccg	ggtaggggag	gcgcttttcc	caaggcagtc	tggagcatgc	3720
20	gcttttagcag	ccccgctggc	acttggcgct	acacaagtgg	cctctggcct	cgcacacatt	3780
	ccacatccac	cggtagcgcc	aaccggctcc	gttctttggg	ggcccccttcg	cgcacttct	3840
25	actcctcccc	tagtcaggaa	gtttccccca	gcaagctcgc	gtcgtgcagg	acgtgacaaa	3900
	tggaagtagc	acgtctcact	agtctcgtgc	agatggacag	caccgctgag	caatggaagc	3960
	gggtaggcct	ttggggcagc	ggccaatagc	agctttgttc	cttcgctttc	tgggctcaga	4020
30	ggctgggaag	gggtgggtcc	gggggcgggc	tcaggggcgg	gctcaggggc	gggcgggcgc	4080
	ccgaagggtcc	tcccagaggcc	cggcattctg	cacgcttcaa	aagcgcacgt	ctgccgcgct	4140
	gttctcctct	tcctcatctc	cgggcctttc	gacctgcagc	ccgggggatac	gatacctaggt	4200
35	gatttaaate	caccatgacc	gagtacaagc	ccacggtgcg	cctcgccacc	cgcgacgacg	4260
	tcccccgggc	cgtacgcacc	ctcgccgccc	cgttcgccga	ctaccccgcc	acgcgccaca	4320
	ccgtcgaccc	ggaccgccac	atcgagcggg	tcaccgagct	gcaagaactc	ttcctcacgc	4380
40	gcgtcgggct	cgacatcggc	aaggtgtggg	tcgcggacga	cggcgcccg	gtggcggtct	4440
	ggaccacgcc	ggagagcgtc	gaagcggggg	cgggtgttcgc	cgagatcggc	ccgcgcagtg	4500
	ccgagttgag	cggttcccgg	ctggccgcgc	agcaacagat	ggaaggcctc	ctggcgccgc	4560
45	accggcccaa	ggagcccgcg	tggttcctgg	ccaccgtcgg	cgtctcgccc	gaccaccagg	4620
	gcaagggtct	gggcagcgcc	gtcgtgctcc	ccggagtggg	ggcgcccgag	cgcgccgggg	4680
	tggccgcctt	cctggagacc	tccgcgcccc	gcaacctccc	cttctacgag	cggctcggct	4740
50	tcaccgtcac	cgcgcacgtc	gagtgcgccg	aggaccgcgc	gacctggtgc	atgaccgcga	4800
	agcccgggtc	ctgacggatc	catcgctccg	gtgcccgtca	gtgggcagag	cgcacatcgc	4860
55	ccacagtccc	cgagaagttg	gggggagggg	tcggcaattg	aaccgggtgc	tagagaaggt	4920
	ggcgcggggt	aaactgggaa	agtgatgtcg	tgtactggct	ccgccttttt	cccagagggtg	4980

EP 2 699 593 B1

	ggggagaacc	gtatataagt	gcagtagtcg	ccgtgaacgt	tcttttttcgc	aacgggtttg	5040
	ccgccagaac	acagctgcgg	ccgcgttaac	catggtggtc	atggcccctc	gaactctgtt	5100
5	cctgctgctg	agtggggctc	tgaccctgac	agagtccgga	atccagcgga	cccccaagat	5160
	tcaggtgtac	agcagacacc	ctgcagagaa	cggcaaatac	aacttcctga	attgctatgt	5220
	gtctgggttt	catcccagtg	acatcgaagt	cgatctgctg	aagaatggcg	agagaattga	5280
10	aaaagtcgag	cactctgacc	tgagcttctc	caaggattgg	tccttttacc	tgctgtacta	5340
	taccgagttt	actccaaccg	aaaaagacga	gtatgcctgt	aggggtgaacc	atgtcacact	5400
	gagccagccc	aagatcgtga	aatgggaccg	cgatatgggc	gggggaggct	cagggggagg	5460
15	cgggagcgga	ggcgggggct	ccggcggggg	aggatccggt	tctcactcct	tgaagtattt	5520
	ccacacttcc	gtgtcccggc	ccggccgcgg	ggagccccgc	ttcatctctg	tgggctacgt	5580
20	ggacgacacc	cagttcgtgc	gcttcgacaa	cgacgccgcg	agtccgagga	tgggtccgcg	5640
	ggcgccgtgg	atggagcagg	aggggtcaga	gtattgggac	cgggagacac	ggagcgccag	5700
	ggacaccgca	cagattttcc	gagtgaatct	gcggacgctg	cgcggtact	acaatcagag	5760
25	cgaggccggg	tctcacaccc	tgcaagtggat	gcatggctgc	gagctggggc	ccgacggggc	5820
	cttcctccgc	gggtatgaac	agttcgccct	cgacggcaag	gattatctca	ccctgaatga	5880
	ggacctgctc	tcctggaccg	cggtggacac	ggcggctcag	atctccgagc	aaaagtcaaa	5940
30	tgatgcctct	gaggcggagc	accagagagc	ctacctggaa	gacacatgcg	tggagtggct	6000
	ccacaaatac	ctggagaagg	ggaaggagac	gctgcttcac	ctggagcccc	caaagacaca	6060
35	cgtgactcac	caccccatct	ctgaccatga	ggccaccctg	aggtgctggg	ccctgggctt	6120
	ctaccctgcg	gagatcacac	tgacctggca	gcaggatggg	gagggccata	cccaggacac	6180
	ggagctcgtg	gagaccaggc	ctgcagggga	tggaaccttc	cagaagtggg	cagctgtggt	6240
40	ggtgccttct	ggagaggagc	agagatacac	gtgccatgtg	cagcatgagg	ggctacccga	6300
	gcccgtcacc	ctgagatgga	agccggcttc	ccagcccacc	atccccatcg	tgggcatcat	6360
	tgctggcctg	gttctccttg	gatctgtggt	ctctggagct	gtggttgctg	ctgtgatatg	6420
45	gaggaagaag	agctcaggtg	gaaaaggagg	gagctactct	aaggctgagt	ggagcgacag	6480
	tgccagggg	tctgagtctc	acagcttgta	atctagagcg	gccgcgactc	tagatcaggc	6540
	gcgccgttac	caagcagcta	tggaagctta	tggacctcag	agaggaagta	acgaggagag	6600
50	ggtgtggtgg	aatgtcacta	gaaaccaggg	aaaacaagga	ggagagtatt	acagggaagg	6660
	aggtgaagaa	cctcattacc	caaatactcc	tgctcctcat	agacgtacct	gggatgagag	6720
55	acacaagggt	cttaaattgt	cctcattcgc	tactccctct	gacatccaac	gctggactac	6780
	taactctaga	ttgtacggga	ggctcttcac	tactcgctgc	gtcgagagtg	tacgagactc	6840

EP 2 699 593 B1

	tccaggtttg	gtaagaaata	ttttatattg	ttataatgtt	actatgatcc	attaacactc	6900
	tgcttataga	ttgtaagggt	gattgcaatg	ctttctgcat	aaaactttgg	ttttcttggt	6960
5	aatcaataaa	ccgacttgat	tcgagaacca	actcctatat	tattgtctct	tttatacttt	7020
	attaagtaaa	aggatttgta	tattagcctt	gctaaggag	acatctagt	atataagtgt	7080
	gaactacact	tatcttaaat	gatgtaactc	cttaggataa	tcaatataca	aaattccatg	7140
10	acaattggcg	ataccgtcga	ccgttcagct	gcattaatga	atcggccaac	gcgcggggag	7200
	aggcggtttg	cgtattgggc	gctcttccgc	ttcctcgctc	actgactcgc	tgcgctcggt	7260
	cgttcggctg	cgcgagcg	tatcagctca	ctcaaaggcg	gtaatacgg	tatccacaga	7320
15	atcaggggat	aacgcaggaa	agaacatgtg	agcaaaaggc	cagcaaaagg	ccaggaaccg	7380
	taaaaaggcc	gcgttgctgg	cgtttttcca	taggctccgc	ccccctgacg	agcatcacia	7440
	aaatcgacgc	tcaagtcaga	ggtggcgaaa	cccgacagga	ctataaagat	accaggcggt	7500
20	tccccctgga	agctccctcg	tgcgctctcc	tggtccgacc	ctgccgctta	ccggatacct	7560
	gtccgccttt	ctcccttcgg	gaagcgtggc	gctttctcaa	tgctcacgct	gtaggtatct	7620
	cagttcggtg	taggtcggtc	gctccaagct	gggctgtgtg	cacgaacccc	ccgttcagcc	7680
25	cgaccgctgc	gccttatccg	gtaactatcg	tcttgagtcc	aaccggtaaa	gacacgactt	7740
	atcgccactg	gcagcagcca	ctggtaacag	gattagcaga	gcgaggtatg	taggcgggtg	7800
30	tacagagttc	ttgaagtgg	ggcctaacta	cggctacact	agaaggacag	tatttggtat	7860
	ctgcgctctg	ctgaagccag	ttaccttcgg	aaaaagagtt	ggtagctctt	gatccggcaa	7920
	acaaaccacc	gctggtagcg	gtggtttttt	tgtttgcaag	cagcagatta	cgcgagaaa	7980
35	aaaaggatct	caagaagatc	ctttgatctt	ttctacgggg	tctgacgctc	agtggaaacga	8040
	aaactcacgt	taagggattt	tggtcatgag	attatcaaaa	aggatcttca	cctagatcct	8100
	tttaaattaa	aaatgaagtt	ttaaatcaat	ctaaagtata	tatgagtaaa	cttggtctga	8160
40	cagttaccaa	tgcttaata	gtgaggcacc	tatctcagcg	atctgtctat	ttcggtcatc	8220
	catagttgcc	tgactccccg	tcgtgtagat	aactacgata	cgaggaggct	taccatctgg	8280
	ccccagtgct	gcaatgatac	cgcgagaccc	acgctcaccg	gctccagatt	tatcagcaat	8340
45	aaaccagcca	gccggaagg	ccgagcgag	aagtggctct	gcaactttat	ccgcctccat	8400
	ccagtctatt	aattggtgcc	gggaagctag	agtaagtagt	tcgccagtta	atagtttgcg	8460
	caacgttggt	gccattgcta	caggcatcgt	ggtgtcacgc	tcgtcgtttg	gtatggcttc	8520
50	attcagctcc	ggttcccaac	gatcaaggcg	agttacatga	tcccccatgt	tgtgcaaaaa	8580
	agcggtagc	tccttcgggc	ctccgatcgt	tgtcagaagt	aagttggccg	cagtgttatc	8640
55	actcatgggt	atggcagcac	tgcataattc	tcttactgtc	atgccatccg	taagatgctt	8700
	ttctgtgact	ggtgagtact	caaccaagtc	attctgagaa	tagtgtatgc	ggcgaccgag	8760

EP 2 699 593 B1

ttgctcttgc cccggcgtcaa tacgggataa taccgcgccca catagcagaa ctttaaaagt 8820
 gctcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac cgctgttgag 8880
 5 atccagttcg atgtaaccga ctcgtgcacc caactgatct tcagcatctt ttactttcac 8940
 cagcgtttct ggggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg gaataagggc 9000
 gacacggaaa tgttgaatac tcatactctt cctttttcaa tattattgaa gcatttatca 9060
 10 gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata aacaaatagg 9120
 ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc taagaaacca ttattatcat 9180
 15 gacattaacc tataaaaaata ggcgtatcac gaggcccttt cgtc 9224

<210> 18

<211> 476

<212> PRT

20 <213> Artificial Sequence

<220>

<223> HLA-gBE

25 <400> 18

Met Ala Pro Arg Thr Leu Phe Leu Leu Leu Ser Gly Ala Leu Thr Leu
 1 5 10 15
 30 Thr Glu Ser Gly Ile Gln Arg Thr Pro Lys Ile Gln Val Tyr Ser Arg
 20 25 30
 35 His Pro Ala Glu Asn Gly Lys Ser Asn Phe Leu Asn Cys Tyr Val Ser
 35 40 45
 40 Gly Phe His Pro Ser Asp Ile Glu Val Asp Leu Leu Lys Asn Gly Glu
 50 55 60
 Arg Ile Glu Lys Val Glu His Ser Asp Leu Ser Phe Ser Lys Asp Trp
 65 70 75 80
 45 Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu Lys Asp
 85 90 95
 50 Glu Tyr Ala Cys Arg Val Asn His Val Thr Leu Ser Gln Pro Lys Ile
 100 105 110
 Val Lys Trp Asp Arg Asp Met Gly Gly Gly Gly Ser Gly Gly Gly Gly
 115 120 125
 55 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ser His Ser Leu
 130 135 140

EP 2 699 593 B1

	Lys	Tyr	Phe	His	Thr	Ser	Val	Ser	Arg	Pro	Gly	Arg	Gly	Glu	Pro	Arg	
	145					150					155					160	
5	Phe	Ile	Ser	Val	Gly	Tyr	Val	Asp	Asp	Thr	Gln	Phe	Val	Arg	Phe	Asp	
					165					170					175		
10	Asn	Asp	Ala	Ala	Ser	Pro	Arg	Met	Val	Pro	Arg	Ala	Pro	Trp	Met	Glu	
				180					185					190			
15	Gln	Glu	Gly	Ser	Glu	Tyr	Trp	Asp	Arg	Glu	Thr	Arg	Ser	Ala	Arg	Asp	
			195					200					205				
20	Thr	Ala	Gln	Ile	Phe	Arg	Val	Asn	Leu	Arg	Thr	Leu	Arg	Gly	Tyr	Tyr	
		210					215					220					
25	Asn	Gln	Ser	Glu	Ala	Gly	Ser	His	Thr	Leu	Gln	Trp	Met	His	Gly	Cys	
	225					230					235					240	
30	Glu	Leu	Gly	Pro	Asp	Gly	Arg	Phe	Leu	Arg	Gly	Tyr	Glu	Gln	Phe	Ala	
					245					250					255		
35	Tyr	Asp	Gly	Lys	Asp	Tyr	Leu	Thr	Leu	Asn	Glu	Asp	Leu	Arg	Ser	Trp	
				260					265					270			
40	Thr	Ala	Val	Asp	Thr	Ala	Ala	Gln	Ile	Ser	Glu	Gln	Lys	Ser	Asn	Asp	
			275					280					285				
45	Ala	Ser	Glu	Ala	Glu	His	Gln	Arg	Ala	Tyr	Leu	Glu	Asp	Thr	Cys	Val	
		290					295					300					
50	Glu	Trp	Leu	His	Lys	Tyr	Leu	Glu	Lys	Gly	Lys	Glu	Thr	Leu	Leu	His	
	305					310					315					320	
55	Leu	Glu	Pro	Pro	Lys	Thr	His	Val	Thr	His	His	Pro	Ile	Ser	Asp	His	
					325					330					335		
60	Glu	Ala	Thr	Leu	Arg	Cys	Trp	Ala	Leu	Gly	Phe	Tyr	Pro	Ala	Glu	Ile	
				340					345					350			
65	Thr	Leu	Thr	Trp	Gln	Gln	Asp	Gly	Glu	Gly	His	Thr	Gln	Asp	Thr	Glu	
			355					360					365				
70	Leu	Val	Glu	Thr	Arg	Pro	Ala	Gly	Asp	Gly	Thr	Phe	Gln	Lys	Trp	Ala	
		370					375					380					
75	Ala	Val	Val	Val	Pro	Ser	Gly	Glu	Glu	Gln	Arg	Tyr	Thr	Cys	His	Val	
	385					390					395					400	

EP 2 699 593 B1

	Gln His Glu Gly Leu Pro Glu Pro Val Thr Leu Arg Trp Lys Pro Ala	
	405	410 415
5	Ser Gln Pro Thr Ile Pro Ile Val Gly Ile Ile Ala Gly Leu Val Leu	
	420	425 430
10	Leu Gly Ser Val Val Ser Gly Ala Val Val Ala Ala Val Ile Trp Arg	
	435	440 445
15	Lys Lys Ser Ser Gly Gly Lys Gly Gly Ser Tyr Ser Lys Ala Glu Trp	
	450	455 460
20	Ser Asp Ser Ala Gln Gly Ser Glu Ser His Ser Leu	
	465	470 475
	<210> 19	
	<211> 9287	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
25	<223> Vector sequence for HLA-bGBE	
	<400> 19	
30	ctcgaggagc ttggcccatt gcatacgttg tatccatatac ataatatgta catttatatt	60
	ggctcatgtc caacattacc gccatgttga cattgattat tgactagtta ttaatagtaa	120
	tcaattacgg ggtcattagt tcatagccca tatatggagt tccgcgttac ataacttacg	180
35	gtaaatggcc cgcctggctg accgcccac gacccccgcc cattgacgtc aataatgacg	240
	tatgttccca tagtaacgcc aatagggact ttccattgac gtcaatgggt ggagtattta	300
	cgctaaactg cccacttggc agtacatcaa gtgtatcata tgccaagtac gcccctatt	360
40	gacgtcaatg acggtaaatg gcccgctgg cattatgccc agtacatgac cttatgggac	420
	tttcctactt ggcagtacat ctacgtatta gtcacgcta ttaccatggg gatgcggttt	480
45	tggcagtaca tcaatgggag tggatagcgg ttgactcac ggggatttcc aagtctccac	540
	cccattgacg tcaatgggag tttgttttgg caccaaaatc aacgggactt tccaaaatgt	600
	cgtaacaact ccgccccatt gacgcaaag ggcggtaggc gtgtacgggt ggaggtctat	660
50	ataagcagag cttctagatt gtacgggagc tcttcactac tcgctgcgtc gagagtgtac	720
	gagactctcc aggttttgta agaaatattt tatattgtta taatgttact atgatccatt	780
	aacactctgc ttatagattg taagggtgat tgcaatgctt tctgcataaa actttggttt	840
55	tcttgtaaat caataaacgg acttgattcg agaacctact catatattat tgtctctttt	900
	atactttatt aagtaaaagg atttgtatat tagccttgct aaggagaca tctagtata	960

EP 2 699 593 B1

	taagtgtgaa ctacacttat cttaaattgat gtaactcctt aggataatca atatacaaaa	1020
	ttccatgaca attggcgccc aacgtggggc tcgaatataa gtcggggttta tttgtaaatt	1080
5	atccctaggg acctccgagc atagcgggag gcatataaaa gccaatagac aatggctagc	1140
	aggaagtaat gttgaagaat atgaacttga tgttgaagct ctgggttgtaa ttttaagaga	1200
	tagaaatata ccaagaaatc ctttacctgg agaagttata ggtcttcgcc ttactgaagg	1260
10	atggtgggga caaattgaga gatttcagat ggtacgttga tctaaggcta tggatttggc	1320
	catgggacaa gaaatattag tttatagtcc cattgtatct atgactaaaa tacaaaaaac	1380
	tccactacca gaaagaaaag ctttacctcat tagatggata acatggatga cttattttaga	1440
15	agatccaaga atccaatttc attatgataa aaccttacca gaacttaagc atattccaga	1500
	tgtatataca tctagtcagt ctctgtttaa acatccttct caatatgaag gagtgtttta	1560
	tactgatggc tcggccatca aaagtcctga tcctacaaaa agcaataatg ctggcatggg	1620
20	aatagtagat gccacatata aacctgaata tcaagttttg aatcaatggt caataccact	1680
	aggtaatcat actgctcaga tggctgaaat agctgcagtt gaatttgcct gtaaaaaagc	1740
25	tttaaaaata cctggtcctg tattagttat aactgatagt ttctatgtag cagaaagtgc	1800
	taataaagaa ttaccatact ggaaatctaa tgggtttgtt aataataaga aaaagcctct	1860
	taaacatatc tccaaatgga aatctattgc tgagtgttta tctatgaaac cagacattac	1920
30	tattcaacat gaaaaaggca tcagcctaca aataccagta ttcatactga aaggcaatgc	1980
	cctagcagat aagcttgcca cccaaggaag ttatgtggtt aattgtaata ccaaaaaacc	2040
	aaacctggat gcagagttgg atcaattatt acagggcat tatataaaag gatatcccaa	2100
35	acaatataca tatttttttag aagatggcaa agtaaaagtt tccagacctg aaggggttaa	2160
	aattattccc cctcagtcag acagacaaaa aattgtgctt caagcccaca atttggctca	2220
	caccggacgt gaagccactc ttttaaaaat tgccaacctt tattggtggc caaatatgag	2280
40	aaaggatgtg gttaaacaac taggacgctg tcaacagtgt ttaatcacia atgcttccaa	2340
	caaagcctct ggtcctattc taagaccaga taggcctcaa aaaccttttg ataaattctt	2400
	tattgactat attggacctt tgccaccttc acagggatac ctatatgtat tagtagttgt	2460
45	tgatggaatg acaggattca cttgggttata cccactaag gtccttcta ctagcgcaac	2520
	tgttaaactc ctcaatgtac tcactagtat tgcaattcca aagggtgattc actctgatca	2580
	aggtgcagca ttcacttctt caacctttgc tgaatgggca aaggaaagag gtatacat	2640
50	ggaattcagt actccttata acccccaaag tggtagtaag gtggaaagga aaaatagtga	2700
	tataaaacga cttttaacta aactgctagt aggaagacct acaaagtggg atgacctatt	2760
55	gcctgttgta caacttgctt taaacaacac ctatagccct gtattaaaa atactccaca	2820
	tcaactctta tttggtatag attcaaatac tccatttgca aatcaagata cacttgactt	2880

EP 2 699 593 B1

	gaccagagaa gaagaacttt ctcttttaca ggaaattcgt acttctttat accatccatc	2940
	cacctctcca gcctcctctc gttcctggtc tcctgttggt ggccaattgg tccaggagag	3000
5	ggtggctagg cctgcttctt tgagacctcg ttggcataaa ccgtctactg tacttaaggt	3060
	gttgaatcca aggactgttg ttatttttga ccatcttggc aacaacagaa ctgtaagtat	3120
	agataattta aaacctactt ctcatcagaa tggcaccacc aatgacactg caacaatgga	3180
10	tcatttgga aaaaatgaat aaagcgcgtg aggcacttca aaatacaaca actgtgactg	3240
	aacagcagaa ggaacaaatt atactggaca ttcaaatga agaagtacaa ccaactagga	3300
	gagataaatt tagatatctg ctttatactt gttgtgctac tagctcaaga gtattggcct	3360
15	ggatgttttt agtttgtata ttgttaatca ttgttttggg ttcatgcttt gtgactatat	3420
	ccagaatata atggaataag gatattcagg tattaggacc tgtaatagac tggaatgtta	3480
20	ctcaaagagc tgtttatcaa cccttacaga ctagaaggat tgcacgttcc cttagaatgc	3540
	agcatcctgt tccaaaatat gtggaggtaa atatgactag tattccacaa ggtgtatact	3600
	atgaaccca tccggcctcg acggtatcga tggtagcggg atcgataagc ttgataacct	3660
25	cgagagatct aattctaccg ggtaggggag gcgcttttcc caaggcagtc tggagcatgc	3720
	gcttttagcag ccccgctggc acttggcgct acacaagtgg cctctggcct cgcacacatt	3780
	ccacatccac cggtagcgcc aaccggctcc gttcttttgg ggccccttcg cgccacttct	3840
30	actcctcccc tagtcaggaa gtttccccca gcaagctcgc gtcgtgcagg acgtgacaaa	3900
	tggaagtagc acgtctcact agtctcgtgc agatggacag caccgctgag caatggaagc	3960
35	gggtaggcct ttggggcagc ggccaatagc agctttgttc cttcgctttc tgggctcaga	4020
	ggctgggaag ggggtgggtcc gggggcgggc tcaggggagg gctcaggggc gggcgggcgc	4080
	ccgaaggtcc tcccagggcc cggcattctg cacgcttcaa aagcgcacgt ctgccgcgct	4140
40	gttctcctct tcctcatctc cgggcctttc gacctgcagc ccgggggatc gatcctaggt	4200
	gattttaaate caccatgacc gagtacaagc ccacggtgcg cctcgccacc cgcgacgacg	4260
	tcccccgggc cgtacgcacc ctgcgcgccc cgttcgcca ctaccccgcc acgcgccaca	4320
45	ccgtcgaccc ggaccgccac atcgagcggg tcaccgagct gcaagaactc ttcctcacgc	4380
	gcgtcgggct cgacatcgcc aaggtgtggg tcgcggacga cggcgccgcg gtggcggtct	4440
	ggaccacgcc ggagagcgtc gaagcggggg cgggtgttcgc cgagatcggc ccgcgcatgg	4500
50	ccgagttgag cggttcccg gctggccgcg agcaacagat ggaaggcctc ctggcgccgc	4560
	accggcccaa ggagcccgcg tggttcctgg ccaccgtcgg cgtctcgccc gaccaccagg	4620
55	gcaaggggtct gggcagcgcc gtcgtgctcc ccggagtggg ggcggccgag cgcgccgggg	4680
	tgcccgctt cctggagacc tccgcgcccc gcaacctccc cttctacgag cggctcggct	4740

EP 2 699 593 B1

	tcaccgtcac	cgccgacgtc	gagtgtcccga	aggaccgcgc	gacctggtgc	atgacccgca	4800
	agcccgggtgc	ctgacggatc	catcgctccg	gtgcccgtca	gtgggcagag	cgcacatcgc	4860
5	ccacagtccc	cgagaagttg	gggggagggg	tcggcaattg	aaccgggtgc	tagagaaggt	4920
	ggcgcggggt	aaactgggaa	agtgatgtcg	tgtactggct	ccgccttttt	cccgaggggtg	4980
	ggggagaacc	gtatataagt	gcagtagtcg	ccgtgaacgt	tctttttcgc	aacgggtttg	5040
10	ccgccagaac	acagctgcgg	ccgcgttaac	catgagccga	tccgtggcac	tggctgtcct	5100
	ggctctgctg	tctctgagtg	gcctggaagc	agtgatggcc	cctagaacac	tgttcctggg	5160
	cggagggcgg	tccggaggag	gaggggtctg	aggcggggga	agtatccagc	ggactcccaa	5220
15	gattcaggtc	tacagcagac	accctgccga	aaacgggaaa	tccaacttcc	tgaattgcta	5280
	tgtgtcaggc	tttcatccca	gcgacatcga	ggtcgatctg	ctgaagaatg	gcgagcggat	5340
	tgaaaaagtg	gagcactctg	acctgtcatt	cagcaaggat	tggagctttt	acctgctgta	5400
20	ctatactgag	tttaccctaa	cagaaaaaga	cgagtatgcc	tgtagggtga	accatgtcac	5460
	cctgagtcag	cccaagatcg	tgaaatggga	ccgcgatatg	ggcgggggag	gctccggggg	5520
	aggcggtccc	ggcggcgggg	gaagtggcgg	gggaggatcc	ggttctcact	ccttgaagta	5580
25	tttccacact	tccgtgtccc	ggcccggccg	cggggagccc	cgcttcatct	ctgtgggcta	5640
	cgtggacgac	accagtttcg	tgcgcttcga	caacgacgcc	gcgagtccga	ggatggtgcc	5700
30	gcgggcgccc	tggatggagc	aggaggggtc	agagtattgg	gaccgggaga	cacggagcgc	5760
	cagggacacc	gcacagattt	tccgagtga	tctgcggacg	ctgcgcggct	actacaatca	5820
	gagcgaggcc	gggtctcaca	ccctgcagtg	gatgcatggc	tgcgagctgg	ggcccgcagg	5880
35	gcgcttcctc	cgcgggtatg	aacagttcgc	ctacgacggc	aaggattatc	tcaccctgaa	5940
	tgaggacctg	cgctcctgga	ccgcggtgga	cacggcggtc	cagatctccg	agcaaaagtc	6000
	aatgatgcc	tctgaggcgg	agcaccagag	agcctacctg	gaagacacat	gcgtggagtg	6060
40	gctccacaaa	tacctggaga	aggggaagga	gacgctgctt	cacctggagc	ccccaaagac	6120
	acacgtgact	caccacccca	tctctgacca	tgaggccacc	ctgaggtgct	gggccctggg	6180
	cttctaccct	gcggagatca	cactgacctg	gcagcaggat	ggggagggcc	ataccagga	6240
45	cacggagctc	gtggagacca	ggcctgcagg	ggatggaacc	ttccagaagt	gggcagctgt	6300
	ggtggtgcct	tctggagagg	agcagagata	cacgtgccat	gtgcagcatg	aggggctacc	6360
	cgagcccgtc	accctgagat	ggaagccggc	ttcccagccc	accatcccca	tcgtgggcat	6420
50	cattgctggc	ctggttctcc	ttggatctgt	ggtctctgga	gctgtggttg	ctgctgtgat	6480
	atggaggaag	aagagctcag	gtggaaaagg	agggagctac	tctaaggctg	agtggagcga	6540
55	cagtgccag	gggtctgagt	ctcacagctt	gtaatctaga	gcggccgcga	ctctagatca	6600
	ggcgcgccgt	taccaagcag	ctatggaagc	ttatggacct	cagagaggaa	gtaacgagga	6660

EP 2 699 593 B1

	gaggggtgtgg	tggaatgtca	ctagaaacca	gggaaaacaa	ggaggagagt	attacaggga	6720
	aggaggtgaa	gaacctcatt	acccaaatac	tcctgctcct	catagacgta	cctgggatga	6780
5	gagacacaag	gttctttaat	tgtcctcatt	cgctactccc	tctgacatcc	aacgctggac	6840
	tactaactct	agattgtacg	ggaggctctt	cactactcgc	tgcgtcgaga	gtgtacgaga	6900
	ctctccaggt	ttggttaagaa	atattttata	ttgttataat	gttactatga	tccattaaca	6960
10	ctctgcttat	agattgtaag	ggtgattgca	atgcttttctg	cataaaactt	tggtttttctt	7020
	gttaatcaat	aaaccgactt	gattcgagaa	ccaactccta	tattattgtc	tctttttatac	7080
	tttattaagt	aaaaggattt	gtatattagc	cttgctaagg	gagacatcta	gtgatataag	7140
15	tgtgaactac	acttatctta	aatgatgtaa	ctccttagga	taatcaatat	acaaaattcc	7200
	atgacaattg	gcgataccgt	cgaccgttca	gctgcattaa	tgaatcggcc	aacgcgcggg	7260
20	gagaggcggt	ttgcgtattg	ggcgcctctt	cgcttcctcg	ctcactgact	cgctgcgctc	7320
	ggtcgttcgg	ctgcggcgag	cggatcagc	tcactcaaag	gcggtaatac	ggttatccac	7380
	agaatcaggg	gataacgcag	gaaagaacat	gtgagcaaaa	ggccagcaaa	aggccaggaa	7440
25	ccgtaaaaag	gccgcgttgc	tggcgttttt	ccataggctc	cgccccctg	acgagcatca	7500
	caaaaatcga	cgctcaagtc	agaggtggcg	aaacccgaca	ggactataaa	gataccaggc	7560
	gtttccccct	ggaagctccc	tcgtgcgctc	tcctgttccg	accctgccgc	ttaccggata	7620
30	cctgtccgcc	tttctccctt	cgggaagcgt	ggcgccttct	caatgctcac	gctgtaggta	7680
	tctcagttcg	gtgtaggtcg	ttcgtcccaa	gctgggctgt	gtgcacgaac	cccccgttca	7740
35	gcccgaccgc	tgcgcccttat	ccggtaacta	tcgtcttgag	tccaacccgg	taagacacga	7800
	cttatcgcca	ctggcagcag	ccactggtaa	caggattagc	agagcgaggt	atgtaggcgg	7860
	tgctacagag	ttcttgaagt	ggtggcctaa	ctacggctac	actagaagga	cagtatttgg	7920
40	tatctgcgct	ctgctgaagc	cagttacctt	cggaaaaaga	gttggtagct	cttgatccgg	7980
	caaacaaacc	accgctggta	gcggtggttt	ttttgtttgc	aagcagcaga	ttacgcgcag	8040
	aaaaaaagga	tctcaagaag	atcctttgat	cttttctacg	gggtctgacg	ctcagtggaa	8100
45	cgaaaactca	cgттаaggga	ttttggtcat	gagattatca	aaaaggatct	tcacctagat	8160
	cctttttaaat	taaaaatgaa	gttttaaatc	aatctaaagt	atatatgagt	aaacttggtc	8220
	tgacagttac	caatgcttaa	tcagtgaggc	acctatctca	gcgatctgtc	tatttcggtc	8280
50	atccatagtt	gcctgactcc	ccgtcgtgta	gataactacg	atacgggagg	gcttaccatc	8340
	tggccccagt	gctgcaatga	taccgcgaga	cccacgctca	ccggctccag	atttatcagc	8400
55	aataaaccag	ccagccggaa	gggccgagcg	cagaagtggg	cctgcaactt	tatccgcctc	8460
	catccagtct	attaattggt	gccgggaagc	tagagtaagt	agttcgccag	ttaatagttt	8520

EP 2 699 593 B1

	gcgcaacggtt gttgccattg ctacaggcat cgtggtgtca cgctcgtcgt ttggtatggc	8580
	ttcattcagc tccggttccc aacgatcaag gcgagttaca tgatccccc tgttggtgcaa	8640
5	aaaagcgggtt agctccttcg gtcctccgat cgttgtcaga agtaagttgg ccgcagtgtt	8700
	atcactcatg gttatggcag cactgcataa ttctcttact gtcatgccat ccgtaagatg	8760
10	cttttctgtg actggtgagt actcaaccaa gtcattctga gaatagtgtg tgcggcgacc	8820
	gagttgctct tgcccggcgt caatacggga taataccgcg ccacatagca gaactttaaa	8880
	agtgtcatc attggaaaac gttcttcggg gcgaaaactc tcaaggatct taccgctgtt	8940
15	gagatccagt tcgatgtaac ccactcgtgc acccaactga tcttcagcat cttttacttt	9000
	caccagcgtt tctgggtgag caaaaacagg aaggcaaaat gccgcaaaaa agggaataag	9060
	ggcgacacgg aaatgttgaa tactcatact cttccttttt caatattatt gaagcattta	9120
20	tcagggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaacaaat	9180
	aggggttccg cgcacatttc cccgaaaagt gccacctgac gtctaagaaa ccattattat	9240
25	catgacatta acctataaaa ataggcgtat cagcaggccc tttcgtc	9287

<210> 20
 <211> 500
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> HLA-bGBE

<400> 20

EP 2 699 593 B1

	Met	Ser	Arg	Ser	Val	Ala	Leu	Ala	Val	Leu	Ala	Leu	Leu	Ser	Leu	Ser
	1				5					10					15	
5	Gly	Leu	Glu	Ala	Val	Met	Ala	Pro	Arg	Thr	Leu	Phe	Leu	Gly	Gly	Gly
				20					25					30		
10	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Ile	Gln	Arg	Thr
			35					40					45			
15	Pro	Lys	Ile	Gln	Val	Tyr	Ser	Arg	His	Pro	Ala	Glu	Asn	Gly	Lys	Ser
		50					55					60				
20	Asn	Phe	Leu	Asn	Cys	Tyr	Val	Ser	Gly	Phe	His	Pro	Ser	Asp	Ile	Glu
	65					70					75				80	
25	Val	Asp	Leu	Leu	Lys	Asn	Gly	Glu	Arg	Ile	Glu	Lys	Val	Glu	His	Ser
					85					90					95	
30	Asp	Leu	Ser	Phe	Ser	Lys	Asp	Trp	Ser	Phe	Tyr	Leu	Leu	Tyr	Tyr	Thr
				100					105					110		
35																
40																
45																
50																
55																

EP 2 699 593 B1

	Glu	Phe	Thr	Pro	Thr	Glu	Lys	Asp	Glu	Tyr	Ala	Cys	Arg	Val	Asn	His	
			115					120					125				
5	Val	Thr	Leu	Ser	Gln	Pro	Lys	Ile	Val	Lys	Trp	Asp	Arg	Asp	Met	Gly	
		130					135					140					
10	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	
	145					150					155					160	
15	Gly	Gly	Ser	Gly	Ser	His	Ser	Leu	Lys	Tyr	Phe	His	Thr	Ser	Val	Ser	
				165						170					175		
20	Arg	Pro	Gly	Arg	Gly	Glu	Pro	Arg	Phe	Ile	Ser	Val	Gly	Tyr	Val	Asp	
				180					185					190			
25	Asp	Thr	Gln	Phe	Val	Arg	Phe	Asp	Asn	Asp	Ala	Ala	Ser	Pro	Arg	Met	
			195					200					205				
30	Val	Pro	Arg	Ala	Pro	Trp	Met	Glu	Gln	Glu	Gly	Ser	Glu	Tyr	Trp	Asp	
	210						215					220					
35	Arg	Glu	Thr	Arg	Ser	Ala	Arg	Asp	Thr	Ala	Gln	Ile	Phe	Arg	Val	Asn	
	225					230					235					240	
40	Leu	Arg	Thr	Leu	Arg	Gly	Tyr	Tyr	Asn	Gln	Ser	Glu	Ala	Gly	Ser	His	
					245					250					255		
45	Thr	Leu	Gln	Trp	Met	His	Gly	Cys	Glu	Leu	Gly	Pro	Asp	Gly	Arg	Phe	
			260						265					270			
50	Leu	Arg	Gly	Tyr	Glu	Gln	Phe	Ala	Tyr	Asp	Gly	Lys	Asp	Tyr	Leu	Thr	
			275					280					285				
55	Leu	Asn	Glu	Asp	Leu	Arg	Ser	Trp	Thr	Ala	Val	Asp	Thr	Ala	Ala	Gln	
	290						295					300					
60	Ile	Ser	Glu	Gln	Lys	Ser	Asn	Asp	Ala	Ser	Glu	Ala	Glu	His	Gln	Arg	
	305					310					315					320	
65	Ala	Tyr	Leu	Glu	Asp	Thr	Cys	Val	Glu	Trp	Leu	His	Lys	Tyr	Leu	Glu	
				325						330					335		
70	Lys	Gly	Lys	Glu	Thr	Leu	Leu	His	Leu	Glu	Pro	Pro	Lys	Thr	His	Val	
				340					345					350			
75	Thr	His	His	Pro	Ile	Ser	Asp	His	Glu	Ala	Thr	Leu	Arg	Cys	Trp	Ala	

EP 2 699 593 B1

	355		360		365												
5	Leu	Gly	Phe	Tyr	Pro	Ala	Glu	Ile	Thr	Leu	Thr	Trp	Gln	Gln	Asp	Gly	
	370						375					380					
	Glu	Gly	His	Thr	Gln	Asp	Thr	Glu	Leu	Val	Glu	Thr	Arg	Pro	Ala	Gly	
10	385					390					395					400	
	Asp	Gly	Thr	Phe	Gln	Lys	Trp	Ala	Ala	Val	Val	Val	Pro	Ser	Gly	Glu	
					405					410					415		
15	Glu	Gln	Arg	Tyr	Thr	Cys	His	Val	Gln	His	Glu	Gly	Leu	Pro	Glu	Pro	
				420					425					430			
	Val	Thr	Leu	Arg	Trp	Lys	Pro	Ala	Ser	Gln	Pro	Thr	Ile	Pro	Ile	Val	
20			435					440					445				
	Gly	Ile	Ile	Ala	Gly	Leu	Val	Leu	Leu	Gly	Ser	Val	Val	Ser	Gly	Ala	
25		450					455					460					
	Val	Val	Ala	Ala	Val	Ile	Trp	Arg	Lys	Lys	Ser	Ser	Gly	Gly	Lys	Gly	
	465					470					475					480	
30	Gly	Ser	Tyr	Ser	Lys	Ala	Glu	Trp	Ser	Asp	Ser	Ala	Gln	Gly	Ser	Glu	
					485					490					495		
35	Ser	His	Ser	Leu													
				500													

<210> 21

<211> 7159

<212> DNA

40 <213> Artificial Sequence

<220>

<223> Vector sequence for pA2-B2METKNpA

45 <400> 21

50

55

EP 2 699 593 B1

	ctgcgcgctc gctcgctcac tgaggccgcc cgggcaaagc ccgggcgctc ggcgaccttt	60
	ggtcgcccgg cctcagtgag cgagcgagcg cgcagagagg gagtggccaa ctccatcact	120
5	aggggttcct gcggccgcga tgcagtccaa actctcacta aaattgccga gccctttgtc	180
	ttccagtgtc taaaatatta atgtcaatgg aatcaggcca gagtttgaat tctagtctct	240
	tagcctttgt ttcccctgtc cataaaatga atgggggtaa ttctttcctc ctacagttta	300
10	tttatatatt cactaattca ttcattcatc catccattcg ttcattcggg ttactgagta	360
	cctactatgt gccagcccct gttctagggt ggaaactaag agaatgatgt acctagaggg	420
15	cgttggaagc tctaaagccc tagcagttac tgcttttact attagtggtc gtttttttct	480
20		
25		
30		
35		
40		
45		
50		
55		

EP 2 699 593 B1

	cccccccgcc	ccccgacaaa	tcaacagAAC	aaagaaaatt	acctaaacag	caaggacata	540
	gggaggaact	tcttggcaca	gaactttcca	aacacttttt	cctgaagggg	tacaagaagc	600
5	aagaaaggta	ctcttttact	aggaccttct	ctgagctgtc	ctcaggatgc	ttttgggact	660
	atTTTTctta	cccagagaat	ggagaaaccc	tgcagggaat	tcccaagctg	tagttataaa	720
	cagaagttct	ccttctgcta	ggtagcattc	aaagatctta	atcttctggg	tttccgtttt	780
10	ctcgaatgaa	aaatgcaggt	ccgagcagtt	aactggctgg	ggcaccatta	gcaagtcact	840
	tagcatctct	ggggccagtc	tgcaaagcga	gggggcagcc	ttaatgtgcc	tccagcctga	900
	agtcctagaa	tgagcgcccc	gtgtcccaag	ctggggcgcg	cacccagat	cggagggcg	960
15	cgatgtacag	acagcaaact	cacccagtct	agtgcattgc	ttcttaaaca	tcacgagact	1020
	ctaagaaaag	gaaactgaaa	acgggaaagt	ccctctctct	aacctggcac	tgcgtcgctg	1080
20	gcttggagac	aggtgacggt	ccctgcgggc	cttgtcctga	ttggctgggc	acgcgtttaa	1140
	tataagtgga	ggcgtcg	tgggggcat	tcctgaagct	gacagcattc	gggccgagat	1200
	ctagataact	tcgtataatg	tatgctatac	gaagttatgg	atccatcgat	tctgcgatcg	1260
25	ctccggtgcc	cgtcagtggg	cagagcgcac	atcgcccaca	gtccccgaga	agttgggggg	1320
	aggggtcggc	aattgaaccg	gtgcctagag	aaggtggcgc	ggggtaaact	gggaaagtga	1380
	tgctcgtgtac	tggtctccgc	tttttccga	gggtggggga	gaaccgtata	taagtgcagt	1440
30	agtcgccgtg	aacgttcttt	ttcgcaacgg	gtttgccgcc	agaacacagc	tgaagcttcc	1500
	accatgccc	cgctactgcg	ggtttatata	gacggtcccc	acgggatggg	gaaaaccacc	1560
	accacgcaac	tgctgggtgg	cctgggttcg	cgcgacgata	tcgtctacgt	acccgagccg	1620
35	atgacttact	ggcgggtgct	gggggcttcc	gagacaatcg	cgaacatcta	caccacacaa	1680
	caccgcctcg	accaggtga	gatatcgcc	ggggacgcgc	cggtggtaat	gacaagcgcc	1740
40	cagataacaa	tgggcatgcc	ttatgccgtg	accgacgccg	ttctggctcc	tcatatcggg	1800
	ggggaggctg	ggagctcaca	tgccccgcc	ccggccctca	ccctcatctt	cgaccgccat	1860
	cccatcgccg	ccctcctgtg	ctacccgcc	gcgcggtacc	ttatgggcag	catgaccccc	1920
45	caggccgtgc	tggtgttcgt	ggccctcatc	ccgccgacct	tgcccgccac	caacatcggt	1980
	cttggggccc	ttccggagga	cagacacatc	gaccgcctgg	ccaaacgcca	gcgccccggc	2040
	gagcggctgg	acctggctat	gctggctgcg	attcgccgcg	tttacgggct	acttgccaat	2100
50	acggtgcggt	atctgcagtg	cggcgggtcg	tggtgggagg	actggggaca	gctttcgggg	2160
	acggccgtgc	cgccccaggg	tgccgagccc	cagagcaacg	cgggcccacg	accccatatc	2220
55	ggggacacgt	tatttaccct	gtttcggggc	cccagattgc	tggcccccaa	cggcgacctg	2280
	tataacgtgt	ttgcctgggc	cttggtgcgc	ttggccaaac	gcctccgttc	catgcacgtc	2340

EP 2 699 593 B1

	tttatcctgg	attacgacca	atcgcccgcc	ggctgccggg	acgccctgct	gcaacttacc	2400
	tccgggatgg	tccagaccca	cgtcaccacc	cccggctcca	taccgacgat	atgcgacctg	2460
5	gcgcgcacgt	ttgcccggga	gatgggatcg	gccattgaac	aagatggatt	gcacgcaggt	2520
	tctccggccg	cttggttgga	gaggctattc	ggctatgact	gggcacaaca	gacaatcggc	2580
	tgctctgatg	ccgccgtggt	ccggctgtca	gcgcaggggc	gcccggttct	ttttgtcaag	2640
10	accgacctgt	ccggtgccct	gaatgaactg	caggacgagg	cagcgcggtc	atcgtggctg	2700
	gccacgacgg	gcgttccttg	cgcagctgtg	ctcgacgttg	tcactgaagc	gggaagggac	2760
	tggctgctat	tgggcgaagt	gccggggcag	gatctcctgt	catctcacct	tgctcctgcc	2820
15	gagaaagtat	ccatcatggc	tgatgcaatg	cggcggctgc	atacgcttga	tccggctacc	2880
	tgcccattcg	accaccaagc	gaaacatcgc	atcgagcgag	cacgtactcg	gatggaagcc	2940
	ggtcttgtcg	atcaggatga	tctggacgaa	gagcatcagg	ggctcgcgcc	agccgaactg	3000
20	ttcgccaggc	tcaaggcgcg	catgcccagc	ggcgaggatc	tcgtcgtgac	ccatggcgat	3060
	gcctgcttgc	cgaatatcat	ggtggaaaat	ggccgctttt	ctggattcat	cgactgtggc	3120
	cggctgggtg	tggcggaccg	ctatcaggac	atagcgttgg	ctaccogtga	tattgctgaa	3180
25	gagcttggcg	gcgaatgggc	tgaccgcttc	ctcgtgcttt	acggtatcgc	cgctcccgat	3240
	tcgcagcgca	tcgccttcta	tcgccttctt	gacgagttct	tctgagggtc	tctagcataa	3300
	cttcgtataa	tgtatgctat	acgaagttat	aataaaagat	ccttattttc	attggatctg	3360
30	tgtgttgggt	ttttgtgtgg	gatccgtcga	taccgtcgac	tgtctcgctc	cgtggcctta	3420
	gctgtgctcg	cgtactctc	tctttctggc	ctggaggcta	tccagcgtga	gtctctccta	3480
35	ccctcccgtc	ctggctcctc	ctctcccgtc	ctgcaccctc	tgtggccctc	gctgtgctct	3540
	ctcgtccgt	gacttccctt	ctccaagttc	tccttgggtg	cccgccgtgg	ggctagtcca	3600
	gggctggatc	tcggggaagc	ggcgggggtg	cctgggagtg	gggaaggggg	tgcgcacccg	3660
40	ggacgcgcgc	tacttgcccc	tttcggcggg	gagcagggga	gacctttggc	ctacggcgac	3720
	gggagggctg	ggacaaagtt	tagggcgctg	ataagcgtca	gagcgccgag	gttgggggag	3780
	ggtttctctt	ccgtcttttc	gcggggcctc	tggctcccc	agcgcagctg	gagtggggga	3840
45	cgggtaggct	cgtcccaaag	gcgcggcgct	gaggtttgtg	aacgcgtgga	ggggcgcttg	3900
	gggtctgggg	gaggcgctgc	ccgggtaagc	ctgtctgctg	cggctctgct	tcccttagac	3960
	tggagagctg	tggacttcgt	ctaggcgccc	gctaagttcg	catgtcctag	cacctctggg	4020
50	tctatgtggg	gccacaccgt	ggggaggaaa	cagcacgcga	cgtttgtaga	atgcttggct	4080
	gtgatacaaa	gcggtttcga	ataattaact	tatttgttcc	catcacatgt	cacttttaaa	4140
55	aaattataag	aactaccggt	tattgacatc	tttctgtgtg	ccaaggactt	tatgtgcttt	4200
	gcgtcattta	attttgaaaa	cagttatctt	ccgccataga	taactactat	ggttatcttc	4260

EP 2 699 593 B1

	tgcctctcac	agatgaagaa	actaaggcac	cgagatttta	agaaacttaa	ttacacaggg	4320
	gataaatggc	agcaatcgag	attgaagtca	agcctaacca	gggcttttgc	gggagcgcat	4380
5	gccttttggc	tgtaattcgt	gcgcggccgc	aggaaccctt	agtgatggag	ttggccactc	4440
	cctctctgcg	cgctcgctcg	ctcactgagg	ccgggcgacc	aaaggtcgcc	cgacgcccgg	4500
	gctttgcccg	ggcggcctca	gtgagcgagc	gagcgcgagc	ctgcctgcag	gggcgcctga	4560
10	tgcggtat	tctccttacg	catctgtgcg	gtatttcaca	ccgcatacgt	caaagcaacc	4620
	atagtacgcg	ccctgtagcg	gcgcattaag	cgcggcgggt	gtggtggtta	cgcgagcggt	4680
	gaccgctaca	cttgccagcg	ccctagcgcc	cgctcctttc	gctttcttcc	cttcctttct	4740
15	cgccacgttc	gccggctttc	cccgtcaagc	tctaaatcgg	gggctccctt	tagggttccg	4800
	athtagtgct	ttacggcacc	tgcaccccaa	aaaacttgat	ttgggtgatg	gttcacgtag	4860
20	tgggcatcg	ccctgataga	cggtttttcg	ccctttgacg	ttggagtcca	cgttctttta	4920
	tagtggactc	ttgttcctaa	ctggaacaac	actcaaccct	atctcgggct	attcttttga	4980
	tttataaggg	atthtgcga	tttcggccta	ttgggttaaaa	aatgagctga	tttaacaaaa	5040
25	atthaacgcg	aatthtaaca	aaatattaac	gtttacaatt	ttatggtgca	ctctcagtac	5100
	aatctgctct	gatgccgcat	agttaagcca	gccccgacac	ccgccaacac	ccgtgacgc	5160
	gccctgacgg	gcttgtctgc	tcccggcatc	cgcttacaga	caagctgtga	ccgtctccgg	5220
30	gagctgcatg	tgctagaggt	tttcaccgtc	atcacgaaa	cgcgcgagac	gaaagggcct	5280
	cgtgatacgc	ctatthttat	aggttaatgt	catgataata	atggtttctt	agacgtcagg	5340
35	tggcactttt	cggggaaatg	tgcgcggaac	ccctatthgt	ttatthttct	aaatacatth	5400
	aaatatgtat	ccgtctcatg	gacaataacc	ctgataaatg	cttcaataat	attgaaaaag	5460
	gaagagtatg	agtattcaac	atthccgtgt	cgcccttatt	ccctthtttg	cggcatthtg	5520
40	ccttctgtt	tttgctcacc	cagaaacgct	ggtgaaagta	aaagatgctg	aagatcagtt	5580
	gggtgcacga	gtgggttaca	tcgaactgga	tctcaacagc	ggtaagatcc	ttgagagttt	5640
	tcgccccgaa	gaacgtthtc	caatgatgag	cactthttaa	gttctgctat	gtggcgcggt	5700
45	attatcccg	attgacgccg	ggcaagagca	actcggtcgc	cgcatacact	attctcagaa	5760
	tgacttggtt	gagtactcac	cagtcacaga	aaagcatctt	acggatggca	tgacagtaag	5820
	agaattatgc	agtgtgccca	taaccatgag	tgataacact	gcggccaact	tacttctgac	5880
50	aacgatcgga	ggaccgaagg	agctaaccgc	ttthttgcac	aacatggggg	atcatgtaac	5940
	tcgccttgat	cgttggggaa	cggagctgaa	tgaagccata	caaacgacg	agcgtgacac	6000
55	cacgatgcct	gtagcaatgg	caacaacggt	gcgcaacta	ttactggcg	aactacttac	6060
	tctagcttcc	cggcaacaat	taatagactg	gatggaggcg	gataaagttg	caggaccact	6120

EP 2 699 593 B1

	tctgcgctcg gcccttccgg ctggctggtt tattgctgat aaatctggag ccggtgagcg	6180
	tgggtctcgc ggtatcattg cagcactggg gccagatggt aagccctccc gtatcgtagt	6240
5	tatctacacg acggggagtc aggcaactat ggatgaacga aatagacaga tcgctgagat	6300
	aggtgcctca ctgattaagc attggtaact gtcagaccaa gtttactcat atatacttta	6360
10	gattgattta aaacttcatt tttaatttaa aaggatctag gtgaagatcc tttttgataa	6420
	tctcatgacc aaaatccctt aacgtgagtt ttcgttccac tgagcgtcag accccgtaga	6480
	aaagatcaaa ggatcttctt gagatccttt ttttctgcgc gtaatctgct gcttgcaaac	6540
15	aaaaaaacca ccgctaccag cggtggtttg tttgccggat caagagctac caactctttt	6600
	tccgaaggta actggcttca gcagagcgca gataccaaat actgtccttc tagtgtagcc	6660
	gtagttaggc caccacttca agaactctgt agcaccgcct acatacctcg ctctgctaata	6720
20	cctgttacca gtggctgctg ccagtggcga taagtcgtgt cttaccgggt tggactcaag	6780
	acgatagtta ccggataaag cgcagcggtc gggctgaacg ggggggttcgt gcacacagcc	6840
	cagcttggag cgaacgacct acaccgaact gagataccta cagcgtgagc tatgagaaag	6900
25	cgccacgctt cccgaaggga gaaaggcggg caggtatccg gtaagcggca gggtcggaac	6960
	aggagagcgc acgagggagc ttccaggggg aaacgcctgg tatctttata gtcctgtcgg	7020
30	gtttcgccac ctctgacttg agcgtcgatt tttgtgatgc tcgtcagggg ggcggagcct	7080
	atggaaaaac gccagcaacg cggccttttt acggttcctg gccttttgct ggccttttgc	7140
	tcacatgtcc tgcaggcag	7159
35	<210> 22 <211> 7199 <212> DNA <213> Artificial Sequence	
40	<220> <223> Vector sequence for pA2-B2MEHyTKpA	
	<400> 22	
45		
50		
55		

EP 2 699 593 B1

	cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcaaag cccgggcgtc	60
	gggcgacctt tggtcgcccg gcctcagtga gcgagcgagc gcgcagagag ggagtggcca	120
5	actccatcac taggggttcc tgcggccgcg aaactaagag aatgatgtac ctagagggcg	180
	ctggaagctc taaagcccta gcagttactg cttttactat tagtggtcgt ttttttctcc	240
10	ccccgcccc ccgacaaatc aacagaacaa agaaaattac ctaaacagca aggacatagg	300
	gaggaacttc ttggcacaga actttccaaa cactttttcc tgaaggata caagaagcaa	360
	gaaaggtagt ctttcactag gaccttctct gagctgtcct caggatgctt ttgggactat	420
15	ttttcttacc cagagaaatg agaaaccctg cagggaattc ccaagctgta gttataaaca	480
	gaagttctcc ttctgctagg tagcattcaa agatcttaat cttctgggtt tccgttttct	540
20		
25		
30		
35		
40		
45		
50		
55		

EP 2 699 593 B1

	cgaatgaaaa atgcaggtcc gagcagttaa ctggctgggg caccattagc aagtcactta	600
	gcatctcttg ggccagtctg caaagcgagg gggcagcctt aatgtgcctc cagcctgaag	660
5	tcctagaatg agcgcccggg gtcccaagct ggggcgcgca cccagatcg gagggcgccg	720
	atgtacagac agcaaactca cccagtctag tgcattgcctt cttaaaccatc acgagactct	780
	aagaaaagga aactgaaaac gggaaagtcc ctctctctaa cctggcactg cgtcgtctggc	840
10	ttggagacag gtgacgggtcc ctgcgggcct tgtcctgatt ggctgggcac gcgtttaata	900
	taagtggagg cgtcgcgctg gcgggcattc ctgaagctga cagcattcgg gccgagatct	960
	agataacttc gtataatgta tgctatacga agttatggat ccatcgattc tgcgatcgct	1020
15	ccggtgcccg tcagtgggca gagcgcacat cgcccacagt ccccgagaag ttggggggag	1080
	gggtcggcaa ttgaaccggg gcctagagaa ggtggcgcgg ggtaaaactgg gaaagtgatg	1140
20	tcgtgtactg gctccgcctt tttcccagg gtgggggaga accgtatata agtgcagtag	1200
	tcgccgtgaa cgttcttttt cgcaacgggt ttgccgccag aacacagctg aagcttccac	1260
	catgaaaaag cctgaactca ccgcgacgtc tgtcgagaag tttctgatcg aaaagtccga	1320
25	cagcgtctcc gacctgatgc agctctcgga gggcgaagaa tctcgtgctt tcagcttcga	1380
	tgtaggaggg cgtggatatg tcctgcgggg aaatagctgc gccgatggtt tctacaaaga	1440
	tcgttatgtt tatcggcact ttgcatcggc cgcgctcccg attccggaag tgcttgacat	1500
30	tggggaattc agcgagagcc tgacctattg catctcccgc cgtgcacagg gtgtcacgtt	1560
	gcaagacctg cctgaaaccg aactgcccgc tgttctgcag ccggtcgcgg aggccatgga	1620
	tgcgatcgct gcggccgatc ttagccagac gagcgggttc ggcccattcg gaccgcaagg	1680
35	aatcgggtcaa tacactacat ggcgtgattt catatgcgcg attgctgatc cccatgtgta	1740
	tcactggcaa actgtgatgg acgacaccgt cagtgcgtcc gtcgcgcagg ctctcgatga	1800
40	gctgatgctt tgggcccagg actgccccga agtccggcac ctctgacag cggtattcgg	1860
	ctccaacaat gtctgacgg acaatggccg cataacagcg gtcattgact ggagcgaggc	1920
	gatgttcggg gattcccaat acgaggtcgc caacatcttc ttctggaggc cgtggttggc	1980
45	ttgtatggag cagcagacgc gctacttcga gcggaggcat ccggagcttg caggatcgcc	2040
	gcggctccgg gcgtatatgc tccgcattgg tcttgaccaa ctctatcaga gcttggttga	2100
	cggcaatttc gatgatgcag cttgggcgca gggtcgatgc gacgcaatcg tccgatccgg	2160
50	agccgggact gtcgggctga cacaaatcgc ccgcagaagc gcggccgtct ggaccgatgg	2220
	ctgtgtagaa gtcgcgtctg cgttcgacca ggctgcgcgt tctcgcggcc atagcaaccg	2280
55	acgtacggcg ttgcgccctc gccggcagca agaagccacg gaagtccgcc cggagcagaa	2340
	aatgcccacg ctactgcggg tttatataga cgggtcccac gggatgggga aaaccaccac	2400

EP 2 699 593 B1

	cacgcaactg	ctggtggccc	tgggttcgcg	cgacgatatc	gtctacgtac	ccgagccgat	2460
	gacttactgg	cgggtgctgg	gggcttccga	gacaatcgcg	aacatctaca	ccacacaaca	2520
5	ccgcctcgac	cagggtgaga	tatcgggccg	ggacgcggcg	gtggtaatga	caagcgccca	2580
	gataacaatg	ggcatgcctt	atgccgtgac	cgacgccgtt	ctggctcctc	atatcggggg	2640
	ggaggctggg	agctcacatg	ccccgcccc	ggcctcacc	ctcatcttcg	accgccatcc	2700
10	catcgccgcc	ctcctgtgct	acccggccgc	gcggtacctt	atgggcagca	tgacccccca	2760
	ggccgtgctg	gcgttcgtgg	ccctcatccc	gccgaccttg	cccggcacca	acatcgtgct	2820
	tggggccctt	ccggaggaca	gacacatcga	ccgcctggcc	aaacgccagc	gccccggcga	2880
15	gcggctggac	ctggctatgc	tggctgcgat	tcgccgcgtt	tacgggctac	ttgccaatac	2940
	ggtgcggtat	ctgcagtgcg	gcgggtcgtg	gcgggaggac	tggggacagc	tttcggggac	3000
	ggccgtgccg	ccccagggtg	ccgagcccca	gagcaacgcg	ggcccacgac	cccatatcgg	3060
20	ggacacgtta	tttaccctgt	ttcggggccc	cgagttgctg	gcccccaacg	gcgacctgta	3120
	taacgtgttt	gcctgggcct	tggacgtctt	ggccaaacgc	ctccgttcca	tgcacgtctt	3180
25	tatcctggat	tacgaccaat	cgcccgccgg	ctgccgggac	gccctgctgc	aacttacctc	3240
	cgggatggtc	cagaccacag	tcaccacccc	cggctccata	ccgacgatat	gcgacctggc	3300
	gcgcacgttt	gcccgggaga	tgggggaggc	taactgaggt	ctctagcata	acttcgtata	3360
30	atgtatgcta	tacgaagtta	taataaaaga	tccttatttt	cattggatct	gtgtgttggg	3420
	tttttgtgtg	ggatccgtcg	ataccgtcga	ctgtctcgct	ccgtggcctt	agctgtgctc	3480
	gcgctactct	ctctttctgg	cctggaggct	atccagcgtg	agtctctcct	accctcccgc	3540
35	tctggtcctt	cctctcccgc	tctgcaccct	ctgtggccct	cgtctgtgctc	tctcgtcccg	3600
	tgacttccct	tctccaagtt	ctccttggtg	gcccgccgtg	gggctagtcc	agggctggat	3660
	ctcggggaag	cggcggggtg	gcctgggagt	ggggaagggg	gtgcgcaccc	gggacgcgcg	3720
40	ctacttgccc	ctttcggcgg	ggagcagggg	agaccttg	cctacggcga	cgggagggtc	3780
	gggacaaaagt	ttagggcgtc	gataagcgtc	agagcgccga	ggttggggga	gggtttctct	3840
	tccgctcttt	cgcggggcct	ctggctcccc	cagcgcagct	ggagtggggg	acgggtaggc	3900
45	tcgtcccaaa	ggcgcggcgc	tgaggtttgt	gaacgcgtgg	aggggcgctt	ggggtctggg	3960
	ggaggcgtcg	cccgggtaag	cctgtctgct	gcggctctgc	ttcccttaga	ctggagagct	4020
50	gtggacttcg	tctaggcgcc	cgctaagttc	gcatgtccta	gcacctctgg	gtctatgtgg	4080
	ggccacaccg	tggggaggaa	acagcacgcg	acgtttgtag	aatgcttggc	tgtgatacaa	4140
	agcggtttcg	aataattaac	ttatttggtc	ccatcacatg	tcacttttaa	aaaattataa	4200
55	gaactacccg	ttattgacat	ctttctgtgt	gccaaaggact	ttatgtgctt	tgcgtcattt	4260
	aattttgaaa	acagttatct	tccgccatag	ataactacta	tggttatctt	ctgcctctca	4320

EP 2 699 593 B1

	cagatgaaga aactaaggca ccgagatttt aagaaactta attacacagg ggataaatgg	4380
	cagcaatcga gattgaagtc aagcctaacc agggcttttg cgggagcgca tgccttttg	4440
5	ctgtaattcg tgcgcggccg caggaacccc tagtgatgga gttggccact ccctctctgc	4500
	gcgctcgctc gctcactgag gccgggcgac caaaggctcg cgcacgcccg ggctttgccc	4560
	gggcgccctc agtgagcgag cgagcgcgca gctgcctgca gggcgccctg atgcggtatt	4620
10	ttctccttac gcatctgtgc ggtatttcac accgcatacg tcaaagcaac catagtacgc	4680
	gccctgtagc ggcgcattaa gcgcggcggg tgtggtggtt acgcgcagcg tgaccgctac	4740
	acttgccagc gccctagcgc ccgctccttt cgctttcttc ccttcctttc tcgccacgtt	4800
15	cgccggcttt ccccgtaag ctctaaatcg ggggctccct ttagggttcc gatttagtgc	4860
	tttacggcac ctcgacccca aaaaacttga tttgggtgat ggttcacgta gtgggccatc	4920
20	gccctgatag acggtttttc gccctttgac gttggagtcc acgttcttta atagtggact	4980
	cttgttccaa actggaacaa cactcaaccc tatctcgggc tattcttttg atttataagg	5040
	gattttgccg atttcggcct attggttaaa aaatgagctg atttaacaaa aatttaacgc	5100
25	gaattttaac aaaatattaa cgtttacaat tttatggtgc actctcagta caatctgctc	5160
	tgatgccgca tagttaagcc agccccgaca cccgccaaca cccgctgacg cgccctgacg	5220
	ggcttgctcg ctcccggcat ccgcttacag acaagctgtg accgtctccg ggagctgcat	5280
30	gtgtcagagg ttttcaccgt catcaccgaa acgcgcgaga cgaaagggcc tcgtgatacg	5340
	cctattttta taggttaatg tcatgataat aatggtttct tagacgtcag gtggcacttt	5400
35	tcggggaaat gtgcgcggaa cccctatttg tttatttttc taaatacatt caaatatgta	5460
	tccgctcatg agacaataac cctgataaat gcttcaataa tattgaaaaa ggaagagtat	5520
	gagtattcaa catttcctgt tcgcccttat tccctttttt gcggcatttt gccttcctgt	5580
40	ttttgctcac ccagaaacgc tgggtgaaagt aaaagatgct gaagatcagt tgggtgcacg	5640
	agtgggttac atcgaactgg atctcaacag cggttaagatc cttgagagtt ttcgccccga	5700
	agaacgtttt ccaatgatga gcacttttaa agttctgcta tgtggcgcggt tattatcccg	5760
45	tattgacgcc gggcaagagc aactcggctg ccgcatacac tattctcaga atgacttggt	5820
	tgagtactca ccagtcacag aaaagcatct tacggatggc atgacagtaa gagaattatg	5880
	cagtgtgcc ataaccatga gtgataacac tgcggccaac ttacttctga caacgatcgg	5940
50	aggaccgaag gagctaaccg cttttttgca caacatgggg gatcatgtaa ctcgccctga	6000
	tcgttgggaa ccggagctga atgaagccat accaaacgac gagcgtgaca ccacgatgcc	6060
55	tgtagcaatg gcaacaacgt tgcgcaaact attaactggc gaactactta ctctagcttc	6120
	ccggcaacaa ttaatagact ggatggaggc ggataaagtt gcaggaccac ttctgcgctc	6180

	ggcccttcgcg	gctggctgggt	ttattgctga	taaatctgga	gccgggtgagc	gtgggtctcg	6240
	cggtatcatt	gcagcactgg	ggccagatgg	taagccctcc	cgtatcgtag	ttatctacac	6300
5	gacggggagt	caggcaacta	tggatgaacg	aaatagacag	atcgctgaga	taggtgcctc	6360
	actgattaag	cattggtaac	tgtcagacca	agtttactca	tatatacttt	agattgattt	6420
	aaaacttcat	ttttaattta	aaaggatcta	ggtgaagatc	ctttttgata	atctcatgac	6480
10	caaaatccct	taacgtgagt	tttcggtcca	ctgagcgtca	gaccccgtag	aaaagatcaa	6540
	aggatcttct	tgagatcctt	tttttctgcg	cgtaatctgc	tgcttgcaaa	caaaaaaacc	6600
15	accgctacca	gcgggtggttt	gtttgccgga	tcaagagcta	ccaactcttt	ttccgaaggt	6660
	aactggcttc	agcagagcgc	agataccaaa	tactgtcctt	ctagtgtagc	cgtagttagg	6720
	ccaccacttc	aagaactctg	tagcaccgcc	tacatacctc	gctctgctaa	tcttgttacc	6780
20	agtggctgct	gccagtggcg	ataagtcgtg	tcttaccggg	ttggactcaa	gacgatagtt	6840
	accggataag	gcgcagcgggt	cgggctgaac	gggggggttcg	tgcacacagc	ccagcttgga	6900
	gcgaacgacc	tacaccgaac	tgagatacct	acagcgtgag	ctatgagaaa	gcgccacgct	6960
25	tcccgaaggg	agaaaggcgg	acaggtatcc	ggtaagcggc	agggtcggaa	caggagagcg	7020
	cacgagggag	cttccagggg	gaaacgcctg	gtatctttat	agtcctgtcg	ggtttcgcca	7080
30	cctctgactt	gagcgtcgat	ttttgtgatg	ctcgtcaggg	gggcggagcc	tatggaaaaa	7140
	cgccagcaac	gcggcctttt	tacggttcct	ggccttttgc	tggccttttg	ctcacatgt	7199
35	<210> 23						
	<211> 29						
	<212> PRT						
	<213> Artificial Sequence						
40	<220>						
	<223> HLA-G peptide						
	<400> 23						

45 Met Ala Pro Arg Thr Leu Phe Leu Gly Gly Gly Gly Ser Gly Gly Gly
1 5 10 15
Gly Ser Gly Gly Gly Gly Ser Ile Gln Arg Thr Pro Lys
20 25

Claims

- 55 1. An isolated cell comprising a genetically engineered disruption in a beta-2 microglobulin (*B2M*) gene, wherein the cell is a primate cell, wherein the cell further comprises one or more recombinant immunomodulatory genes, each capable of expressing an immunomodulatory polypeptide in the cell, wherein the one or more immunomodulatory genes comprise a polynucleotide capable of encoding a single chain fusion human leukocyte antigen (HLA) class I protein comprising at least a portion of the B2M protein covalently linked, either directly or via a linker sequence.

to at least a portion of an HLA-I α chain, wherein the single chain fusion human HLA class I protein is capable of normal HLA class I function with respect to forming proper secondary structure of single chain fusion heterodimers on the cell surface, presenting peptides in the HLA I peptide binding cleft, and engaging the inhibitory receptors on the surface of NK cells.

2. The isolated cell of claim 1, wherein the single chain fusion human leukocyte antigen (HLA) class I protein comprises a full length B2M protein or variant thereof, or a B2M protein without the leader sequence or variant thereof.
3. The isolated cell of claim 1 or 2, wherein the single chain fusion human leukocyte antigen (HLA) class I protein comprises an HLA class I α protein or variant thereof, or a leaderless HLA class I α protein or variant thereof.
4. The cell of any one of claims 1-3, wherein the cell comprises genetically engineered disruptions of all copies of the *B2M* gene.
5. The cell of any one of claims 1-4, wherein the cell is a human cell.
6. The cell of any one of claims 1-5, wherein the single chain fusion HLA class I protein comprises
 - a. at least a portion of B2M covalently linked to at least a portion of an HLA class I α chain selected from the group consisting of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F and HLA-G;
 - b. at least a portion of B2M and at least a portion of HLA class I α chain is selected from the group consisting of HLA-E, HLA-G and HLA-A;
 - c. at least a portion of B2M and at least a portion of HLA-A;
 - d. at least a portion of B2M and at least a portion of HLA-A0201;
 - e. at least a portion of B2M and at least a portion of HLA-E;
 - f. at least a portion of B2M and at least a portion of HLA-G;
 - g. at least a portion of B2M and at least a portion of HLA-B;
 - h. at least a portion of B2M and at least a portion of HLA-C; or
 - i. at least a portion of B2M and at least a portion of HLA-F.
7. The cell of any one of claims 1-6, wherein the cell further expresses a target peptide antigen that is presented by the single chain fusion HLA class I protein on the cell surface.
8. The cell of claim 7, wherein the cell further comprises one or more recombinant genes capable of encoding a suicide gene product.
9. The cell of any one of claims 1- 8, wherein the cell
 - a. has a normal karyotype;
 - b. is a non-transformed cell;
 - c. is a stem cell, selected from the group consisting of a hematopoietic stem cell, an induced pluripotent stem cell, a liver stem cell, a neural stem cell, a pancreatic stem cell and a mesenchymal stem cell;
 - d. is a pluripotent stem cell; and/or
 - e. is differentiated.
10. The cell of claim 9, wherein the stem cell is differentiated, and wherein the differentiated cell is selected from the group consisting of a dendritic cell, a pancreatic islet cell, a liver cell, a muscle cell, a keratinocyte, neuronal cell, hematopoietic cell, lymphocyte, red blood cell, platelet, skeletal muscle cell, ocular cell, mesenchymal cell, fibroblast, lung cell, GI tract cell, vascular cell, endocrine cell, adipocyte and a cardiomyocyte.
11. A vaccine comprising the cell of claim 7, wherein the vaccine is capable of eliciting in a primate an immune response specific for the target peptide antigen.
12. The vaccine of claim 11, wherein the primate is a human and the cell is a human cell.
13. A cell of any one of claims 1-10 for use in transplantation in a patient in need thereof, whereby the cell is administered to the patient in an effective amount, wherein

- a. the cell is a differentiated cell;
- b. the patient is human and the cell is a human cell; and/or
- c. the cell further expresses a single chain fusion HLA class I protein.

14. A cell of any one of claims 1-10 for use in treating a disease condition in a patient in need thereof, whereby the cell is administered to the patient in an effective amount, and wherein the disease condition is diabetes, an autoimmune disease, cancer, infection, anemia, cytopenia, myocardial infarction, heart failure, skeletal or joint condition, osteogenesis imperfecta or burns.

15. The cell for use according to claim 14, wherein

- a. the cell is a differentiated cell;
- b. the patient is a human and the cell is a human cell;
- c. the disease condition is diabetes and the cell is a pancreatic islet cell; and/or
- d. the cell further expresses a single chain fusion HLA class I protein.

16. A kit comprising

- a. the cell of any one of claims 1-10;
- b. an implant comprising the cell of any one of claims 1-10; or
- c. the vaccine of claim 11 further comprising an immune adjuvant.

Patentansprüche

1. Isolierte Zelle, umfassend eine genetisch veränderte Unterbrechung in einem Beta-2-Microglobulin (B2M) Gen, wobei die Zelle eine Primatenzelle ist, wobei die Zelle ferner ein oder mehrere rekombinante immunmodulatorische Gene umfasst, von denen jedes in der Lage ist, ein immunmodulatorisches Polypeptid in der Zelle zu exprimieren, wobei das eine oder die mehreren immunmodulatorischen Gens ein Polynukleotid umfassen, das in der Lage ist, ein humanes Einzelketten-Fusions-Leukozyten-Antigen (HLA) Klasse I Protein ("single chain fusion human leukocyte antigen (HLA) class I protein") zu kodieren, welches mindestens einen Teil des B2M Proteins umfasst, welcher kovalent verknüpft ist, entweder direkt oder über eine Linkersequenz, mit mindestens einem Teil einer HLA-I α -Kette, wobei das humane Einzelketten-Fusions-HLA Klasse I Protein in der Lage ist, eine anormale HLA Klasse I Funktion im Hinblick auf die Bifdung einer korrekten ("proper") Sekundärstruktur eines Einzelkatten-Fusions- Heterodimers auf der Zelloberfläche, welche Peptide in der HLA I Peptidbindungspalte präsentiert, aufzuweisen und die inhibitorischen Rezeptoren auf der Oberfläche von NK-Zellen zu binden ("engaging").
2. Isolierte Zelle nach Anspruch 1, wobei das humane Einzelketten-Fusions-Leukozyten-Antigen (HLA) Klasse I Protein ein Vollängen-B2M Protein oder eine Variante hiervon, oder ein B2M Protein ohne die Leader-Sequenz oder eine Variante hiervon, umfasst.
3. Isolierte Zelle nach Anspruch 1 oder 2, wobei das humane Einzelketten-Fusions-Leukozyten-Antigen (HLA) Klasse I Protein ein HLA Klasse I α Protein oder eine Variante hiervon, oder ein HLA Klasse I α Protein ohne Leader oder eine Variante hiervon, umfasst.
4. Zelle nach einem der Ansprüche 1 bis 3, wobei die Zelle genetisch veränderte Unterbrechung von allen Kopien des B2M Gens umfasst.
5. Zelle nach einem der Ansprüche 1 bis 4, wobei die Zelle eine humane Zelle ist.
6. Zelle nach einem der Ansprüche 1 bis 5, wobei das Einzelketten-Fusions-HLA Klasse I Protein umfasst
 - a. mindestens einen Teil von B2M, welcher kovalent verknüpft ist mit mindestens einem Teil einer HLA Klasse I α Kette, ausgewählt aus der Gruppe bestehend aus HLA-A, HLA-B, HLA-C, HLA-E, HLA-F und HLA-G;
 - b. mindestens einen Teil von B2M und mindestens einen Teil HLA Klasse I α Kette, ausgewählt aus der Gruppe bestehend aus HLA-E, HLA-G und HLA-A;
 - c. mindestens einen Teil von B2M und mindestens einen Teil von HLA-A;
 - d. mindestens einen Teil von B2M und mindestens einen Teil von HLA-AO201;

- e. mindestens einen Teil von B2M und mindestens einen Teil von HLA-E;
 - f. mindestens einen Teil von B2M und mindestens einen Teil von HLA-G;
 - g. mindestens einen Teil von B2M und mindestens einen Teil von HLA-B;
 - h. mindestens einen Teil von B2M und mindestens einen Teil von HLA-C; oder
 - 5 i. mindestens einen Teil von B2M und mindestens einen Teil von HLA-F.
7. Zelle nach einem der Ansprüche 1 bis 6, wobei die Zelle ferner ein Ziel-Peptid-Antigen exprimiert, das durch das durch das Einzelketten-Fusions-HLA Klasse I Protein auf der Zelloberfläche präsentiert wird.
- 10 8. Zelle nach Anspruch 7, wobei die Zelle ferner ein oder mehrere rekombinante Gene umfasst, das / die in der Lage ist / sind ein Suizid-Genprodukt zu kodieren.
9. Zelle nach einem der Ansprüche 1 bis 8, wobei die Zelle
- 15 a. einen normalen Karyotyp aufweist;
- b. eine nicht-transformierte Zelle ist;
- c. eine Stammzelle ist, ausgewählt aus der Gruppe bestehend aus einer blutbildenden Stammzelle, einer induzierten, pluripotenten Stammzelle, einer Leberstammzelle, einer neuronalen Stammzelle, einer pankreatischen Stammzelle und einer mesenchymalen Stammzelle;
- 20 d. eine pluripotente Stammzelle ist; und/oder
- e. differenziert ist.
10. Zelle nach Anspruch 9, wobei die Stammzelle differenziert ist, und wobei die differenzierte Zelle ausgewählt ist aus der Gruppe bestehend aus einer dendritischen Zelle, einer pankreatischen Inselzelle, einer Leberzelle, einer Muskelzelle, einer Keratinozyte, neuronalen Zelle, blutbildenden Zelle, Lymphozyte, roten Blutzelle, Blutplättchen, Skelettmuskelzelle, okularen Zelle, mesenchymalen Zelle, Fibroblast, Lungenzelle, GI Trakt Zelle, vaskulären Zelle, endokrinen Zelle, Adipozyt und einer Herzmuskelzelle.
- 25 11. Vakzine, umfassend die Zelle nach Anspruch 7, wobei die Vakzine in der Lage ist, in einem Primaten eine Immunantwort hervorzurufen, die spezifisch für das Zielpeptid-Antigen ist.
- 30 12. Vakzine nach Anspruch 11, wobei der Primat ein Mensch ist und die Zelle eine humane Zelle ist.
13. Zelle nach einem der Ansprüche 1 bis 10 zur Verwendung in der Transplantation bei einem Patienten mit Bedarf hierfür, wobei die Zelle dem Patienten in einer effektiven Menge verabreicht wird, wobei
- 35 a. die Zelle eine differenzierte Zelle ist;
- b. der Patient ein Mensch ist und die Zelle eine humane Zelle ist; und/oder
- c. die Zelle ferner ein Einzelketten-Fusions-HLA Klasse Protein exprimiert.
- 40 14. Zelle nach einem der Ansprüche 1 bis 10 zur Verurteilung in der Behandlung eines Erkrankungszustandes bei einem Patienten mit Bedarf hierfür, wobei die Zelle dem Patienten in einer effektiven Menge verabreicht wird, und wobei der Erkrankungszustand Diabetes, eine Autoimmunerkrankung, Krebs, Infektion, Anämie, Zytopenie, Herzinfarkt, Herzinsuffizienz, Skelett- oder Gelenkzustand, Osteogenese imperfecta oder Verbrennungen ist / sind.
- 45 15. Zelle nach Anspruch 14, wobei
- a. die Zelle eine differenzierte Zelle ist;
- b. der Patient ein Mensch ist und die Zelle eine humane Zelle ist;
- 50 c. der Erkrankungszustand Diabetes ist und die Zelle eine pankreatische Inselzelle ist; und/oder
- d. die Zelle ferner ein Einzelketten-Fusions-HLA Klasse I Protein exprimiert.
16. Kit umfassend
- 55 a. die Zelle nach einem der Ansprüche 1 bis 10;
- b. ein Implantat, das die Zelle nach einem der Ansprüche 1 bis 10 umfasst; oder
- c. die Vakzine nach Anspruch 11, die ferner ein Immun-Adjuvans umfasst.

Revendications

1. Cellule isolée comprenant une interruption génétiquement conçue du gène de la bêta-2-microglobuline (*B2M*), dans laquelle la cellule est une cellule de primate, dans laquelle la cellule comprend en outre un ou plusieurs gènes immunomodulateurs recombinants, chacun capable d'exprimer un polypeptide immunomodulateur dans la cellule, dans laquelle l'un ou plusieurs gènes immunomodulateurs comprennent un polynucléotide capable de coder pour une protéine de fusion à chaîne unique d'antigène des leucocytes humains (HLA) de classe I comprenant au moins une partie de la protéine B2M liée de façon covalente, soit directement soit par l'intermédiaire d'une séquence de liaison, à au moins une partie d'une chaîne α de HLA-I, dans laquelle la protéine de fusion à chaîne unique de HLA humain de classe I est dotée d'une fonction normale de HLA de classe I en ce qui concerne la formation d'une structure secondaire correcte des hétérodimères de fusion à chaîne unique à la surface de la cellule, la présentation des peptides dans le site de liaison peptidique de HLA I, et l'engagement des récepteurs inhibiteurs sur la surface des cellules NK.
2. Cellule isolée selon la revendication 1, dans laquelle la protéine de fusion à chaîne unique d'antigène des leucocytes humains (HLA) de classe I comprend une protéine B2M de longueur complète ou l'un de ses variants, ou une protéine B2M sans la séquence de tête ou l'un de ses variants.
3. Cellule isolée selon la revendication 1 ou 2, dans laquelle la protéine de fusion à chaîne unique d'antigène des leucocytes humains (HLA) de classe I comprend une protéine α de HLA de classe I ou l'un de ses variants, ou une protéine α de HLA de classe I sans la séquence de tête ou l'un de ses variants.
4. Cellule selon l'une quelconque des revendications 1 à 3, dans laquelle la cellule comprend des interruptions génétiquement conçues de toutes les copies du gène *B2M*.
5. Cellule selon l'une quelconque des revendications 1 à 4, dans laquelle la cellule est une cellule humaine.
6. Cellule selon l'une quelconque des revendications 1, à 5, dans laquelle la protéine de fusion à chaîne unique de HLA de classe I comprend
 - a. au moins une partie de B2M liée de façon covalente à au moins une partie d'une chaîne α de HLA de classe I choisie dans le groupe consistant en HLA-A, HLA-B, HLA-C, HLA-E, HLA-F et HLA-G ;
 - b. au moins une partie de B2M et au moins une partie de chaîne α de HLA de classe I choisie dans le groupe consistant en HLA-E, HLA-G et HLA-A ;
 - c. au moins une partie de B2M et au moins une partie de HLA-A;
 - d. au moins une partie de B2M et au moins une partie de HLA-A0201;
 - e. au moins une partie de B2M et au moins une partie de HLA-E;
 - f. au moins une partie de B2M et au moins une partie de HLA-G;
 - g. au moins une partie de B2M et au moins une partie de HLA-B ;
 - h. au moins une partie de B2M et au moins une partie de HLA-C ; ou
 - i. au moins une partie de B2M et au moins une partie de HLA-F.
7. Cellule selon l'une quelconque des revendications 1 à 6, dans laquelle la cellule exprime en outre un peptide antigénique cible qui est présenté par la protéine de fusion à chaîne unique de HLA de classe I à la surface de la cellule.
8. Cellule selon la revendication 7, dans laquelle la cellule comprend en outre un ou plusieurs gènes recombinants capables de coder pour le produit d'un gène suicide.
9. Cellule selon l'une quelconque des revendications 1 à 8, dans laquelle la cellule
 - a. a un caryotype normal ;
 - b. est une cellule non transformée ;
 - c. est une cellule souche, choisie dans le groupe consistant en une cellule souche hématopoïétique, une cellule souche pluripotente induite, une cellule souche hématique, une cellule souche neurale, une cellule souche pancréatique et une cellule souche mésenchymateuse ;
 - d. est une cellule souche pluripotente ; et/ou
 - e. est différenciée.

10. Cellule selon la revendication 9, dans laquelle la cellule souche est différenciée, et dans laquelle la cellule différenciée est choisie dans le groupe consistant en une cellule dendritique, une cellule d'îlot pancréatique, une cellule hépatique, une cellule musculaire, un kératinocyte, une cellule neuronale, une cellule hématopoïétique, un lymphocyte, un érythrocyte, une plaquette, une cellule musculaire squelettique, une cellule oculaire, une cellule mésenchymateuse, un fibroblaste, une cellule pulmonaire, une cellule du tube digestif, une cellule vasculaire, une cellule endocrine, un adipocyte et un cardiomyocyte.

11. Vaccin comprenant la cellule selon la revendication 7, dans lequel le vaccin est capable de déclencher chez un primate une réponse immunitaire spécifique du peptide antigénique cible.

12. Vaccin selon la revendication 11, dans lequel le primate est un humain et la cellule est une cellule humaine.

13. Cellule selon l'une quelconque des revendications 1 à 10 pour une utilisation dans une transplantation chez un patient en ayant besoin, par laquelle la cellule est administrée au patient dans une quantité efficace, dans laquelle

- a. la cellule est une cellule différenciée;
- b. le patient est humain et la cellule est une cellule humaine ; et/ou
- c. la cellule exprime en outre une protéine de fusion à chaîne unique de HLA de classe I.

14. Cellule selon l'une quelconque des revendications 1 à 10 pour une utilisation dans le traitement d'une affection pathologique chez un patient en ayant besoin, par laquelle la cellule est administrée au patient dans une quantité efficace, et dans laquelle l'affection pathologique est le diabète, une maladie auto-immune, le cancer, une infection, une anémie, une cytopénie, un infarctus du myocarde, une insuffisance cardiaque, une affection squelettique ou articulaire, une ostéogenèse imparfaite ou des brûlures.

15. Cellule pour une utilisation selon la revendication 14, dans laquelle

- a. la cellule est une cellule différenciée ;
- b. le patient est un être humain et la cellule est une cellule humaine ;
- c. affection pathologique est le diabète et la cellule est une cellule d'îlot pancréatique ; et/ou
- d. la cellule exprime en outre une protéine de fusion à chaîne unique de HLA de classe I.

16. Kit comprenant

- a. la cellule selon l'une quelconque des revendications 1 à 10 ;
- b. un implant comprenant la cellule selon l'une quelconque des revendications 1 à 10 ; ou
- c. le vaccin selon la revendication 11 comprenant en outre un adjuvant immunologique.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 6514752 B1 [0005]
- WO 9209688 A1 [0005]
- US 20080219956 A [0025]
- WO 9110470 A [0062]
- WO 9110425 A [0062]
- US 5837234 A [0062]
- US 5011472 A [0062]
- US 4892538 A [0062]

Non-patent literature cited in the description

- **SAMBROOK et al.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1989 [0018]
- **INNIS et al.** PCR Protocols: A Guide to Methods and Applications. Academic Press, 1990 [0018]
- **KHAN et al.** *Protocol*, 2011, vol. 6, 482-501 [0026]
- **PAZMANY et al.** *Science*, 1996, vol. 274, 792-795 [0040]
- **BIX et al.** *Nature*, 1991, vol. 349, 329-331 [0066] [0088]
- **SLUKVIN et al.** *J Immunol*, 2006, vol. 176, 2924-32 [0067]
- **CHANG et al.** *Blood*, 2006, vol. 108, 1515-23 [0067]
- **DEYLE et al.** *Mol Ther.*, 2012, vol. 20 (1), 204-13 [0068]
- **DI LORENZO et al.** *Clin Exp Immunol*, 2007, vol. 148, 1-16 [0070]
- **KROON et al.** *Nat Biotechnol*, 2008, vol. 26, 443-452 [0071] [0072]
- **LAFLAMME et al.** *Nat Biotechnol*, 2007, vol. 25, 1015-1024 [0074]
- **ITOH et al.** *PNAS USA*, 2011, vol. 108, 8797-8802 [0075]
- **KHAN et al.** *Protocol*, 2011, vol. 482, 482-501 [0084]
- **KHAN et al.** *Science*, 1990, vol. 248, 1227-30 [0084]
- **DEYLE et al.** *J. Virol*, 2010, vol. 84, 9341-9 [0086]
- **GHWAN et al.** *Mol Ther*, 2007, vol. 15, 1827-1833 [0086]
- **CREW et al.** *Mol Immunol*, 2005, vol. 42, 1205-1214 [0090]
- **STORKUS et al.** *PNAS USA*, 1989, vol. 86, 2361-2364 [0091]